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General inlroduc lion 
Background 
Inflammatory disorders such as serious infection and rheumatoid diseases are a major health 
problem in the human population In search for a new treatment, the intake of specific 
polyunsaturated fatty acids (PUFAs) is of interest In fact, promising results have been 
obtained with dietary fish and borage oil in patients with inflammatory diseases The 
mechanism by which these oils exert beneficial effects has been subject of many 
investigations, but has not been fully elucidated yet Some studies suggested that a change in 
production of the soluble mediators from the immune system, cytokines and eicosanoids, 
could be responsible for the beneficial effects To gain more insight in the underlying 
mechanisms, the current thesis focuses on the immune-modulatory potential of specific 
PUFAs and the routes by which the effects are induced 
In this chapter, first a description of immune responses in general and the role of cytokines 
and eicosanoids in inflammatory processes are outlined, followed by the description of sepsis 
as an example of a serious inflammatory disorder Subsequently, a description of the 
nomenclature, function, metabolism and immune-modulatory effect of PUFAs is given In the 
last paragraphs the aims and outline of the current thesis are presented 
7.7 Immunity 
Inflammation is a host response to a foreign challenge, such as an infectious organism, aimed 
to preserve the body's homeostasis The two main integral components of the host's defence 
are the innate and adaptive immune response12 Innate (non-specific) immunity is present at 
all times in human individuals Therefore, this system is ready for action always, so even 
before infectious agents enter the body Cells that mediate innate immune responses are 
phagocytic cells, such as polymorphonuclear neutrophils (PMNs), monocytes, and 
macrophages Adaptive immunity is the specific reaction lo a challenge with an immunogenic 
agent Thus, this specific part of the immune system is activated after the pathogen has evaded 
the innate response and entered the body There arc two classes of adaptive immunity 
humoral, mediated by B-lymphocytes, and cellular, mediated by T-lymphocytes Most 
immune responses are organized by a combination of innate and specific immune 
components, characterized by intensive interaction between phagocytes and lymphocytes 
Therefore, innate immunity not only acts as the first line of defence against harmful material, 
but also provides the necessary signals to instruct the adaptive immune system to mount a 
response after recognition of an agent/stimulus12 
7.2 Cytokines 
An inflammatory reaction is communicated by the sequential release of mediators such as 
cytokines and hpid-denved eicosanoids' Cytokines are small proteins that are synthesized by 
a variety of cell types and act on the majority of tissues and organs The whole panel of 
cytokines can be subdivided into pro-inflammatory and anti-inflammatory cytokines4 Pro-
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inflammatory cytokines, such as tumor necrosis factor-α (TNF-a) and interleukin-1 β (IL-Iß), 
mediate the primary response of the host to inflammatory stimuli, they induce fever and 
activate Β and Τ lymphocytes, and endothelial cells In contrast, anti-inflammatory cytokines, 
such as interleukin-10 (IL-10), counteract pro-inflammatory cytokines and therefore mediate 
the resolution of an immune response Anti-inflammatory cytokines are usually produced in 
response to inflammatory cytokines5 
TNF-a 
TNF-a is one of the first pro-inflammatory cytokines that is released upon challenge with 
lipopolysacchande (LPS) or another stimulus (viruses, mitogens), and can also be initiated by 
other cytokines like interferon-γ (IFN-γ)6 TNF-a was originally identified for Us ability to 
induce cachexia and lysis of tumor cells" It is a pleiotropic factor that can induce its own 
production, formation of other mediators and stimulate production of antagonizing signals 
such as IL-10 
The major source of TNF-a is activated monocytes/macrophages, although it is also produced 
by lymphocytes, mast cells, basophils, eosinophils, natural killer (NK) cells, Β cells, Τ cells, 
Kupffer cells, keratinocytes and epithelial cells4 TNF-a is synthesized as a 26 kDa 
membrane-bound precursor that is cleaved proteolytically to a mature 17 kDa form with the 
pro-sequence polypeptide remaining associated to the membrane The peptide is bioaclivc as a 
51 kDa tnmer, which can be recognized by two different receptors, TNFR1 (p55 or CD 120a) 
and TNFR2 (p75 or CD 120b) In human, these receptors are known as p60 and p80 
respectively TNFR1 is present in the majority of cellular types, whereas TNFR2 is restricted 
to haemopoietic cells10 The interaction of TNF-a with its receptor triggers a cascade of 
intracellular reactions that change the activities of the cell Signal transduction distal to the 
TNF-reccptors involves phosphohpase C (PLC), sphingomyelinases, protein kinases and 
nuclear translocation of nuclear factor kappa Β (NFKB)" NFKB plays a role in activating key 
components that confer cellular immunity12 In addition to the membrane bound TNF-
receptors, soluble forms of the two receptors exist, which have a higher degree of affinity for 
the cytokine than the corresponding membrane bound forms Binding of TNF-a to these 
soluble receptors prevents interaction with the membrane forms and may therefore constitute 
a way of regulating TNF-a actions'1 
In healthy humans, circulating TNF-a levels arc usually very low'4 By contrast, high 
concentrations of plasma TNF-a have been detected in a variety of infectious and 
inflammatory diseases (Table 1)" Theoretically, a therapeutic benefit can be expected for 
TNF-a inhibitors in conditions that are mediated by TNF-a16'7 Current anti-TNF-a agents 
can be divided into three groups The first group is targeted on inhibition of the synthesis of 
TNF-a, like anti-inflammatory cytokines (such as IL-10) or other mediators (such as 
corticosteroids) The second group inhibits processing of the TNF-pro-protcin (inhibitors of 
the TNF metallo-protease) and the third group antagonizes the effects of released TNF by 
— 9 — 
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soluble TNF-receptors or anti-TNF antibodies" These latter TNF-a blockers were effective 
in some conditions, among which rheumatoid arthritis and Crohn's disease"" 
Table 1. Some human (inflammatory) diseases with detectable plasma concentrations of 
TNF-a and the effects of TNF-a blocking agents on disease activity 
Severe infections 
Inflammatory diseases 
(non infectious) 
Skin diseases 
Others 
Disease 
Sepsis 
Bacterial meningitis 
Cerebral malaria 
Rheumatoid arthritis 
Crohn's disease 
Ulcerative colitis 
Multiple sclerosis 
Graft versus host disease 
Psoriasis 
Dermatitis 
Cachexia 
Depression 
TNF-a blocking 
Possibly ineffective 
Possibly beneficial* 
Possibly beneficial 
Beneficial 
Beneficial 
No conclusive effects 
Possibly harmful 
No conclusive effects 
Partial improvement 
Possibly beneficial* 
Possibly beneficial 
Unknown 
References 
19 21 
22 24 
25 26 
27 
28 29 
30 13 
34 35 
36 37 
38 39 
m 
4M1 
ΦΜ6 
Adopted from tiglcr et al (1997) * Based on experimental data with rodents only 
IL-1 
A second important pro-inflammatory cytokine that is triggered by LPS or other activating 
factors (among which TNF-a) is IL-1 IL-1 is present in two mature forms IL-la, which is 
mainly cell-associated, and IL-Iß that is released into the extracellular environment after 
stimulation" Activated monocytes and macrophages are the primary cells responsible for 
producing large amounts of IL-1 IL-la and IL-Iß both bind to type I and II receptors and can 
thereby activate nuclear translocation of NF-κΒ, phosphohpase-A (PLA) or PLC activity, 
induce Ca2+ influx, cyclic AMP (cAMP) production, phosphoinositol metabolism, and 
cyclooxygenase-1 (COX-1) and COX-2 expression in macrophages and other cells48 Local 
effects of IL-1 include enhancement in Τ and Β lymphocyte function, Chemotaxis of 
neutrophils, lymphocytes and monocytes, and increased expression of adhesion molecules on 
endothelial cells In joint diseases IL-1 is a major factor in tissue destruction it stimulates the 
production of collagcnase and other proteinases and production of prostaglandin^ (PGE2) by 
synovial cells, chondrocytes and bone-derived cells'"'",0 
IL-6 
An other important cytokine that is produced in high amounts during inflammation is IL-6 
IL-6 is produced by monocytes, Τ lymphocytes and fibroblasts The most important function 
of IL-6 appears to be the induction of synthesis of acute-phase proteins in the liver51" The 
production of acute phase proteins by the liver is critical for homeostasis and recovery after 
injury Proteins that arc synthesized in large amounts by the liver are C-reactive protein 
(CRP), fibrinogen, serum amyloid Ρ and A, haptoglobin and a-1 antitrypsin", which overall 
— 10 
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contribute to enhanced protection against microorganisms and change inflammatory responses 
by affecting the cell trafficking and mediator release". Other biologic effects of IL-6 arc 
modulation of growth and differentiation of T-lymphocytes and enhancement of 
immunoglobulin production by Β cells. Production of IL-6 can be induced by inflammatory 
cytokines such as IL-1 and TNF-a. Many studies indicate that IL-6 mainly acts as an anti­
inflammatory cytokine: unlike TNF-a and IL-1, IL-6 does not up-regulale PGE2, nitric oxide 
or matrix metallo-proteinases and does not induce synthesis of adhesion molecules. 
Moreover, IL-6 inhibits synthesis of LPS-induced TNF-a and IL-1 in vivo and in vitro**. IL-6 
may therefore play a role in the negative feedback mechanism that down-regulates synthesis 
of pro-inflammatory cytokines. 
IL-10 
IL-10 is a major anti-inflammatory cytokine that is produced at later time points than the pro­
inflammatory cytokines TNF-a and IL-1-. IL-10 is synthesized by monocytes/macrophages, 
CD4+ T-helper 2 cells and B-cells, mainly in response to TNF-α56. IL-10 is an important 
inhibitor of T-helper-1 cytokine production (IL-2 and IFN-γ) and a potent deactivator of 
monocyte/macrophage proinflammatory cytokine synthesis (TNF-α, IL-1 and IL-6),,"<\ For 
this, IL-10 promotes degradation of messenger-RNA for the pro-inflammatory cytokines, 
inhibits the LPS recognition- and signalling molecule-CD14 and inhibits NFKB translocation 
after LPS stimulation. IL-10 also attenuates surface expression of TNF receptors, promotes 
the shedding of TNF receptors into the systemic circulation and inhibits COX-2 expression". 
1.3 Eicosanoids 
Phospholipases 
As was mentioned before, a second group of soluble mediators are the eicosanoids. 
Eicosanoids are lipid-derived mediators, in contrast to cytokines, which are small proteins. 
For the synthesis of eicosanoids, substrale-PUFAs are released from membrane phospholipids 
by specific phospholipases60·61. A principal enzyme that liberates fatty acids from the 
phospholipids during immune cell stimulation is phospholipase A2 (PLA2)64. PLA2 cleaves on 
position sn-2 of the phospholipid (the second C atom of the polar head). A variety of 19 
structurally diverse PLA2 enzymes exist, which can be functionally categorized as secretory 
(SPLA2), cytosolic Ca2+-dependent (CPLA2) and cytosolic Ca2+-independent (iPLA2)6i66. 
During activation of immune cells by endotoxin, CPLA2 is activated by stimulus-induced 
phosphorilation of serine residues of the enzyme, induced by MAP kinase (MAPK) or other 
kinases. The activated enzyme is subsequently translocated to substrate membranes within the 
cell and releases predominantly arachidonic acid (AA, 20:4«-6) since this is usually the most 
prevalent PUFA on the sn-2 position of phospholipids67. Following the activation of CPLA2, 
SPLA2 is activated and released to the extracellular medium. Subsequently, SPLA2 re-
associates with the outer cellular surface where it hydrolyzes phospholipids6". 
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Cyclooxygcnascs and lipoxygenases 
Eicosanoids are not stored by cells, but rather synthesized and released rapidly Three major 
pathways within the eicosanoid cascade are COX, lipoxygenase (LOX) and epoxygenase 
pathways, each named after the enzymes that catalyze the first committed step6869 These 
pathways generate a pool of different types of metabolites with different biological activities 
COX enzymes are responsible for the production of prostanoids, which include prostaglandins 
and thromboxanes™ Lipoxygenase enzymes generate leukotnenes, lipoxins and 
hydroxyeicosatetraenoic acids (HETEs) The less-known third pathway is the metabolism of 
AA by multiple cytochromes P450 into three types of eicosanoid production, under which 
HETEs and epoxyeicosatetnenoics (EETs)71 In addition, some arachidomc acid may undergo 
free radical oxidation to form isoprostanes and isoleukotnenes6"2 
COX catalyzes the first enzymatic step in the conversion of arachidomc acid into PGG2, and 
onward into the common precursor PGH2 The generation of the endoperoxide PGG2 involves 
a cyclooxygcnasc reaction in which two oxygen molecules are inserted into the fatty acid 
Formation of PGH2 out of PGG2 involves hydroperoxidase activity, a two-electron reduction 
of the 15-hydroperoxide group of PGG2 Both the cyclooxygenase and hydroperoxidase 
activities arc catalyzed by COX PGH2 is thereafter converted into the various prostanoids 
through the actions of their respective PG-synthascs and thromboxanc-A (TXA)-synthases 
The five primary prostanoids comprise the prostaglandins PGE2, PGD2, PGF2a and PGI2 
(prostacyclin), and TXA2 Individual prostaglandins are designated by the symbol that assigns 
the nature of the cyclopentane unit 
To date, two isoforms of COX have been described COX-1 and COX-2 In essence, COX-1 
is the enzyme responsible for basal, constitutive prostanoid synthesis, whereas COX-2 is 
important in various inflammatory and 'induced' settings69" However, upregulation of COX-
1 has also been described after LPS administration to human volunteers73 COX isoforms are 
encoded by two different genes, thus being independently regulated The crystal structures of 
COX-1 and COX-2 are rather similar, with one notable amino acid difference74 COX-1 is 
expressed in almost all tissues including platelets, and its prostaglandm-products are thought 
to mediate physiological responses, such as vascular homeostasis and gaslro-prolection 
COX-2 is often undetectable in resting cells, but is induced as an immediate early gene m 
macrophages, neutrophils and endothelial cells at sites of inflammation70 COX-2 is therefore 
responsible for the majority of eicosanoids produced during an inflammatory response7576 
Recently, presence of a variant of COX-1 was suggested, designated COX-3 COX-3 is 
encoded in the COX-1 gene and its role in inflammation and pain induction is not revealed 
yet77 
In addition, COX enzymes arc the targets for inhibition by aspirin and other non-steroidal 
anti-inflammatory drugs (NSAIDs) or the more recently developed COX-1 and COX-2 
selective inhibitors For instance, aspirin selectively acetylates a serine residue in the 
cyclooxygenase-activity-site and therefore prevents the first oxygen-insertion It is suggested 
that specific COX-2 inhibitors would reduce the gastrointestinal toxicity7" of non-specific 
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COX inhibitors79, although it was reported that the renal toxicity is similar to traditional 
NSAIDs80. 
5-, 12-, and 15-Lipoxygenases catalyze the introduction of oxygen into the C-5, C-12 and C-
15 positions of PUFAs respectively, resulting into hydroperoxy fatty acids. The lipoxygenase 
subtypes are differentially expressed in cells and species. It was reported that in human, 
polymorphonuclear leucocytes (PMN) have 5- and 15-lipoxygenase activity81 and human 
platelets have 12-lipoxygenase activity only82. Human peripheral monocytes express 5-
lipoxygenasc, whereas 15-lipoxygenase can also be delected when the cells develop into 
macrophages*'"5. Lymphocytes carry receptors for LTB4 and are important targets to LTB4 
effects8*, but do not produce significant amounts of LTB487. 
Prostaglandin-Ei 
The main prostaglandin synthesized from arachidonic acid (AA) after stimulation of immune 
cells is prostaglandin^ (PGE2)88, in which the number 2 represents the number of double 
bonds outside the cyclopentane ring. Prostaglandins synthesized from dihomo-y-linolenic acid 
(DGLA, 20:3n-6) or eicosapentaenoic acid (EPA, 20:5n-3) have one or three double bonds 
resulting in the designation of PGEi and PGE3, respectively89. It has recently been suggested 
that specific terminal PGE-synlhases may play different roles in PGE2 formation. The 
inducible PGE-synthases were upregulated during COX-2 dependent PGE2 production, while 
cytosolic PGE-synthases were demonstrated to couple more efficiently with COX-1 as 
compared with COX-29092. Four receptor subtypes were identified that bind PGE2: EP| to EP4, 
which are members of a distinct subfamily of the G protein-coupled receptor superfamily of 
seven-transmembrane spanning proteins. EP2 and EP4 receptors signal through G-mediated 
increases in intracellular cyclic adenosine monophosphate (cAMP). The EP| receptor signals 
through G
s
-mediatcd increases in intracellular calcium and the EPi receptor is regarded as an 
'inhibitory' receptor that couples to G, and decreases cAMP formation. The potent anti-
pyrogenic effects of NSAIDs have provided strong indications for a role of prostaglandins in 
fever. It is thought that LPS or other challenges induce cytokine networks that stimulate the 
neural pathways that raise body temperature. This stimulation is considered to be mediated by 
PGE2 synthesized by COX-2 in the Organum vasculosa lamina terminalis (OVLT), at the 
midline of the pre-optic area, and the neurons surrounding the OVLT that express the EP3 
receptor'594. 
Although PGE2 induces reactions that mediate several of the cardinal features of 
inflammation such as edema95, it is also a potent modulator of immunity'6. PGE2 can strongly 
inhibit LPS/bacterial induced pro-inflammatory cytokine production such as TNF-a9 7 "" and 
some reported enhanced the synthesis of anti-inflammatory cytokines such as IL-IO102"" or IL-
6HKM 10s b y p G E 2 I n addition, PGE2 down-regulated Thl cytokines such as IFN-γ and IL-2, 
while Th2 cytokine-production was unaffected or upregulated97 "* m. PGE2 appears to mediate 
its inhibitory effects by raising cAMP levels in macrophages and other leukocytes"0 "2. In line 
with this, NSAIDs, which inhibit PGE2 synthesis, up-regulated TNF-a, IFN-γ and IL-2 
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production by human leukocytes"3"4 Another route via which PGE2 might have anti­
inflammatory activities is via amplifying lipoxin-A2 (LXA4) expression by 
polymorphonuclear neutrophils (PMNs) LXA4 is a 15-LOX product, which exerted potent 
anti-inflammatory effects such as resolution of pleural inflammation" 
Thromboxanc-B: 
Thromboxanes (TX) are derived from thrombanoic acid, which contains a six-carbon ring in 
contrast to the cyclopentane ring in prostaglandins In general, the only thromboxanes found 
in appreciable quantities in human/animals are TXA2 and its stable derivative TXB2 The 
human TX A2 receptor is called Τ prostanoid receptor or TP receptor, of which two isoforms 
were discovered"5 Presence of a TXA2 receptor in human peripheral blood monocytes and 
platelets was recently reported"6"7 A major role of TXA2 lays, next to PGI2 (prostacyclin), in 
the local control of vascular haemostasis TXA2 is a potent stimulator of platelet aggregations 
and causes vasoconstriction, whereas PGI2 acts directly opposite to these effects 
Furthermore, TXA2 can stimulate PGI2 release from endothelial cells TXA2 also affects 
cytokine production a TXA2 agonist stimulated TNF-a and IL-Iß production by 
monocytes/macrophages, while inhibition of TXA2 synthesis decreased production of these 
cytokines"8 
Leukotrienes 
Leukotnenes arc potent biologically active compounds that are synthesized by way of the 5-
lipoxygenase pathway'" LTB4 is a stimulant of neutrophil Chemotaxis and adherence to 
venule walls It also stimulales neutrophil lysosomal enzyme release and the generation of 
superoxide radicals'20 In some studies exogenous LTB4 stimulated IL-Iß, TNF-α and IFN-γ 
production121122 and inhibition of LTB4 synthesis suppressed the production of TNF-α and IL-
J123125 j
n
 Qontrast, other studies report that LTB4 does not play a role in cytokine production 
by human leucocytes'26127 Finally, it was observed that natural killer and natural cytotoxic cell 
activity against tumor cells or virus-infected target cells are significantly enhanced by 
LTB412812' 
The cysteinyl leukotrienes, LTC4 and its metabolites, LTD4 and LTE4, are potent 
inflammatory agents involved in allergy and hypersensitivity, in particular bronchial asthma 
LTC4 is produced by basophils/mast cells, eosinophils and monocytes/macrophages, and 
under certain circumstances by platelets, since these cells have LTC4 synthase activity130 
— 14 — 
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1.4 Sepsis 
Although the immune response has the central purpose to preserve and protect the host, it can 
have deleterious effects in some circumstances. Sepsis is an example of such an inflammatory 
condition and is characterized by a harmful activation of the innate immune response and 
over-production of inflammatory mediators. Sepsis is the most common cause of death in 
intensive care units. A prominent molecule that is responsible for the clinical features in 
sepsis is LPS complex (also called endotoxin) associated with the outer envelope of Gram-
negative bacteria. The structure of LPS consists of an endotoxic lipid A, to which LPS is 
anchored in the bacterial membrane, and a polysaccharide unit presented at the cell surface 
that is specific to bacterial species. The biological activity of endotoxin is associated with 
lipid component A (Lipid A) and immunogenicity is associated with the polysaccharide 
components. Injection of living or killed Gram-negative cells, or purified LPS into 
experimental animals causes a wide spectrum of non-specific pathophysiological reactions 
such as fever, hypotension, changes in white blood cell counts, disseminated intravascular 
coagulation, shock and can eventually result in death1" "'. 
LPS binds to cell surfaces by a complex of three molecules: the glycerophosphoinositol-
linked CD14, a transmembrane protein Toll-like receptor (TLR, especially TLR-4) and MD-
2IH.13S -phg jnjtiai binding of LPS is greatly enhanced by the plasma factors designated LPS-
binding proteins (LBP). LBP is an acute phase reactant made by the liver in response to IL-Iß 
and IL-6, and binds to the lipid A portion of LPS'36. The activation of TLR-4 by the LPS-LBP 
complex leads to NFKB activation, the expression of inflammatory cytokines and the 
expression of the inducible COX-2 in monocytes and macrophages12'"lw. This process is 
outlined in Figure 1. In addition, LPS induces complement and stimulates Chemotaxis and 
accumulation of neutrophils resulting in inflammation in in vivo situations. LPS also elicits a 
blood clotting cascade that leads to coagulation, thrombosis, acute disseminated intravascular 
coagulation, which depletes platelets and various clotting factors resulting in internal 
bleeding112. 
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LPS-binding 
protein 
Gram-negative 
bacteria 
LPS 
LPS-LBP 
complex 
Monocytes 
or ηιφ 
Complex binding 
Cytokine production 
TNF-a, IL-6, IL-10 
i 
Lipid mediator production: 
cylooxygcnase: 
lipoxygenase: 
PGE2 
TXA2 
LTB4 
Phospholipid bilayer: 
arachidonic acid is released by PLA2 
Figure 1. LPS binding and activation of monocytes or macrophages (πιφ). LPS, derived 
from gram-negative bacteria, binds to LBP (LPS-binding protein) present in scrum. This 
strongly accelerates LPS-binding to CD14, TLR and MD-2 and induces cell activation 
(NHKB translocation) resulting in production of cytokines and eicosanoids. 
The septic shock is associated with dramatically elevated levels of inflammatory cytokines 
such as TNF-a, IL-1 and IL-6141. The serum levels of the main pro- and anti-inflammatory 
cytokines have a prognostic value for the severity of disease and mortality'42'46. Infusion of 
these cytokines into rodents mimicked many features of septic shock, while passive 
immunization with antibodies to specific cytokines, such as TNF-a, improved survival'42. The 
effects of TNF-a inhibitors in sepsis patients is however tentative. 
From experimental studies is has become apparent that LPS is cleared from the plasma mainly 
by the liver. Within the liver, Kupffer cells are primarily responsible for the uptake of LPS 
from the blood. Endothelial and parenchymal cells of the liver contribute to the clearance of 
LPS to a lesser extent. Interestingly, more recently it was found that lipoproteins, such as low-
, high-, very-high-density proteins (LDL, HDL, VLDL) and chylomicrons, can bind 
endotoxin, and thereby reduce the toxic properties of LPS'47 "". The mechanism of the reduced 
toxicity might involve redirection of LPS from Kupffer cells to the parenchymal cells in the 
liver"1. As a consequence, the reduced activation of Kupffer cells can result in a strong 
inhibition of the production of cytokines and protection against LPS or bacterial shock'51. It 
has therefore been postulated that the production of triglyceride-rich lipoproteins contributes 
to the host's defence mechanism against endotoxin. 
16-
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1.5 Fatty acids 
Fatty acids are main constituents of cell membranes and, as mentioned above, can function as 
substrate for synthesis of lipid mediators, such as eicosanoids. In the next paragraphs the 
different types, nomenclature, physiological functions and metabolism of fatty acids will be 
discussed. Also, the role of anti-oxidants in the prevention of lipid peroxidation is discussed 
briefly. 
Fatty acid types 
The general definition of a lipid is a biological material that is soluble in organic solvents 
such as ether or chloroform. Examples of lipids are triacylglycerols, cholesterol, glyccrol-
based phospholipids (including phosphatidylcholine (PC), phosphatidylethanolaminc (PE), 
phosphatidylserine (PS) and phosphatidylinositol (PI)) or sphingosine-based lipids (including 
sphingomyelin and glycosphingolipids). Furthermore, each lipid species exhibits a 
characteristic fatty acid composition. Glyccrol-bascd phospholipids, for example, usually 
have a saturated fatty acid esterificd at the 1-position of the glycerol backbone, whereas the 2-
position usually contains an unsaturated fatty acid. PE and PS are in general more unsaturated 
than other phospholipids. 
A variety of techniques have been developed for isolation of lipids from membranes. In 
general, the first step involves disruption of the membrane in a solvent, which denatures and 
precipitates most of the protein, and solubilizes the lipid compartment. The Bligh and Dyer 
method is commonly employed, and involves incubation of the membrane in a one phase 
system of a chloroform-methanol-water mixture (1:2:0.8 v/v/v)'52. Subsequent addition of 
chloroform and water to the mixture containing the extracted lipids results in a two-phase 
system where the lower chloroform phase contains most of the membrane lipids. Column 
chromatography is usually subsequently employed for isolation of individual lipid species or 
for characterization of the fatly acid content. 
Nomenclature 
The nomenclature of fatty acids is based on the length of the carbon chain, the number of 
double bonds and the location of the first double bond within the chain153. For instance, 
dihomo-y-linolenic acid (DGLA) is indicated as 20:3/7-6, in which 20 is the number of carbon 
atoms and 3 the number of double bonds (Figure 2). The n-6 (omega-6 or ω6) implies that this 
fatty acid is designated within a 'family' of structurally related fatty acids, that is, the first 
double bond is at the ό"1 carbon atom from the methyl end of the chain. In general, the double 
bond configuration is cis. 
— 17 — 
General introduction 
Figure 2. The structure image of dihomo-y-linolemc acid (DGLA) also designated 20 3/i-
6, in which 20 is the number of carbon-atoms, 3 the number of double bonds and «-6 
indicates that the first double bond is at carbon-atom 6 from the methyl end of the fatty 
acid 
To assign the position of an individual double bond or specificity of an enzyme inserting it 
(such as desaturase enzymes), the delta (Δ) nomenclature is used The number after the Δ-sign 
then describes a bond position relative to the carboxyl carbon of the acyl chain For instance, 
A6-desaturase inserts a double bond in C-alom 6 from the carboxyl end of linoleic acid (LA, 
18 2n-6) resulting in γ-linolemc acid (GLA, 18 3«-6) 
Physiological function 
Dietary fat is an important macronutnent in the diet of all animals1541" Fat is especially 
essential for the integrity of lipid bilayer of cell membranes and forms an important source of 
energy via oxidation pathways156 The cellular membranes of animals and humans are 
composed primarily of phophoglycerides containing two fatty acids per molecule, cholesterol 
and proteins The specificity, composition and molar ratios of these compounds vary between 
cells and determine the cell membrane functionality Structurally, a cell membrane can be 
imagined as a molecular bilayer in which the lipids are arranged with the hydrophobic 
moieties in the centre of the membrane and the hydrophilic groups at the two surfaces This 
lipid bilayer organization provides a permeability barrier between exterior and interior 
compartments, and a matrix with which membrane proteins are associated as integral proteins 
This allows surface association of peripheral proteins via electrostatic interactions The inner 
and outer leaflets of the membrane bilayer may exhibit different lipid compositions, with the 
majority of phospholipids that exhibit a net negative charge at physiological pH (PS and PI) 
limited to the cytosolic half of the bilayer Altogether, this gives rise to a transmembrane 
potential (negative within the cell) and other membrane mediated processes Within 
membrane phospholipids, acyl chain length and the number and position of double bonds 
markedly influence fluidity, permeability and stability of biological membranes Presence of 
cis double bonds dramatically increases the fluidity of membranes The fatty acid composition 
of cells depends on specific transport and metabolism of fatty acids within the cell, and the 
providence of fatty acids by dietary intake 
Metabolism 
Dietary lipids are taken up and metabolized by the intestinal system and transported via the 
lymph into plasma either as unestenfied fatty acids complexed to serum albumin or in the 
form of tnacylglycerols associated with lipoproteins Triacylglycerols are hydrolyzed outside 
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cells by lipoprotein lipase to yield free fatty acids. Dietary intake and de-novo synthesis alone 
are normally insufficient to meet all the requirements of lipids in biological membranes and 
storage depots. Therefore, during normal life substantial metabolism and rearrangement 
within body tissues occurs'". The mechanisms involved in the transport of fatly acids across 
biological membranes are still poorly understood. Studies have indicated that fatty acid 
transport from extracellular space into cells is likely to involve both protein-facilitated 
transport as well as passive diffusional uptake',\ Several putative fatty acid transport proteins 
have been characterized, under which the transmembrane fatty acid transport protein (FATP) 
and fatty acid translocase (FAT or CD36 in human cells)""60. On the intracellular side of the 
plasma membrane, cytosolic fatty acid binding proteins are present, which are thought to 
function in shuttling the fatty acids to different cellular compartments'61,63. Most of the fatty 
acids present in cells are bound within cell membranes, although a varying amount of fatty 
acids can exist intracellular in an unacylated form. The fatty acid composition of immune 
cells is largely dependent on the fatty acids present in plasma and can therefore be altered by 
dietary intake of fatty acids. In quiescent, unstimulated cells, remodelling of fatty acids in the 
phospholipid pools is already present. The balance of fatty acids is created by the combined 
occurrence of reacylation, deacylation and in part transacylation of fatty acids. Transacylation 
reactions catalyze the transfer of a fatty acid from one phospholipid to another without using a 
CoA or free fatty acid intermediate'64. 
Humans can synthesize all of the lipids necessary with the exception of those belonging to the 
n-6 and «-3 families of long chain fatty acids. For this purpose, dietary intake of linoleic acid 
(LA, 18:2«-6) and a-linolenic acid (LNA, 18:3«-3) is essential to provide substrates for 
synthesis of other n-6 and n-3 fatty acids respectively. The series of n-6 and «-3 fatty acids are 
metabolites with either one double bond extra (desaturalion) or 2-carbon chain elongated. For 
example, consumed LA can be converted via γ-linolenic acid (GLA, 18:3w-6) and dihomo-γ-
linolenic acid (DGLA, 20:3«-6) into arachidonic acid (AA, 20:4«-6) by the pathway outlined 
in Figure 3. Using the same pathway of desaturases and elongases, dietary LNA can be 
converted into stearidonic acid (SA, 18:4M-3) and eicosapentaenoic acid (EPA, 20:5/1-3). 
Furthermore, studies indicate that in human formation of docosahexaenoic acid (DHA, 22:6n-
3) from 20:5n-3 or formation of 22:5/i-6 from AA (20:4/1-6) involves a direct chain elongation 
(with 4 C-atoms) and A6-desaturation of these precursors followed by a 2-carbon chain 
shortening (also called the Sprecher pathway)165167. 
Desaturalion is an oxidative process requiring oxygen, reduced pyridine nucleotide and an 
electron transfer system consisting of a cytochrome and related reductase enzyme. Animals 
and humans cannot introduce double bonds beyond the Δ9 position, in contrast to plants and 
insects that have Δ12 and Δ15 desaturases. Clear evidence exists for Δ5, Δ6, Δ9 desaturases in 
a variety of animal and human tissues'68. In contrast, Δ4 desaturase has not been confirmed by 
direct enzyme characterization. The 2-carbon elongation process comprises a number of 
component reactions involving fatty acyl-CoA synthetases, condensation enzymes, reductases 
and dehydrases. The liver has high activity of both elongase and desaturase enzyme systems. 
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However, when long chain fatty acids are not supplied adequately in the diet, the most 
important source of acyl chains larger then 16 carbons is from chain elongation in the 
endoplasmatic riticulum in many tissues. Elongase and desaturase enzymes can be influenced 
by diet. For instance, fasting was shown to depress elongation. Since n-6 and w-3 fatty acids 
are desaturated and elongated by the same enzymes, they compete in the synthesis of their 
metabolites (Figure 3). Actually, simultaneous feeding of deuterated-LA and LNA to human 
subjects indicated that conversion of LNA to EPA and DHA exceeds conversion of LA to 
AA"9. 
The precise proportion of AA in human immune cells varies according to the culture/society, 
the exact cell types studies, and the lipid fraction examined. A common mixture of human 
mononuclear cells from a Western society contains approximately 15-25% arachidonic acid, 
6-10% LA, 1-2% DGLA, 0.1-0.8% EPA and 2-4% DHA170171. 
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Anti-oxidants for prevention of lipid peroxidation 
Polyunsaturated fatty acids are susceptible for peroxidation Vitamin E is a fat-soluble anti­
oxidant that protects PUFAs in phospholipids of biological membranes and in plasma 
lipoproteins against lipid peroxidation presumably by functioning as a electron donor to free 
radicals'7' Vitamin E is the general term for all tocopherols and tocotrienols, which consist of 
four homologues the α-, β-, γ-, and δ-tocopherols or tocotrienols The biologically most 
active form is a-tocophcrol, which is also the most widely available from of vitamin E in 
food174 The requirement of vitamin E increases with the amount and degree of unsaturation of 
the PUFAs consumed However, the precise amount of vitamin E required to compensate for 
the increased demand caused by dietary PUFA has not been determined exactly yet and are 
merely extrapolated from animal data173 Interestingly, the vitamin E content of lymphocytes 
and mononuclear cells is usually ten times greater than that found in platelets and red blood 
cells175 In membrane lipids a synergism of vitamin E and ascorbic acid (vitamin C) to provide 
anti-oxidant protection was suggested17"77 For this, vitamin C would donate an electron for 
the regeneration of tocopherol from the tocopheryl radical178 Deficiency in vitamin E and C 
was associated with an impaired immune response, while supplementation of these vitamins 
was shown to improve the immunity in some, but not all, studies179 '82 
1.6 Effect of polyunsaturated fatty acids (PUFAs) on immune function 
Most studies on «-6 and M-3 fatty acids are performed by administration of naturally occurring 
oils rich in these PUFAs Below an overview of common applied oils and their expected fatty 
acid composition is given 
Table 2 bxample;. of the expected falty acid composition of some edible oils"0 l8'' 
Percentage of fatty acids 
Oil source 
Olive 
Maize 
Soybean 
Sunflower 
Borage 
Evening primrose 
Blackcurrant seed 
Linseed 
Echium 
Fish (menhaden) 
SAFA 
18 
13 
16 
12 
15 
8 
8 
10 
11 
29 
MUFA 
75 
28 
26 
21 
24 
12 
14 
18 
16 
24 
LA 
15 
56 
54 
62 
37 
72 
46 
14 
15 
1 
GLA 
1 
-
-
-
23 
8 
15 
-
10 
-
AA 
-
-
-
-
-
-
-
-
-
2 
LNA 
-
1 
6 
0 1 
0 3 
-
14 
54 
33 
2 
SA LP 
-
-
-
-
-
-
3 
-
14 -
16 
Abbreviations SAFA, saturated fatty acids, MUt-A, mono-unsaturated fatty acids, LA, Imoleic acid 
(18 2«-6), GLA, γ-linolcnic acid (18 3η-6), AA, arachidonic acid (20 4n-6), LNA, linolcmc acid 
(18 3«-3), SA, steandonic acid (18 4n-3), EPA, eicosapcntaenoic acid (20 5n-3) DMA, 
docosahexaenoic acid (22 6«-3) 
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#1-6 PUFAs 
In immune-cells, liver and most other tissues of animals, the members of the n-6 family that 
accumulate in relatively large quantities are LA and AA. Much lower levels of the 
intermediates GLA and DGLA are observed. Dietary supplementation with GLA or AA rich 
oils increased the amount of PGEi or PGE2 produced by leucocytes (Figure 3)'85187. 
Effects of LA, which can be found in sunflower oil, on immune function have only been 
reported in a limited amount of studies. Overall, these studies suggest that dietary LA exerts 
little inhibitory effects on lymphocyte proliferation, NK activity and IgG and IgM production 
in rodents and human171 """'". 
Several studies described that GLA has anti-inflammatory effects190. GLA inhibited TNF-a 
and IL-lß production in in vitro studies with monocytes""92. Studies with healthy human 
individuals report decreased production of TNF-a, IL-1 and IL-6 by monocytes after 
supplementation of GLA-rich oils191 '". GLA also inhibited proliferation of human and rodent 
T-cells in in vivo and in vitro studies"4"'9'. Intake of GLA rich products reduced the symptoms 
of rheumatoid arthritis200202. However, a number of other supplementation studies that 
supplemented less than 1 g GLA per day reported no effects17'20,2M. It was therefore suggested 
that intake of approximately 1 to 2.4 g per day is required to have immuno-modulatory effects 
in humans188. 
Effects of DGLA are outlined below. 
Although in literature AA is usually linked to unwanted effects on immunity, in vivo or 
human studies have actually no been able to confirm this. No effects of AA supplementation 
were found on lymphocyte proliferation, natural killer (NK) cell activity, delayed type 
hypersensitivity (DTH) responses, cytokine production by monocytes and antibody responses 
in human studies'88. However, a few in vitro studies reported increased IL-lß production by 
monocyles20\ increased tissue factor expression206, and, in contrast, inhibition of lymphocyte 
proliferation and IL-2 production188. 
n-3 PUFAs 
The most abundant n-3 fatty acids in animal tissues are EPA and DHA. Enrichment of n-3 
fatty acids in body tissues is dependent on the levels of dietary intake of these PUFAs. 
Generally, increases in n-3 content are at the expense of n-6 fatty acids, within a narrow limit 
of an overall unsaturated fatty acid content in biological membranes. As a result of this, a 
change in production of eicosanoid-subclasses is induced: synthesis of 3-series prostanoids 
(PGE3, TXA3) and series-5 leukotrienes (LTB5) is increased, whereas the 2-series eicosanoids 
are decreased (Figure i)1»7207208. 
In vitro and dietary studies with rodents indicated that LNA reduced PGE2 synthesis209 and 
inhibits production of IL-2, lymphocyte proliferation, NK cell activity and the graft versus 
host response"8. High intake of LNA by humans (>12g/day) significantly reduced IL-1 and 
TNF-a production by LPS stimulated monocytes210, lymphocyte proliferation and the DTH 
response2". Supplementing human individuals with 2 g/day of LNA did not change NK cell 
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activity, lymphocyte proliferation and cytokine production by mononuclear cells212 
Steandonic acid (SA, 18 4«-3), the direct elongase product of LNA, has only been studied 
scarcely In vitro studies described inhibition of platelet aggregation by SA2" and inhibition of 
the lipoxygenase pathway214 A dietary study with mice reported inhibition of TNF-a 
production by whole blood cultures215 
EPA and DHA are abundantly studied fatty acids In most human studies, immune-
suppression was reported EPA/DHA supplementation reduced the amount of AA in 
tissues"021"" and the eicosanoid production from AA (PGE2, prostacyclin, LTB4)2172"225 In 
vitro and in vivo studies describe that EPA/DHA inhibit IL-2 production"*, T-cell 
proliferation, NK and graft versus host responses1"226227 Also, activity of mononuclear 
phagocytes was inhibited by EPA/DHA a decreased production of TNF-a and/or IL-Iß was 
observed in studies with mice228, rats222229 and in human studies2"22*21" EPA/DHA also 
inhibited the antigen-presenting fimction of rat dendritic cells2" and human monocytes2322" 
Surprisingly, in other studies using mice, EPA/DHA increased in vivo or ex vivo TNF-a 
production2202252'4257 
A number of mechanisms were suggested by which w-3 PUFAs exert beneficial effects Fish 
oil decreased the macrophage TNF-a gene transcription, possibly by altering the NFKB 
activity2382" Since EPA and DHA inhibited the increase in tissue factor expression and TXA2 
synthesis induced by AA, and it was suggested that «-3 PUFAs modulate the procoagulant 
activity of AA206 It was also suggested that n-3 PUFAs inhibit the expression of COX-2 by 
the inhibition of TLR-mediated signalling pathways and target gene expression137 Opposite to 
this, another m vitro study described augmentation of COX-2 expression, which was related 
to reduced PGE2 synthesis induced by EPA240 Also, EPA and DHA inhibited MAP-kinase 
activation of human Τ cells via PKC-dependent and independent pathways241 
1.7 Dihomo-Y-linolenic acid (DGLA) 
Human studies 
DGLA was administered orally to healthy human individuals in a few studies'™,4 ,'" All 
studies describe that DGLA is well tolerated and absorbed The first study from Kernoffet al 
(1977)8' applied DGLA (0 1 to 2 g/day of free acid, methyl or ethyl esters, and duration 
maximal 2 weeks) in order to investigate Us anti-thrombosis potentidl"' After prolonged 
DGLA supplementation of one case (1 to 2 g/day, free acid), increased DGLA A A ratio was 
observed from 0 2 to 0 6 in plasma and from 0 05 to 0 18 in platelets Small increases in 
plasma AA content, but not platelets, were sometimes observed The PGE: production by 
platelets was increased to a maximum of approximately four-fold This was paralleled by a 
less considerable increases in PGE2 production, although the absolute concentrations of PGE2 
were not shown Moreover, DGLA supplementation inhibited ex vivo platelet aggregation A 
second study from Stone et al (1979) using deuterium-labelled DGLA again showed that the 
DGLA AA ratio in plasma is increased from 0 2 to 0 6 after dietary supplementation of 0 5 to 
2 g/day Only a minor dose-response curve was observed between the amount of DGLA 
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administered and the DGLA concentration in plasma. This indicates that 0.5 g/day already 
exerts pronounced effects on the plasma fatty acid composition. The majority of DGLA was 
found in the phosphatidylcholine and triglyceride fractions. Also, PGE| synthesis by thrombin 
activated platelets was increased after supplementation. In contrast to other studies, PGE2 
synthesis was also increased and strongly exceeded the increase in PGEi in absolute amounts. 
This finding is difficult to interpret, as no appearance of in deuterium-labelled AA was found 
in platelets after DGLA supplementation. In the third study from El-Boustiani (1986)245 a 2 g 
bolus of deuterium-labelled DGLA was applied. It was described that only very small 
amounts of AA metabolized from DGLA occurred in plasma, whereas in platelets DGLA was 
not further metabolized to AA. 
Animal studies 
Oral supplementation of rats with 300 mg/day of DGLA (ethyl ester) increased the DGLA 
concentrations in plasma and tissue triacylglycerols and to a much lesser extent in 
phospholipids. In platelets no increase in AA levels was observed after DGLA 
supplementation244, which is in line with the human studies described above. Furthermore, it 
has been shown that guinea pigs supplemented with DGLA transformed DGLA by the 
epidermis into PGEi and the 15-LOX product 15-hydroxy-eicosatrienoic acid (15-HETrE}245. 
One study on dimelhylzcnz(alpha)anthracene-induccd mammary tumors in rats showed no 
pronounced effects of DGLA on tumor growth24*. 
In vitro studies 
In vitro studies with human neutrophils247, murine macrophages, human monocytes and 
human platelets24" demonstrated that that supplementation of DGLA lead to increased DGLA, 
but not AA, concentrations in these cells. This indicates that these cells lack or have little Δ5-
desaturase activity. Furthermore, increased DGLA concentrations, obtained by incubation 
with GLA, showed that the majority of the DGLA was present in the triacylglycerols and less 
in the phospholipid fraction24'. 
In murine peritoneal macrophages, DGLA was converted into IS-HETrE24* and this product 
effectively inhibited leukotriene (LTB4) generation in peritoneal macrophages250. Similar 
observations were found for human mononuclear leukocytes and neutrophils after DGLA 
supplementation and stimulation with a calcium ionophore214247251. 
Studies on monocytes and cytokine production reported conflicting effects of exogenously 
added DGLA. In a study from Rothman et al. DGLA (30-100 μΜ, 24 h pre-incubalion) 
increased the IL-1 β secretion of LPS stimulated THP-I cells and human PBMC252. Similar 
results were obtained in a study using a human monocyte cell line (U937) and a similar 
concentration range of DGLA205. In contrast, DeLuca el al.1" have shown inhibition of TNF-a 
and IL-Iß production of DGLA by LPS stimulated human PBMC. Results of an in vitro study 
using human blood monocytes indicated that DGLA positively influenced phagocytic 
activity25'254. 
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In a study using adherent synovial cells in tissue culture DGLA suppressed the proliferation 
of these cells The effects were related to the production of PGE| from DGLA, since PGEi 
was found more effective than PGE2 in exerting anti-prolifcrative effects, whereas 
indomelhacin abolished the effects of DGLA25S The described effects of DGLA on mitogen 
induced human T-cell proliferation or IL-2 production are merely inhibitory"825625" DGLA 
also strongly inhibited the mitogen induced proliferation of synovial fluid and tissue 
lymphocytes'" and IL-2 induced proliferation of a murine T-cell line2" Two studies reported 
that the effects on IL-2 production or T-cell proliferation were independent of COX 
activation257259 It was also indicated that the inhibitory effects on T-cell proliferation were not 
due to a non-specific impairment of the Ca2H influx through membrane Ca2+ channels25" It 
was hypothesized that DGLA supplementation of the PI phospholipid fraction might result in 
synthesis of DGLA-nch diacylglycerol (DAG) after cell stimulation259 DAG stimulates 
protein kinase-C (PK.C) directly and it was therefore suggested that DGLA enriched DAG can 
influence PK.C activity differently than the usual DAG acyl groups (such as AA or LA) In 
fact, the acyl groups of DAG were shown critical determinants of PK.C activity260261 and a 
commercial PK.C activator reversed the inhibitory effects of DGLA259 Also, DGLA 
suppressed the total PKC activity of Τ cells in response to PMA activation2'2 
In line with the human studies described above, inhibition of human platelet aggregation by 
DGLA (80 μΜ) in vitro was observed265 It was found that human platelets produce equal 
amounts of TXBi and PGEi from DGLA, whereas after incubation with AA, TXB2 was the 
dominant product and PGE2 was produced in less amounts264 Therefore, the anti-aggretory 
effects of DGLA might relate to the anti-aggretory effects of PGEi or the decreased 
production of thromboxanes 
Furthermore, in vitro studies have indicated that the C20 fatty acids DGLA and EPA have a 
different specificity for COX-1 and COX-2 enzymes DGLA was found to have a lower 
specificity for COX-1, whereas COX-2 affinity was similar to the specificity of AA65166 EPA 
had a much lower affinity for both COX-1 and COX-2 than AA'65 
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1.8 This dissertation 
Aim 
The studies of this thesis are focused on the effects of PUFAs in general and DGLA more 
specifically, on cellular fatty acid composition, cytokine production, endotoxemia and cancer. 
Outline of the thesis 
Although the exact mechanisms by which GLA and EPA-rich oils influence inflammatory 
conditions are still unknown, it was suggested that a change in synthesis between the PGE-
subtypes could be involved. Therefore, in Chapter 2, we aimed to answer the question 
whether the PGE-subtypes derived from DGLA (PGE,), AA (PGE2) and EPA (PGE3) differ 
in their capacity to modulate cytokine production. In Chapter 3 direct effects of PUFAs on the 
fatty acid composition and endotoxin induced cytokine production of PBMCs were 
investigated. In addition, we aimed to find the mechanism by which one particular fatty acid, 
DGLA, modulated cytokine production. For that reason, direct effects of some eicosanoids 
and inhibition of COX activity were studied. Subsequently, we investigated effects of dietary 
DGLA in mice. These studies, described in Chapter 4, were conducted to gain more 
information about the effects of DGLA on endotoxin induced cytokine production and tissue 
fatty acid composition after in vivo application. An attempt was made to correlate the effects 
on cytokine production to a change in survival after endotoxemia. In chapter 5 we describe a 
comparison of DGLA, GLA, AA and EPA for their effects on melanoma growth and 
metastasis in mice, correlated to differences in fatty acid metabolism and a change in DTH 
response. Chapter 6 describes an in vivo study, in which combinations of oral SA, GLA and 
EPA are used in order to stimulate DGLA accumulation. Finally, in Chapter 7 the main 
results of this thesis are discussed and a summery of results is presented in Chapter 8. 
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The modulatory effects of prostaglandin-E on cytokine production by 
human PBMC are independent of the prostaglandin subtype 
Abstract 
The production of inflammatory mediators, relevant to (auto)immune diseases and chronic 
inflammatory conditions, can be modulated by dietary intake of «-3 and w-6 long chain 
polyunsaturated fatty acids (PUFAs). It was suggested that these effects are related to the 
formation of different series of eicosanoids, in particular prostaglandin-E (PGE). In this study 
we investigated whether prostaglandin subtypes metabolized from arachidonic acid (PGE2), 
dihomo-y-linolenic acid (PGE|) or eicosapentaenoic acid (PGE3) have different effects on T-
cell proliferation and cytokine production in vitro. Freshly isolated human peripheral blood 
mononuclear cells (PBMC) were stimulated with concanavalin-A (ConA) or 
lipopolysaccharide (LPS) in the presence or absence of exogenous PGEi, PGE2 or PGE3. We 
found that tumor necrosis factor-α (TNF-a), interferon-γ (IFN-γ) and to a lesser extent 
interleukin-10 (IL-10) production was inhibited by all PGE-subtypes in ConA stimulated 
PBMC concomitant with unaffected IL-2 levels. The modulated cytokine production of ConA 
stimulated cells was independent of T-cell proliferation. PGE2 and PGEi moderately 
stimulated proliferation, while PGE3 inhibited the proliferative response to some extent. In 
LPS stimulated PBMC, TNF-a production was inhibited by all PGE-subtypes, whereas IL-6 
remained unaffected and IL-10 production was increased. Time course experiments on the 
effects of PGE-subtypes on cytokine production after ConA or LPS stimulation showed these 
effects to be time dependent, but indifferent of the prostaglandin subtype added. Overall, the 
modulatory effects of PGE on cytokine production were irrespective of the subtype. This may 
implicate that the immuno-modulatory effects of PUF As, with respect to cytokine production, 
are not caused by a shift in the subtype of PGE. 
Maaike M.B.W. Dooper, Lianne Wassink, Laura M'Rabet and Yvo M.F. Graus 
Immunology. 107(1), 152-159,2002. 
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Introduction 
Nutrition is a feasible tool for modulating immunity and its potential use was increasingly 
subjected to human studies during the last decade. Special attention has been paid to the 
modulatory effects of the nutritional components long chain polyunsaturated fatty acids 
(PUFAs) on immune function267268. The inclusion of marine derived «-3 PUFA in the diet for 
instance was shown to decrease the production of pro-inflammatory cytokines like tumor 
necrosis factor-α (TNF-a) and interleukin-1 β (IL-Iß) by monocytes in healthy subjects2102"226, 
and in patients with rheumatoid arthritis26'. From these studies on the modulatory effects on 
cytokine production a role was suggested for prostaglandins, a class of lipid mediators 
(eicosanoids), which arc derived from 20 carbon atom PUFA2™. 
In non-supplemented individuals the prostaglandin-E (PGE) subtype usually synthesized in 
large quantities during an inflammatory response is PGE2. The immediate precursor of PGE2 
is the n-6 fatty acid arachidonic acid (AA, 20:4«-6), which is one of the most abundant PUFA 
in mammalian cellular membrane phospholipids67. Consumption of fish oil rich in 
eicosapentaenoic acid (EPA, 20:5«-3) results in decreased AA levels and increased EPA 
levels. As EPA is the precursor fatty acid for the synthesis of the prostaglandin subtype PGE3, 
this consequently results in increased production of PGE3 at the expense of PGE22'7270273. Thus, 
the change in fatty acid composition consequently shifts the production of eicosanoids from 
AA, such as PGE2, to eicosanoids derived from EPA, such as PGE3. In addition, an alternative 
prostaglandin subtype PGEi is synthesized from the M-6 fatty acid dihomo-y-linolenic acid 
(DGLA, 20:3/1-6), which is a metabolite from γ-linolenic acid (GLA, 18:3«-6) that is naturally 
occurring for instance in borage oil190·274. Similar to fish oil, consumption of GLA rich oils was 
found to exert beneficial effects in inflammatory disorders2"0202275 and to reduce production of 
pro-inflammatory cytokines'" "2. 
In vitro and in vivo studies have shown that prostaglandins can affect cytokine production 
directly during an inflammatory response. For instance, the production of T-helper cell-1 
(Thl) cytokines like intcrferon-γ (IFN-γ)276277 and monocyte derived cytokines like TNF-a are 
downregulated by PGE2 in vitro"" '0127". In general, PGE] and PGE3 are thought to have a 
distinct biologically potency than PGE2 and arc therefore usually associated with a decreased 
inflammatory response. Thus, it has been anticipated that as a result of changing the amounts 
and types of eicosanoids produced, fish oil and borage oil influence the magnitude of immune 
responses27'. 
In this study, we investigated whether the immuno-modulatory effects of dietary PUFAs are 
mediated by a shift in production of the type of PGE by investigating the direct effect of 
exogenous PGEi, PGE2 and PGE3 on cytokine production of human peripheral blood 
mononuclear cells (PBMC) induced by T-cell mitogen or endotoxin. From these experiments 
it becomes apparent that a shift in PGEi or PGEi over PGE2 production by dietary fatty acid 
modulation can not solely explain the reduction in pro-inflammatory cytokine production 
observed in human dietary studies with GLA or EPA rich sources. 
— 28 — 
Chapter 2 
Methods 
Materials 
Cells were cultured in RPMI 1640 containing 25 mM HEPES and 2 mM L-glutamine 
supplemented with 20% heat-inactivated human serum (HuS) (Bio-Whittaker, Vervicrs, 
Belgium), 12 5 mM D-glucose (Sigma-Aldnch Chemie BV, Zwijndrechl, The Netherlands), 
100 U/ml penicillin/streptomycin and 1 mM sodium pyruvate (both obtained from Gibco 
BRL, Life Technologies, Breda, The Netherlands) PGE| and PGE2 were obtained from 
Sigma-Aldnch Chemie BV (Zwijndrechl, The Netherlands), PGE3 was obtained from 
Cayman Chemical Company (Ann Arbor, USA) Lipopolysacchande (LPS, B05 55), (±)-a-
tocopherol and ascorbic acid were obtained from Sigma-Aldnch Chemie BV FicoU (Ficoll-
Paque®) was obtained from Amersham Pharmacia Biotech AB (Uppsala, Sweden) 
Concanavalm-A (ConA) and 5-bromo-2'-deoxyuridine (BrdU) assays were obtained from 
Boehringcr Mannheim WST-1 assay was obtained from Roche Diagnostics Nederland BV 
(Almere, The Netherlands) Indomethacin was obtained from ICN Biochemicals (Zoetermecr, 
The Netherlands) 
Cell isolation and culture conditions 
PBMC were isolated from buffy coats by density-gradient centrifiigation In short, buffy coat 
cells were dispensed over five 50 ml falcon tubes, phosphate buffered saline (PBS)/2% fetal 
calf serum (FCS) solution was added to reach a volume of 20 ml and 10 ml Ficoll-Paque® 
was gently added under the diluted buffy coat cells Centrifiigation was performed at 400 χ g 
for 20 minutes at room temperature (RT) and washing of PBMC was done three times with 
PBS/2%FCS Culture of freshly isolated PBMC was performed in the presence of 20% HuS 
Shortly before addition to cells, HuS was enriched with alpha-tocopherol and L-ascorbic acid 
to the final culture concentrations of 25 and 75 μΜ respectively PGE stock solution was 
prepared by dissolving PGE in ethanol and diluting the solution 1 10 in PBS to a 
concentration of 1 mg PGE per ml Addition of PGE to culture medium was performed by 
adding the adequate amount of PGE stock solution to HuS resulting in final concentrations as 
indicated in the text The ethanol concentration in the culture medium never exceeded 0 1% 
Indomethacin (105 M) was added to the culture medium to inhibit endogenous production of 
prostaglandins Cells were plated at 1 5 106 cells/ml in flat bottom 96-wells culture plates in 
a volume of 200 μΐ per well and incubated at 370C in a humidified 5% CO2 atmosphere T-
cell proliferation was induced by ConA stimulation (10 μg/ml) for 48 h and monocyte 
stimulation was performed with LPS (100 ng/ml) for 20 h 
PCEi and PGE2 measurements in culture medium 
ELISA kits from R&D systems were used (Wiesbaden-Nordenstadt, Germany) to measure 
PGE| in culture medium PGE2 was quantified by the Biotrak PGE2 competitive enzyme 
immunoassay system (Amersham Pharmacia Biotech, Freiburg, Germany) The cross-
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reactivity of the PGEi ELISA was 21% with PGE2 and 2% with PGE3. The PGE2 ELISA 
cross-reacted 4% with PGE, and 33% with PGE3. 
Proliferation assay 
Cell proliferation was measured by a colorimetrie immunoassay using incorporated nuclear 
BrdU according the manufacturers guidelines. In short, cells were stimulated with ConA for 
48 h and BrdU incorporation was allowed over the final 16 h of culture. After removal of the 
culture medium, cells were fixed to the bottom of the plates and incorporated BrdU was 
quantified by anti-BrdU-peroxidase antibody and tetramethylbenzidinc (TMB) substrate. 
Extinction was measured at 450 nm. 
Measurement of cytokine production 
The concentrations of cytokines in culture supematants were determined by specific ELISA 
according to the manufacturer suggestions. TNF-a and IL-6 were measured with ELISA kits 
from BioSource (Nivelle, Belgium). IFN-γ and IL-10 were measured with ELISA kits from 
the Central Laboratory for Blood Transfusion (Amsterdam, The Netherlands). IL-2 was 
determined using antibody pairs from Pharmingen (Hamburg, Germany). Results for all 
cytokines represent the mean of triplicate incubations. 
Statistical analysis 
Statistical evaluation of differences among PGE treated cells and control cells were calculated 
by two-way analysis of variance (ANOVA) with factors 'PGE concentration' and 'donor'. 
Parameters to be analyzed were viability, proliferation and cytokine production. Differences 
were considered significant at P<0.05. 
Results 
Kinetics of cytokine production during ConA or LPS stimulation of human PBMC. 
In order to characterize the in vitro model used, we measured the kinetics of cytokine 
production in supematants at different time intervals after addition of ConA or LPS. TNF-a 
was the first cytokine detected after stimulation with ConA and increased in concentration 
during the incubation period of 48 h. IFN-γ was detectable from 6 h on and maximal amounts 
of IFN-γ were measured at 24 and 48 h of ConA stimulation. IL-2 and IL-10 were not 
detected until 8 h after addition of ConA, but increased during the remaining 40 h stimulation 
period (Figure 1). 
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Figure 1. Kinetics of ConA or LPS induced cytokine production. Human PBMC were 
cultured with ConA (10 μ^πιΐ) or LPS (100 ng/ml) and the amount of cytokines released 
into the culture supernatant was measured at the time points indicated by ELISA. Each 
data point represents the mean ± SD of 5 determinations from one representative donor 
(11=3). 
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Figure 2. Effects of prostaglandins on ConA induced cytokine production. PBMC were 
stimulated with ConA for 48 h in presence or absence (control) of PGEi, PGE2 or PGE^ 
Values are expressed as percentages of control and are mean ± SD for triplicate 
determinations using PBMC from 6 blood donors. The absolute values of the controls 
were 2471±788 (TNF-ct), 245±137 (IL-2), 1678±1432 (IFN-γ) and 68±21 (1L-10). * 
P<0.05 for values of both PGE,, PGE2 and PGE3 compared to control. 
Effects of PGE-subtypes on production of T-cell cytokines and T-cell proliferation. 
To investigate the effects of PGE-subtypes on a T-cell dependent immune response, PBMC 
were cultured with different concentrations of PGEi, PGE2 or PGE3 added to the culture 
medium and stimulated at the same time with ConA for 48 h. The background of 
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prostaglandins in the culture medium containing 20 % human serum in absence of cells was 
4.8 ng/ml (1.3· 10"" M) PGE, and 0.5 ng/ml ( lAlO" 1 4 M) PGEj. 
PGE subtypes dose dependently inhibited TNF-a, IFN-γ and to a lesser extent IL-10 
production, whereas IL-2 levels were unaffected (Figure 2). TNF-a production was inhibited 
by approximately 80% (IC-50 at 0.5-10-7 M PGE) and simultaneously IFN-γ production was 
inhibited by approximately 50% (IC-50 at 110-6 M of PGE). Production of IL-10 was 
decreased at concentrations of 1-108 to 110-6 M by approximately 25%. Moreover, the 
effects seen on production of the four different cytokines were irrelevant of the subtype of 
PGE. 
Subsequently, we investigated whether the modulatory effects of PGEs on cytokine 
production were reflected by a change in proliferation. PGE2 moderately stimulated T-cell 
proliferation at concentrations of 1-10"8 to 110"" M, whereas PGEi induced similar increases 
in proliferation at 1-I0'9 to 110"" M. In contrast, addition of PGEj induced a decrease in 
proliferation at concentrations of 1-10-7 and 1-10-6 M (Figure 3). Therefore, it appears that 
the PGE-subtype independent effects on cytokine production arc not closely mirrored by the 
proliferative response. 
PGEi PGE2 
rctidOM) PGL.OOM) 
Figure 3. Effects of prostaglandins on 
ConA induced T-cell proliferation. PBMC 
were stimulated with ConA for 48 h in 
presence or absence (control) of PGEi, 
PGE2 or PGE3. Values are expressed as 
percentages of conlrol and are mean ± SD 
for triplicate determinations using PBMC 
from 8 blood donors. Mean stimulation 
index of controls was 2.51 ± 0.75. *P < 
0.05 from control value. 
Effects of PGE-subtypes on LPS induced cytokine production. 
We investigated the effects of PGEi, PGE2 and PGEj on cytokine production of LPS 
stimulated PBMC. PGEi, PGE2 and PGE3 induced a dose dependent modulation of cytokine 
production (Figure 4). A strong inhibition of TNF-a to almost undetectable levels was 
— 32 — 
PGEj 
3 
I - 1 
S-'* 
ί* 
Chapter 2 
observed (IC-50 at 0.5· 10-7 M of PGE), whereas IL-6 levels were unaffected. In contrast, IL­
IO increased dose dependently to a maximum of approximately 200 percent compared to 
control incubations. Overall, we observed these dose response effects to be independent of the 
subtype of prostaglandin added. 
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Figure 4. Effects of prostaglandins on LPS 
induced cytokine produclion. PBMC were 
stimulated with LPS for 20 h in presence or 
absence (control) of PGEi, PGH2 or PGEj. Values 
arc expressed as percentages of control and are 
mean ± SD for triplicate dclerminalions using 
PBMC from 9 blood donors The absolute values 
of the controls were 7028±3314 (TNFct), 
32981 ±22452 (IL-6) and 1059±624 (1L-10) pg/ml. 
* /»-cO.OS for values of both PGE,, PGE2 and PGEj 
compared to control values. 
Time course of modulatory effects of PGE-subtypes on cytokine production. 
As we observed no differential effects between the PGE-subtypes on cytokine production 
when PGE was added just before cell stimulation, we investigated whether the subtypes differ 
in their effects at time points after stimulation. Therefore, we stimulated PBMC with ConA or 
LPS and added the PGE-subtypes just before or at different time intervals after addition of the 
stimulus. It was found that the ability of the PGE-subtypes to exert inhibitory effects on 
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cytokine production declined during the culture period. The inhibition of TNF-α production 
remained constant during the first 6 h of ConA stimulation and was abrogated when the PGE-
subtypes were added at later time points (Figure 5). The inhibitory effect on TNF-a 
production by PBMC after stimulation with LPS remained apparent for 1 h after stimulation 
and then gradually declined to control levels within the following 5 h (Figure 5). Moreover, 
we observed no differential effects of the PGE-subtypes when added at different time 
intervals after ConA or LPS stimulation. 
ConA 
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Figure 5. Time course of inhibitory effect of prostaglandins on TNF-α production. 
PBMC were stimulated with LPS at timepoint 0 and subsequently PGE,, PGE2 or PGE3 
(ΙΟ"6 M for ConA and ΙΟ"7 M for LPS stimulation) was added at different time points. 
Supernatants were analyzed for cytokine production 48 h (ConA) or 20 h (LPS) after 
stimulation. Values are expressed as percentages of control (no PGE added) and are mean 
± SD for triplicate determinations using PBMC from 4 (ConA) or 6 (LPS) blood donors. 
*P<0.05 of values compared to control (no PGE added). 
Discussion 
The modulation of immune function by dietary «-3 or «-6 PUFAs has been studied 
intensively267. It was suggested that the mechanism of these modulatory effects on the immune 
response by PUFAs might involve eicosanoid synthesis from DOLA, AA or EPA into PGEi, 
PGE2 or PGE2 respectively270. PGEs are physiologically present in body fluids at low 
concentrations within the range of picomolar to nanomolar concentrations, but may locally 
rise to micromolar concentrations during inflammatory conditions"1". By investigating 
relevant PGE concentrations, we found that PGEi, PGE2 and PGEj have similar effects on 
cytokine production by PBMC indifferent of the time point of PGE addition, that is, before or 
after induction of cell stimulation. This indicates that changes in cytokine production by 
specific dietary PUFAs may not be mediated by a shift from predominantly PGE2 to other 
PGE subtypes. Therefore, w-3 and n-6 PUFA rich oils like fish oil (rich in EPA) and borage 
oil (rich in GLA) may exert their beneficial effects on cytokine production in inflammatory 
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conditions via a PGE-subtype independent mechanism 
The effects of PGE2 on cytokine production of T-cells using an in vitro cell system have been 
described before Downregulation of Thl cytokine production accompanied by largely 
unaffected Th2 cell function by PGE2 was described for human T-cells280 and T-cell 
clones'06281 In line with this, we observed a bias towards down regulation of Thl over Th2 
cytokine production in ConA stimulated PBMC dependent on the levels of PGE present 10 
M PGE inhibited production of both Thl cytokine IFN-γ and Th2 cytokine IL-10, whereas 
very high concentrations of PGE (10"6 M) inhibited IFN-γ production more than IL-10 
production The m vivo significance of this observation is unclear PGE2 determinations in 
joint fluid of rheumatoid arthritis patients have shown levels of approximately 10 10 M282 and 
similar levels were found in plasma of mice after intraperitoneal injection of LPS22' However, 
it is anticipated that local PGE production may reach 10-6 M, since PGE levels within the 
micromolar range were found after ex-vivo rcstimulation of osteo-arthntis affected human 
cartilage75281 Moreover, the administration of cyclooxygenase inhibitors to Balb/c mice was 
found to promote a Thl response284 and antigen-specific IFN-γ production107, indicating 
involvement of PGE2 in Thl downregulation in vivo 
Despite the fact that we observed no differences in cytokine production between PGE-
subtypes, we measured differential effects on T-cell proliferation PGEi exerted inhibitory 
effects at high concentrations while PGE| and PGE2 induced an increase in proliferation at 
low concentrations This is in contrast with previous findings that have shown that both PGE2 
and PGE3 induced a strong reduction of T-cell proliferation using rat285™ or human1"2812'7288 
lymphocytes In the study using ConA stimulated human PBMC287, PGE3 was described to be 
more potent than PGE2285, which is in line with our data However, currently described effects 
of PGE-subtypes on T-cell proliferation were marginal and insufficient to induce a PGE-
subtype dependent cytokine production Moreover, it has been known that the proliferative 
responses of T-cells are strongly affected by IL-2 levels289 The IL-2 levels induced in the 
present study were well detectable and within ranges to be expected after ConA stimulation of 
human PBMC in vitro290 Inhibitory effects on IL-2 production by PGE would therefore have 
been detected if present Consequently, it is rational that the unaltered IL-2 production seen in 
our study is not accompanied by strong inhibitory effects on T-cell proliferation Our data 
therefore suggest that during an inflammatory response cytokines like TNF-a and IFN-γ are 
more sensitive to PGE than other cytokines like IL-2 and the proliferative response In 
conclusion, it is conceivable that the immuno-modulatory effects of dietary fish or borage oil 
may not be induced by a PGE-subtype dependent modulation of T-cell proliferation 
Stimulation of PBMC with LPS activates monocytes directly and induces production of a 
wide range of mediators including the cytokines TNF-a, IL-lß, IL-6, IL-10 and IL-12, and 
eicosanoids (prostaglandins, leukotnenes) by the activation of oxygenase enzyme 
expression2"2" Early after stimulation the dominating products in supernatants of PBMC are 
inflammatory cytokines (TNF-a, IL-lß and IL-6) followed by an increased production of 
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anti-inflammatory mediators like IL-IO294 and prostaglandins at high concentrations2952", 
which are associated with resolution of inflammation In this model we observed that 
exogenous PGE induces a strong dose dependent inhibition of TNF-a production 
accompanied by an increase in IL-10 production This is in accordance with other studies 
describing downregulation of endotoxin induced TNF-a gene expression"" and production by 
exogenous PGE2 for human monocytes'8 ""'27e, rat macrophages2*7 and murine macrophages2" 
In addition, upregulation of the ant 1-inflammatory cytokine IL-10 by PGE2 was observed in 
whole blood cultures'03"2 Although IL-10 is sufficient to inhibit prostaglandin5'29'302 and 
TNF-a"2 production, our data suggest that the inhibited TNF-a production by the PGE-
subtypes is independent of IL-10 PGE inhibits TNF-a production until 6 h after induction of 
LPS stimulation, whereas at that time point IL-10 is not yet produced This is in accordance 
with the finding that anti-IL-10 treatment of human monocytes stimulated with LPS did not 
abolish the TNF-a down regulation induced by PGE"2 Altogether, this suggests that the 
increased IL-10 levels seen after exogenous PGE treatment serves as an auto regulatory 
feedback to normalize PGE levels 
In conclusion, observations indicate that PGE|, PGE2 and PGE3 similarly affect cytokine 
production in human PBMC This may implicate that the immune-modulatory effects of 
PUF As, with respect to cytokine production, are not caused by a shift in the subtype of PGE 
Consequently, other mechanisms may be responsible for selective modulations by PUFAs, 
including synthesis of specific oxygenated metabolites from the different fatty acids For 
example, it was found that DGLA is not converted to a leukotnene product but is converted to 
a 15-hydroxyl derivative that can block transformation of A A to (pro-inflammatory) 
leukotnenes303 Individual PUFAs may also differ in their ability to modulate intracellular 
signalling, such as binding lo peroxisome prohferator-activated receplor-γ (PPARy)304305 or 
changing nuclear factor-icB (NFKB) 2 3 8 activity Overall, further studies with focus on 
signalling pathways are necessary to clarify the mechanism of the immuno-modulatory effects 
of PUFAs and the interactions of cytokines and prostaglandins during an inflammatory 
response 
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Dihomo-y-Linolenic Acid inhibits TNF-α production by human leukocytes 
independently of cyciooxygenase activity 
Abstract 
Dietary oils (such as borage oil), rich in γ-linolcnic acid (GLA) have shown to be beneficial 
under inflammatory conditions. Dihomo-y-linolenic acid (DGLA) is synthesized directly from 
GLA and forms a substrate for cyciooxygenase (COX) enzymes resulting in synthesis of lipid 
mediators (eicosanoids). In the present study immune-modulatory effects of DGLA were 
investigated and compared to other relevant fatty acids. Freshly isolated human peripheral 
blood mononuclear cells (PBMC) were cultured in fatty acids (100 μΜ) enriched medium for 
48h. Subsequently, cells were stimulated with lipopolysaccharide (LPS) for 20h and cytokine 
levels were measured in supernatants by ELISA. Phospholipids were analyzed by gas-
chromatography. Fatty acids were readily taken up, metabolized and incorporated into cellular 
phospholipids. Compared to other tested fatty acids, DGLA exerted pronounced modulatory 
effects on cytokine production. Tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) 
levels were reduced to 60% of control levels, whereas IL-6 levels were not affected by 
DGLA. Kinetic studies showed that peak levels of TNF-α early after LPS addition were 
inhibited strongly, whereas IL-10 levels were not affected until 15 h after stimulation. Both 
the reduction of cytokine levels and a decrease in arachidonic levels in these cells induced by 
DGLA were dose dependent, suggesting a shift in eicosanoid-subtype synthesis. However, 
although some DGLA derived eicosanoids similarly reduced TNF-α levels, effects of DGLA 
were likely not mediated by COX products since addition of indomethacin did not change the 
effects of DGLA. In conclusion, these results suggest that DGLA affects cytokine production 
by human PBMC independent of COX activation. 
Maaike M.B.W. Dooper, Boet van Riel, Yvo M.F. Graus and Laura M'Rabct. 
Immunology, 110, 348-357, 2003. 
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introduction 
Dietary intake of polyunsaturated fatty acids (PUFAs) has been recognized as a tool to 
suppress the magnitude of immune responses, which can be beneficial in inflammatory 
conditions18"26"106. Such fatty acids include both «-6 and «-3 PUFAs, for instance γ-linolenic 
acid (GLA, 18:2«-6)™2,>2 and eicosapentaenoic acid (EPA, 20:5w-3)3l>"10 respectively. The 
mechanism by with these fatty acids exert their beneficial effects in inflammatory diseases is 
not completely understood. However, ex vivo stimulation of peripheral blood mononuclear 
cells (PBMC) from human subjects supplemented with EPA- or GLA-rich oils led to 
decreased production of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-a) and 
interlcukin-lß(IL-lß)l,,2l,2M. 
Beside direct effects of PUFAs on cytokine production1" "2, it has been believed that a change 
in lipid mediator (eicosanoid) production is also involved in the effects of PUFAs5". 
Eicosanoids are derived from 20 carbons (C20) PUFAs released from phospholipids"2 and are 
synthesized by a number of enzymatic reactions. Rate limiting enzymes are cyclooxygenases 
(COX), which constitute synthesis of prostaglandins and thromboxanes, and lipoxygenases, 
which are involved in synthesis of leukotrienes"1. In western countries arachidonic acid (AA, 
20:4w-6) usually is the main C20 fatty acid present in phospholipids of immune cells. 
Therefore, AA derived eicosanoids are abundantly produced during inflammation 67. 
However, EPA can effectively reduce amounts of AA2" and intake of GLA results in 
increased amounts of dihomo-y-linolcnic acid (DGLA) by elongase conversion"1. Since EPA 
and DGLA are both C20 fatty acids, they can compete with AA for production of eicosanoids. 
The change in eicosanoid-subclasses might relate to the effects of fish and borage oil on ex 
vivo cytokine production, since some eicosanoids can affect cytokine production directly"8114. 
However, a recent study indicates that the shift in PGE-sublypes is unlikely to be responsible 
for the effects of PUFAs on cytokine production"5. 
As a result of the difficulty in providing dietary supplementation of highly purified fatly 
acids, a straightforward comparison of the abilities of «-3 and «-6 PUFAs to modulate 
cytokine production has not been made yet. Therefore, in the present study the main «-6 and 
«-3 PUFAs were compared for their direct effects on cytokine production of human PBMC. 
In this model, fatty acid composition of cells was effectively changed and cells were 
stimulated to produce cytokines, as well as eicosanoids, by endotoxin. Furthermore, it was 
investigated whether the effects of PUFAs on cytokine production are explained by the 
formation of different subclasses of eicosanoids. 
Materials and Methods 
Chemicals. 
Phosphate buffered saline (PBS), RPMI 1640 medium supplemented with L-glutamine and 25 
mM HEPES, penicillin/streptomycin and sodium pyruvate were obtained from Gibco BRL 
(Life Technologies, Breda, The Netherlands). Fatty acids (free acids), lipopolysaccharide 
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(LPS, B05:55), (±)-a-tocopherol, ascorbic-acid, dimethylsulfoxide (DMSO), BHT (butylated 
hydroxyloluene), ethylenediamineletraacetic acid (EDTA), prostaglandin-Ei (PGEi), PGE2, 
propidium iodide, and boron-trifluoride (BF3) were purchased from Sigma-Aldrich Chemie 
BV (Zwijndrecht, The Netherlands). PGE3, 15(S)-HETrE, leukotriene-B4 (LTB4), 
thromboxane^ (TXB2), TXB3, carbocyclic-thromboxane-A2 (ccTXA:) were obtained from 
Cayman Chemical Company (Ann Arbor, USA). WST-1 (4-[3-(4-lodophenyl)-2-
(nitrophenyl)-2H-5-tetrazolio]-l,3-benzene disulfonatc) reagent was obtained from Roche 
Diagnostics Nederland BV (Almere, The Netherlands). Chloroform, methanol, hcxanc and 
iso-octane were obtained from Merck (Darmstadt, Germany). Human serum was derived from 
Bio-Whittaker (Verviers, Belgium). Ficoll (Ficoll-Paque®) was obtained from Amersham 
Pharmacia Biotech AB (Uppsala, Sweden). Palm oil was purchased from Karlshamns 
(Karlshamns BV, Zaandijk, The Netherlands) and Sunflower oil from Cargill (Minneapolis, 
US). The lipid standard dinonadecanoyl-SN-glycero-phosphatidylcholinc (C19:0) was from 
Avanti Polar Lipids (Birmingham, UK). Phospholipid extraction columns, vacuum system 
and capillary column were obtained from Varian Chrompack (Bergen op Zoom, The 
Netherlands). 
Generation and composition of the control fat blend. 
The fatty acid composition of the control fat blend used in in vitro incubations is given in 
Table 1. For the use of in vitro cultures, free fatty acids from the fat blend were generated by 
saponification. In short, triglycerides were dissolved in 1 Ν ethanol-KOH and heated at 90°C 
under reflux for 1 h. After acidification with concentrated HCl to pH 2-3 free fatty acids were 
extracted with hexane/diethylether (5:1) and washed with H2O. Organic phase was dried with 
sodiumsulfate and removed by rotary evaporation. Free fatty acids were stored under nitrogen 
at -80oC until further use. 
Culture of PBMCs in presence of FA. 
Human peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained 
from buffy coals and prepared by Ficoll gradient centriftigation. In short, 10 ml of Ficoll-
Paque® was stratified under 20 ml of peripheral blood and centriftigation was performed at 
400 X g for 20 minutes at room temperature (RT). Recovered PBMCs were washed with 
PBS/2%FCS three times. Cells were cultured in RPMI-1640 culture medium containing 25 
mM HEPES and 2 mM L-glutamine enriched with 100 U/ml penicillin/streptomycin, 1.0 mM 
sodium-pyruvate, 12 mM D-glucose and 20% human serum. 
Free fatty acids and α-tocopherol were dissolved in 100 % ethanol and kept at -80oC under 
nitrogen until use. Before dissolving fatty acids, human serum was enriched with ascorbic 
acid and α-tocopherol to reach final concentrations of 75 and 25 μΜ in culture wells. Fatty 
acids were dissolved by direct addition of the adequate amount of fatty acid stocks into 
prewarmed human serum. The final ethanol concentration never exceeded 0.2%. For fatty 
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acid analysis, culture of PBMC was performed over 3 days in 6-well flat bottom plates (1 X 
107 cells per well) using a total volume of 5 ml culture medium in a humidified 5% CO2 
atmosphere at 37 °C. LPS stimulation (100 ng/ml) was performed over the final 20 hours of 
incubation. After incubation cells were washed twice with cold PBS and frozen at -80oC until 
analysis. In order to investigate the effects of fatty acids on cytokine production, cells were 
cultured in 96-well plates containing 200 μΐ culture medium as described above for three 
days. Cells were stimulated with LPS as indicated in text. LPS stimulation (100 ng/ml) was 
performed over the final 20 hours of incubation. 
Cytokine, PGEi and thromboxane analysis. 
TNF-a, IL-6 and IL-10 were measured in supematants of cultured cells using ELISA kits 
from BioSourcc (Etten-Leur, The Netherlands). PGEi production was measured in 
supematants using a competitive ELISA from R&D Systems GmbH (Wiesbaden-
Nordenstadt, Germany). Thromboxanes were analyzed by an competitive ELISA from 
Biotrak (Amersham Pharmacia Biotech, Buckinghamshire, UK). All assays were performed 
according to manufacturer recommendations. 
Fatty acid analysis. 
FA extraction of 107 cells was performed according to Bligh and Dyer (1959)1" using C19:0 
as an internal standard. Phospholipids were separated by using Bond-Elut® solid phase 
extraction columns and the Vac-Elut SPS 24™ system. Fatty acids were then converted to 
their methyl esters by using 20% BFi in ethanol at 100°C for 60 min. After hexanc extraction, 
derivatived fatty acids were dissolved in iso-octane and quantified by gas chromatography 
with a capillary column (50m χ 0.25mm, CP-SIL88-fame). Peaks were identified by 
commercial reference standards. 
Cell counting and viability assays. 
Cell countings were performed with a Coulter-Z2 cell counter (Beekman Coulter, USA). In 
order to include all cells present in the culture wells, adherent cells were gently trypsinized. 
Cell viability was assayed using the reagent WST-1, and is based on the cleavage of the 
tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells. The WST-1 assay 
was performed according to the manufacturer's instructions (Roche Diagnostics Nederland 
BV, Almere, The Netherlands). Each experiment was performed over 2 parallel culture plates 
in order to measure cytokine levels as well as cell viability in the same experiment. WST-1 
reagent was added to the culture wells during the final 5h of LPS stimulation, and extinctions 
were measured at 450 nm. 
Apoptosis/necrosis were assessed by a propidium iodide staining kit (Sigma-Aldrich Chemie 
BV, Zwijndrecht, The Netherlands), following the recommendations of the manufacturer and 
with a Coulter Epics XL flow cytometer (Beekman Coulter, USA). 
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Statistical analysis. 
Analyses were preformed using a paired two-tailed Student's / test Significance as indicated 
on graphs represents ρ values < 0 05 
Results 
In vitro fatty acid modulation of human PBMC 
A control fat blend was composed based on the average fatty acid intake in a Western diet and 
contained 80% palm oil and 20% sunflower oil providing mainly 16 0, 18 ln-9 and 18 2M-6 
(Table 1) Lipid analysis of human serum was performed to determine the background of fatly 
acids during incubations and values were in agreement with serum fatty acid concentrations 
expected in a Western society Human PBMC incubated with culture medium enriched with 
100 μΜ of control fat blend for three days had marginal changes in fatty acid profile m 
cellular phospholipids compared to untreated cells (Table 1) Cell viability, studied by WST-
labelling, propidium-iodide staining, cell counting, as well as visual inspection, was not 
affected by the three day culture period and/or treatment with fatty acids 
Table 1. Total fatty acid composition of the control (fat) blend and human serum (A), and 
phospholipid fatty acid from PBMC cultured with or without 100 μΜ control blend (B) 
A ' Β 
ι Control Serum Human PBMC, Human PBMC, 
ι blend ι untreated control blend 
total fatty acids ' phospholipids 
Fatty acid (% of total) 
160 
180 
18 lw-9 
18 2«-6(LA) 
18 3n-6(GLA) 
20 3«-6 (DOLA) 
20 4fl-6 (AA) 
22 4/1-6 
22 5«-6 
18 3/1-3 (LNA) 
18 4/)-3 (SA) 
20 5/1-3 (EPA) 
22 5/1-3 (DPA) 
22 6/)-3 (DHA) 
Others 
36 2 
4 6 
35 0 
20 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 1 
0 0 
00 
0 0 
0 0 
4 6 
24 2 
10 1 
172 
26 4 
0 4 
19 
69 
0 3 
0 3 
0 4 
05 
0 3 
04 
1 1 
96 
23 9 
155 
67 
62 
0 0 
1 1 
20 7 
25 
0 3 
0 1 
0 0 
02 
1 7 
2 1 
190 
20 6 
12 3 
84 
75 
00 
1 3 
21 2 
26 
0 5 
00 
0 1 
04 
20 
2 6 
20 4 
Data are one representative sample out of three, inter-sample variation for the different fatty acids 
analyzed was less than 5% 
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A kinetic study was performed in order to determine the incubation time necessary to induce 
reproducible modulation of cellular fatty acid composition of freshly isolated PBMC Cells 
were cultured with medium enriched with 100 μΜ DGLA for several days and LPS 
stimulation was performed during the last 20 h of incubation Fatty acid analysis of both total 
fatty acid extracts and phospholipid extracts showed that during a culture period of three days 
saturation in the fatty acid incorporation was induced (Figure 1) This resulted in reproducible 
modulation of fatty acid composition of the cells In addition, LPS stimulation did not affect 
the fatty acid composition of cells (data not shown) 
Analyzed fdlty 
* DGLA 
— AA 
acid 
Figure 1. Kinetics of DGLA uptake into total lipid and phospholipids of human PBMC in 
vitro Cells were cultured for 72h m presence of 100 μΜ DGLA and fally acid analysis 
was performed at 1, 24, 48 and 72 h of culture Data represent mean ± SD (n=3) and are 
percentages of total fatty acids 
ft-6 and n-3 fatty acid modulation of human PBMC 
Differences in fatty acid uptake between tested fatty acid were observed (Figure 2) 
Incubation with 100 μΜ of DGLA, AA, EPA and docosahexaenoic acid (DHA, 22 6/7-3) 
resulted in large increases (more than 5%) of these fatty acids in cellular phospholipids, 
whereas incubation with linoleic acid (LA, 18 2/7-6), GLA, α-linolenic acid (LNA, 18 3w-3) 
and steandonic acid (SA, 18 4/J-3) induced less than 3% increases The metabolism of fatty 
acids was restricted to elongation of GLA, AA and EPA into their elongated products, 
whereas fatty acids that are substrates for desaturase enzymes (LA, DGLA and LNA) were 
not further metabolized However, culture of cells with SA resulted in a small increase of 
EPA, a transition that involves activity of both elongase and A5-desaturase enzymes 
Differences in effects on AA concentrations induced by incubation of the PUFAs were seen 
Control cells contained approximately 2 1 % AA and culture with medium enriched with 100 
μΜ AA resulted in AA concentrations of approximately 26% in cells In contrast, EPA and 
DGLA reduced the A A concentrations from 2 1 % to approximately 10% and 15% 
respectively Furthermore, DHA induced a smaller decrease in AA concentrations (from 2 1 % 
to 18%), whereas culture with LA, GLA, LNA or SA enriched medium did not influence AA 
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concentrations. 
In addition, no effects on cell-viability were observed by addition of any of the fatty acids 
(determined by WST-1 assay, shown as part of Figure 3). 
Supplemented n-6 fatty acid: 
Β Control blend 
DLA 
• GL A 
• DGLA 
• AA 
Supplemented n-3 fatty acid; 
Β Control blend 
D LNA 
Β SA 
• EPA 
Π Dl ΙΑ 
Figure 2. The effect of the n-ó fatty acids LA, GLA, DGLA, AA (A) and the n-3 fatty 
acids LNA, SA, EPA and DHA (B) on fatty acid composition of human PBMC in vitro. 
Cells were cultured in medium containing 20% human serum and 100 μΜ of the 
respective fatty acid for three days. LPS stimulation was performed during the last 20h of 
stimulation. Results represent mean from at least two donors (± SD) per fatty acid 
investigated. 
Effects of/1-6 and »-3 PUFAs on cytokine production 
Control cells, which were supplemented with 100 μΜ of the control fat blend (Table 1), 
produced equal amounts of cytokines compared to unsupplemented cells (data not shown). In 
contrast, DGLA and AA decreased TNF-a levels to approximately 66% and 87% of controls 
respectively (Figure 3). The other n-6 fatty acids LA and GLA, as well as the n-3 fatty acids 
LNA, SA, EPA and DHA did not alter TNF-a levels. Furthermore, none of the tested fatty 
acid significantly changed 1L-6 levels (Figure 3). Incubation with DGLA or AA induced high 
levels of IL-6 with 5 of the 12 tested donors, resulting in an overall trend towards increased 
IL-6 production induced by DGLA and AA. In contrast, DGLA and AA reduced IL-10 levels 
to approximately 60 and 50% of controls respectively (Figure 3). In addition, smaller 
LA GLA DOLA AA LNA SA EPA DPA DHA 
Analyzed fatty acid 
LA GLA DOLA AA LNA SA EPA DPA DHA 
Analyzed fatty acid 
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reductions of 1L-10 levels were induced by LA, GLA and LNA. 
WST TNF-a 
LA GLA 1JG1.A AA LNA SA EPA DIIA LA GLA DGLA AA LNA SA EPA DHA 
Figure 3. The effect of «-3 and «-6 fatty acids on viability and cytokine levels of human 
PBMC in vitro. Cells were incubated in presence of 100 μΜ of the respective fatty acid 
and cytokine levels were measured 20 h after induction of LPS stimulation as described 
in the methods section. Cell viability (WST-1 assay) was measured during the final 5 h of 
LPS stimulation as described in methods. Values represent mean from triplicate 
measurements and 12 blood donors ± SEM. Control incubations were cells incubated 
with 100 μΜ of control fat blend (Table 1) and cytokine levels of controls amounted 
1349 ± 251 pg/ml TNF-a, 6576 ± 2082 pg/ml IL-6 and 437 ± 55 pg/ml 1L-10.*: Ρ < 0.05 
vs. control incubations. #: Ρ < 0.05 for DGLA vs. AA (one tailed Student's t test). 
Kinetics of cytokine production altered by DGLA 
In order to monitor the kinetics of the modulatory effects of DGLA, cytokine production from 
DGLA incubated cells were analyzed at several time points after initiation of LPS stimulation. 
In control incubations TNF-α levels increased strongly during the first 7 h of incubation and 
DGLA strongly inhibited these peak levels (Figure 4). In contrast, reduction of IL-10 levels 
did not occur until 15 h after LPS stimulation (Figure 4). 
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Figure 4. Effects of DGLA on kinetics of TNF-a and 1L-10 levels. After culture of cells 
with 100 μΜ Control blend or DGLA for 48 h (Table 1), LPS was added and cytokine 
levels were measured in supcrnatants at time points indicated. Data are mean ± SEM from 
three donors using triplicate incubations. 
Dose response effects of DGLA 
Next, we investigated whether effects of DGLA are dose responsive. Cells were cultured with 
DGLA concentrations ranging from 2.5 to 200 μΜ in culture medium and cytokine 
production was analyzed after 20 h LPS stimulation. DGLA reduced TNF-a levels 
significantly from 50 to 200 μΜ, whereas IL-10 levels were lowered at concentrations 
ranging from 25 to 200 μΜ (Figure 5). 
Dose response effects on incorporation of DGLA into phospholipids showed that DGLA was 
incorporated to approximately 15% of total fatty acids when cells were incubated with 200 
μΜ. Concomitantly to the increased amounts of DGLA in phospholipids, decreased AA levels 
were seen (Figure 5). 
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Figure 5. Dose response effects of DGLA on cytokine levels (A) and fatty acid 
composition of the phospholipid fraction (B) of human PBMC m vitro. Cells were 
incubated with DGLA or control blend for three days and cytokine or fatty acid levels 
were measured after 20 h of LPS stimulation. Figure A: #: % of controls represents the 
value calculated from cells with 0 μΜ control blend added to the culture medium. Data 
are mean ± SEM with cells from 4 (A) or 5 (B) blood donors. 
Direct effects of eicosanoids on cytokine levels 
Since DGLA appears to compete with AA for incorporation into cellular phospholipids, 
different classes of eicosanoids might be produced when COX is activated by LPS activation. 
We therefore investigated direct effects of some eicosanoids that are expected to be produced 
after phospholipid enrichment with DGLA and compared these to eicosanoids derived from 
AA or EPA. In accordance with previous experiments1", 1 μΜ PGEi, PGE2, and PGE3, 
derived from DGLA, AA and EPA respectively, similarly decreased TNF-a production to 
almost undetectable levels (Figure 6A). In contrast, 1 μΜ 15(S)-HETrE and LTB4, which 
were shown to be lipoxygenase products from DGLA and AA respectively, did not affect 
cytokine levels. Also, 1 μΜ TXB2 and TXB3, COX products from AA and EPA respectively, 
did not modulate cytokine levels. In contrast, the stable TXA2 analogue CCTXA2 dose 
dependently inhibited TNF-a, but had not effect on IL-6 and IL-10 levels (Figure 6B). 
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Figure 6. Effects of several eicosanoids (A) and dose response effects of ccTXA: (B) on 
cytokine levels. After a culture period for two days, cells were exposed to the eicosanoids 
(Ι μΜ) outlined and stimulated with LPS at the same time. Supernatants were measured 
20 h after induction of LPS stimulation. Data represent mean ± SEM (A: n=8, B: n=3). 
Control incubations were without eicosanoids. 
Eicosanoid levels and effects of COX inhibition 
Since PGE| and the stable TXA2 analogue CCTXA2, similar to DGLA, inhibited TNF-a 
production, we investigated whether inhibition of COX activation would affect the 
modulatory effects of DGLA on cytokine levels. Therefore, indomethacin (10 μΜ) was added 
during LPS activation and TNF-a levels were measured in supernatants. At this concentration 
indomethacin effectively inhibits LPS induced PGE production, without affecting cell-
viability (measured by WST-labelling, data not shown). Indomethacin inhibited PGEi and 
thromboxane production in both DGLA and control blend supplemented cells (Figure 7A). In 
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absence of indomethacin, concentrations of these eicosanoids were higher in supernatants 
from DGLA incubated cells than in control-blend-trcated cells However, addition of 
indomethacin did not affect the reduction of TNF-a levels induced by DGLA 
supplementation (Figure 7B) 
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Figure 7. Effecls of DGLA on TNF-a levels are independent of COX inhibition by 
indomcthdcin Cells were cultured with 100 μΜ DGLA or Control blend (table 1), 
slimulaled with LPS and PGL, and TXB (Figure 6A) or TNF-a (Figure 6B) were 
measured in supemalants at 20 h after LPS addition Results are mean ± SEM (A n=3, Β 
n=5) *Control incubations were LPS stimulated cells cultured with 100 μΜ Control 
blend in absence of indomethacin 
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Discussion 
Immuno-modulatory effects of PUF As have been described in in vitro, ex vivo as well as in 
vivo studies and the majority of results described immunosuppressive effects on human 
cells'8'267"6. The in vitro model used in the current study is somewhat different from other in 
vitro studies investigating immuno-modulatory effects of PUF A. We added free fatty acids to 
human serum in order to expose PBMC to fatty acids for several days. This is in contrast to 
other reports which used fetal bovine serum205317 or fatly acid-bovine serum albumin 
complexes as a carrier"8'20 and/or used shorter pre-stimulus incubation times ranging from 10 
min to 24 h1" "2205321. In our experiments high levels of albumin were found to affect 
functionality (cytokine production) of cells. A setup, in which the control fatty acid blend was 
dissolved in human serum directly, ensured that the functionality of cells remained 
unchanged. Also, M-3 and n-6 fatty acids were readily taken up and incorporated in 
phospholipids by quiescent, unstimulated PBMC, which was described to occur only 
minimally in a similar study using rat lymphocytes in which fatty acids pre-couplcd to 
albumin were used122. In addition, most studies on incubation times with fatty acids of several 
days focus on (T-ccll) mitogenic stimulation"7»MI·1 «o·'"1^ whereas in the current study 
endotoxin stimulation is used. Therefore, the in vitro study described here is novel in the way 
that it involves freshly isolated human PBMC prctrealed with PUFAs for 48 h followed by 
LPS stimulation. 
In this study wc found that DGLA, but not other structurally related fatly acids (such as GLA 
or EPA), specifically altered cytokine levels. This rather striking finding indicates that dietary 
supplementation of a DGLA rich oil may have more impact on cytokine production induced 
by endotoxin stimulation than use of oils rich in any other PUFA. DGLA has been previously 
described to modulate immune function, although data are limited to in vitro studies. 
Reported immuno-modulatory effects of DGLA on Τ cells were inhibited proliferation and 
IL-2 production of human lymphocytes"6"8·2"257 and murine T-cells25*, whereas others describe 
DGLA not to affect T-cell proliferation of human lymphocytes31,1·3". In line with Ihe current 
study, DeLuca et al.'9' have shown inhibition of TNF-a and IL-Iß production of DGLA by 
LPS stimulated human PBMC. However, the pre-incubation lime with DGLA applied was 
only 30 min and GLA and EPA were also shown to inhibit the pro-inflammatory cytokine 
production in contrast to the present study. Distinctions between the study of DeLuca et al. 
and the present study concerns the differences in fatly acid incorporation and use of anti-
oxidants to prevent lipid-peroxidation during culture. 
Furthermore, it was described that DGLA, used at concentrations similar to those of the 
present study, inhibits LTB4 production by human PBMC induced by a calcium ionophorc 
without altering PGE2 production251. The reduction in LTB4 synthesis was correlated with the 
formation of the 15 lipoxygenase product from DGLA, 15-(S)-HETrE245251. In the current 
study both LTB4 and LTB5 appeared to be ineffective in modulating cytokine production 
induced by LPS activation, in contrast to other studies involving T-cell stimulation, which 
reported immuno-stimulalory1273Ï" and also anti-inflammatory3"-332 effects of leukotncnes. 
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Moreover, the 15-lipoxygenase product from DGLA, 15-(S)-HETrE, did not modulate 
cytokine levels. These findings indicate that leukotrienes are of little influence on cytokine 
production by monocytes or macrophages in contrast to T-cells. The TXAz agonist, CCTXA2, 
specifically inhibited LPS induced TNF-a production, without influencing IL-6 and IL-10 
levels, while cytokine levels of unstimulated cells remained low. This is in contrast to another 
study in which the TXA2 agonist was found to increase TNF-a production of unstimulated 
human monocytes, implying that TXA2 exerts pro-inflammatory activity"8. Furthermore, 
inhibition of COX enzymes by addition of indomethacin did not change the effects of DGLA, 
indicating that the effects arc not caused by altered amounts and subtypes of COX products. 
Overall, these findings imply that DGLA affects cytokine levels directly. 
The mechanism of action whereby DGLA exerts the changes in cytokine levels is, as yet, 
unknown. Interestingly, the total fatty acid analysis showed that a large percentage of DGLA 
is present in cells as free fatty acids, that is, not acetylated in cellular phospholipids, which is 
in contrast to other PUFAs (data not shown). The large pool of unbound DGLA might directly 
affect a number of cellular processes, such as gene transcription and translation, and other 
intracellular events, such as receptor mediated processes"3. Kinetic experiments showed that 
the inhibition of TNF-a by DGLA occurs during the peak levels of TNF-a from, 4 to 9 h after 
LPS stimulation, whereas the onset of cytokine production was not inhibited. Furthermore, 
the decreased IL-10 levels found at later time points might be directly related to the decreased 
peak concentrations of TNF-a, since addition of TNF-a was found to increase IL-10 levels 
(our own data and "). 
In contrast to the general view that «-3 PUFAs are immune-suppressive, we did not observe 
any effects of «-3 PUFAs on cytokine production. Clearly, the lack of such effects found in 
this study cannot be explained by insufficient fatty acid incorporation, since EPA and DHA 
were both incorporated to a notable extent, which was similar to amounts of DGLA after 
DGLA supplementation. Previously published reports, describing the effects on cytokine 
production of human cells by EPA and DHA, merely involve decreased TNF-a and IL-Iß 
production of endotoxin stimulated PBMC after dietary supplementation of 
subjects2"2262""10314. Nonetheless, direct effects of «-3 PUFAs on cytokine production of 
human cells are scarce. Together with the present data, these limited reports, which describe 
the direct effects of EPA and DHA in vitro, suggest that effects of EPA and DHA are only 
observed after in vivo metabolism of these PUFAs. However, the changes in cytokine 
production induced by dietary intake of «-3 or M-6 PUFAs are probably not explained by 
changes in PGE-subtypes, since PGE|, PGE2 and PGE3 were shown to affect LPS-induced 
cytokine levels similarly315 and replacement of AA by EPA did not affect cytokine production. 
Overall, data obtained here clearly suggest that the production of cytokines by LPS stimulated 
human PBMC can be modulated by DGLA. This can be of importance for the treatment of 
inflammatory diseases in which the activation of mononuclear phagocytes plays a role. 
Furthermore, the fact that DGLA probably exerts its effects independent from eicosanoid 
formation raises possibilities for combined use of DGLA and therapy with non-steroid anti-
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inflammatory drugs (NSAID) during harmful inflammation. 
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Dihomo-y-linolenic acid affects murine pro-inflammatory cytokine 
production and survival from endotoxcmia 
Abstract 
The lethal effects of bacterial endotoxin are at least partially mediated by pro-inflammatory 
cytokines and dietary studies have shown that polyunsaturated fatty acids can modulate this 
toxicity. In the present study in mice, the effects of the omega-6 fatty acid dihomo-y-linolenic 
acid (DGLA, 20:3w-6) on ex vivo cytokine production and cndotoxin-induced lethality were 
investigated. Female C57B1/6 mice were supplemented with DGLA (0, 2 or 4% of dietary 
fat). After three weeks of dietary supplementation, serum, spleen and liver showed 
pronounced incorporation of DGLA, as measured by gas-chromatography. Increased amounts 
of the A5-desaturase product of DGLA, arachidonic acid (20:4«-6) were found in serum and 
liver, in contrast to spleen leukocytes. Peritoneal macrophages cultured in serum from DGLA 
supplemented mice showed decreased production of TNF-a, IL-6, IL-10 and intracellular IL-
Ια. Nonetheless, DGLA supplementation increased the susceptibility of mice to lethal 
Escherichia coli endotoxcmia, while mortality to Salmonella typhimurium endotoxin was not 
influenced. Overall, these results indicate that dietary DGLA reduces pro-inflammatory 
cytokine production and, unexpectedly, does not improve survival from endotoxcmia. DGLA 
might however, still be useful in chronic inflammatory diseases, in which blocking of pro­
inflammatory cytokines has conclusively shown to be effective. 
Maaike M.B.W. Dooper, Alieke G. Vonk", Erik Hogenkamp, Bart Jan Kullberg", 
Yvo M.F. Graus, Jos W.M. van der Meer" and Laura M'Rabet. 
* Department General Internal Medicine, UMC St Radboud, Nijmegen. 
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Introduction 
Dietary application of polyunsaturated fatty acids (PUFAs) has been described as a possible 
tool for anti-inflammatory manipulation in harmful conditions'**. Investigations frequently 
focused on the modulation of cytokine production by leukocytes267"5"7. In this respect, GLA-
rich oils were described to relieve symptoms in inflammatory conditions™·202'"' and modulate 
production of pro-inflammatory cytokines""92"'. Although GLA can affect cytokine 
production in vitro directly1"·"2, the effects of GLA-rich oils have often been linked to 
increased dihomo-y-linolenic acid (DGLA, 20:3«-6) levels. DGLA is a direct elongase 
metabolite of γ-linolenic acid (GLA, 18:3M-6) and a substrate for the arachidonic acid (AA, 
20:3M-6) synthesis by A5-desaturalion enzymes. Furthermore, DGLA was recently shown to 
inhibit tumor necrosis factor-α (TNF-a) production by human peripheral blood mononuclear 
cells (PBMC) in vitro™. Until now, DGLA enrichment of tissue phospholipids was usually 
accomplished by dietary supplementation of GLA-rich oils1*5274·341, extracted from seeds of 
borage and evening primrose plants. Dietary supplementation with an oil rich in DGLA 
instead of GLA might increase uptake of DGLA in cells and modulate immune activation 
more efficiently. 
Sepsis is a common and often devastating condition characterized by uncontrolled infection 
and multisystem organ failure542. Bacterial lipopolysaccharide (LPS) is a cell wall component 
of Gram-negative bacteria that strongly contributes to the inflammatory reactions seen in 
endotoxemia343'34S. Administration of LPS to animals elicits a condition similar to clinical 
sepsis involving multiple inflammatory responses, depending on the type of LPS involved. 
Escherichia, coli (E. coli) LPS is a well-studied endotoxin and its effects were strongly 
related to large production of the pro-inflammatory cytokine TNF-a by macΓophagesï4:,·1'"',47. 
Studies have shown that application of TNF-a blocking agents in addition to E. coli LPS 
administration can provide protection against E. coli LPS-induced mortality in mice34*'"1. 
However, lethal endotoxemia induced by LPS from other Gram-negative species can involve 
a cytokine network different from E. coli, since S. typhimurium challenge seems to lead to 
death via mediators other then TNF-a346. 
In view of the fact that DGLA was shown to decrease TNF-a production directly""40, it was 
currently investigated whether DGLA affects cytokine production by peritoneal macrophages 
after dietary administration as well. We thereafter investigated whether the changes in ex vivo 
cytokine production are associated with a change in survival from E. coli or S. typhimurium 
LPS challenge. 
Methods 
Materials 
Phosphate buffered saline (PBS), RPMI 1640 medium, L-glutamine and sodium pyruvate 
were obtained from Gibco BRL (Life Technologies, Breda, The Netherlands). E. coli LPS 
(serotype 055:B5), S. typhimurium LPS, BHT (butylated hydroxytoluene), 
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ethylenediamineletracetic acid (EDTA) and boron-trifluonde (BF3) and heparm-sodium were 
purchased from Sigma-Aldnch Chemie BV (Zwijndrecht, The Netherlands) Chloroform, 
methanol, hexane and iso-octane were obtained from Merck (Darmstadt, Germany) 
LymphohteM was from Cedarlane (Cedarlane Laboratories, Homsby, Ontario, Canada) 
Phospholipid extraction columns, vacuum system and capillary column were acquired from 
Vanan Chrompack (Bergen op Zoom, The Netherlands) Methyl tricosanoate standards were 
purchased from Nu Chek Prep Ine (Elysian, USA) Palm oil was obtained from Karlshamns 
(Karlshamns BV, Zaandijk, The Netherlands), Sunflower oil from Cargill (Cargill, 
Minneapolis, US) 
Experimental design 
Female, 6 weeks old C57B1/6 mice (Jacksons Laboratory, Bar Harbour, ME) were divided 
into groups of 10 animals with a similar mean body weight They were housed under specific 
pathogen-free conditions in a 12-h light-dark cycle and were fed standard laboratory food 
(Hope Farms, The Netherlands) and water ad libitum Dietary supplementation was based on 
standard fatty acid-free synthetic lab chow (Research Diet Services BV , Wijk bij Duurstede, 
The Netherlands) containing 7 5% weight percentage fat The diets were kept under nitrogen 
and stored at -20oC until use The fatty acid composition of the diets is shown in Table 1 
After having received the experimental diets for three weeks, mice were weighed and 
challenged with an intraperitoneal (1 ρ ) injection of either 0 25 mg S tvphimunum LPS, or 
1 0 mg £ coli LPS (serotype 055 B5) and survival was monitored every 12 h for 7 days For 
fatty acid analysis, a subgroup of unchallenged mice was anaesthetized with ether, and blood 
was collected by aorta puncture Thereafter, mice were killed by CO2 asphyxia Spleens were 
dissected and kept on PBS at 4°C until further use Spleen leukocytes were obtained by 
homogemzation and gradient separation using LympholyteM Until further analysis 
splenocytes were stored at -80°C as dry pellets The ethics committee on animal experiments 
of the Nijmegen University had approved the experiments 
Fatty acid analysis of phospholipids. 
FA extraction from pooled serum, liver homogenates or spleen leukocytes was performed 
according to Bligh and Dyer (1959)"2 Phospholipids were separated by using Bond-Elut® 
solid phase extraction columns and the Vac-Elut SPS 24™ system Phospholipid extracts 
were converted to their methyl esters by using 14% BF3 in ethanol at 100°C for 60 mm After 
hexane extraction, denvatized phospholipids were dissolved in iso-octane and analyzed by 
gas chromatography (GC) with a capillary column (50m χ 0 25mm, CP-SIL88-fame) Peaks 
were identified by commercial reference standards 
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Table 1. Fatty acid composition (molar percentage) of experimental diets. 
Fatly 
8:0 
10:0 
12:0 
14.0 
16:0 
17:0 
18:0 
22:0 
24:0 
16:1« 
181« 
20:1« 
acid 
-7 
-7/9 
-9 
18:2«-6(LA) 
18:3n-6(GLA) 
20:3/i-6 (DGLA) 
18:3« -3 (LNA) 
Control group 
3.2 
0.1 
0.6 
1.3 
35.1 
0.1 
4.6 
0.1 
0 0 
0.2 
34.1 
0.1 
19.9 
0.0 
0.0 
0.2 
Diet groups 
2% DGLA group 
2.2 
0.1 
0.6 
1.3 
34.7 
0.1 
4.9 
0.3 
0.5 
0.2 
33.2 
0.1 
19.0 
0.1 
2.1 
0.2 
4% DGLA group 
2.8 
0.1 
0.6 
1.2 
33.9 
0.1 
5.1 
0.4 
0.9 
0.2 
31.2 
0.1 
18.2 
0.2 
4.3 
0.2 
Ex-vivo cytokine production 
Resident peritoneal macrophages were harvested by rinsing the peritoneal cavity aseptically 
with ice-cold PBS containing sodium heparin (50U/ml). Cells were centrifiiged at 550 X g for 
10 min at 4°C, and rcsuspended in RPMI 1640 medium supplemented with 1 mM pyruvate, 2 
mM L-glutamine and 100 μg/ml gentamicin. Cells (lOVwcll) were cultured in 96-well 
microliter plates in RPMI medium in a final volume of 200 μΐ, with or without E. coli or S. 
typhimurium LPS at final concentration of 100 ng/ml. Cells were cultured in medium with or 
without 10% pooled fresh mouse scrum. The supematants were collected after 24 h of 
incubation at 370C, and stored at -80oC until cytokine measurement. 200 μΐ RPMI 1640 were 
added to the remaining macrophages, and the cells were disrupted by three freezc-thaw cycles 
for measurement of cell-associated interleukin-1 α (IL-Ια). Samples were stored at -80oC 
until assay. 
Cytokine measurements 
The concentrations of TNF-a and IL-la were determined using specific radioimmunoassays, 
as described previously"4. The detection limit using a 100 μΐ sample was 40 pg/ml for TNF-a 
and 20 pg/ml for IL-la. IL-10 and IL-6 concentrations were determined by a commercially 
available ELISA kit (BioSource Europe), according to the guidelines of the manufacturer. The 
detection limits were 8 or 150 pg/ml, respectively. 
Statistical analysis 
Cytokine levels were analyzed by two-tailed Students /-test. Survival data were analyzed 
using the Kaplan-Meyer log rank test. 
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Results 
Fatty acid composition of serum, splenocytes and liver. 
After three weeks of dietary supplementation, the fatty acid composition of serum, 
splenocytes and liver differed between the diet groups (Figure 1). Serum phospholipids of 
mice supplemented with DGLA contained increased concentrations of DGLA, AA and 
docosahcxacnoic acid (DHA, 22:6«-3), whereas linolcic acid (LA, 18:2w-6) concentrations 
were decreased. The changes were dose-dependent and, with exception of palmitic acid (16:0) 
and DHA, directly related to the fatty acid composition of the diets. DGLA supplementation 
also increased the DGLA concentrations in the leukocyte fraction of the spleen and this was 
paralleled by decreased concentrations of LA and oleic acid (18:lw-9). The fatty acid content 
of the liver showed similar changes as that of serum phospholipids and was characterized by 
increased DGLA, AA and DHA concentrations, and concomitant decreased LA and oleic acid 
concentrations. Overall, DGLA concentrations were higher in the 4% DGLA group than in 
the 2% DGLA group and an increase in AA concentrations was observed in serum and liver, 
in contrast to the leukocyte fraction of the spleen. 
In addition, no differences in relative weight gains of mice on the different diets over the 3 
weeks feeding period were seen (data not shown). 
Modulation of cytokine production by DGLA 
To assess the immuno-modulatory effects of DGLA, peritoneal macrophages were stimulated 
with E. coli or S. typhimurium LPS. The numbers of cells obtained from the peritoneal cavity 
relatively to the body weight were not different between the diet groups (data not shown). E. 
coli LPS-stimulated macrophages from mice supplemented with 2 or 4% DGLA, cultured in 
2% DGLA serum, produced approximately 30% less TNF-a than macrophages from control 
mice, cultured in control serum (Figure 2). In these cultures, IL-6 and intracellular IL-la 
levels were decreased in DGLA groups, whereas IL-10 concentrations were unaffected. 
In S. typhimurium LPS stimulated macrophages DGLA inhibited TNF-a production similar to 
the E. coli LPS cultures. In contrast, the IL-6 production of S. typhimurium LPS stimulated 
cells was not affected by DGLA, whereas IL-la concentrations were only reduced in cells 
from the group that received 4% DGLA supplementation. In addition, IL-10 levels were 
decreased in DGLA groups. 
Overall, no significant differences were observed in cytokine concentrations between the 2 
and 4% DGLA groups, except for the IL-la levels ofE. Coli stimulated cells in which a dose-
response effect was apparent. 
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Figure 1. Fatty acid composition of serum (pooled per group), splenocytes and liver 
phospholipids of mice supplemented with DGLA enriched diets for three weeks. For 
splenocytes and liver: n=5, data represent mean ± SD. 
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Figure 2. The effect of dietary DGLA on the ex vivo cytokine production by peritoneal 
macrophages. Cells from the control group mice were cultured with pooled serum of the 
control group, whereas cells from the 2% and 4% DGLA groups were cultured in pooled 
serum of 2% DGLA supplemented mice. Stimulation of macrophages with E. coli or 5. 
typhimurium LPS was performed for 24 h. Data represent mean ± SEM of 10 samples per 
group. * P<0.05 compared to control group.a P<0.05 between 2% DGLA and 4% DGLA 
groups. 
We investigated whether effects of dietary supplementation of DGLA on cytokine production 
were directly related to DGLA incorporated in macrophages, or to the presence of DGLA in 
serum that was added to culture medium. Therefore, macrophages from mice supplemented 
with 2% and 4% DGLA were cultured in 10% serum from control mice and vice versa. 
DGLA-enriched serum reduced the TNF-α levels in cultures of macrophages from control 
mice to that of macrophages from DGLA supplemented mice (Figure 3). Furthermore, the use 
of control serum in macrophage cultures from DGLA-supplemented mice did not inhibit 
TNF-α production, as observed before with DGLA-rich serum. Therefore, it appeared that the 
reduction of TNF-α levels was directly related to the presence of DGLA-rich serum in the 
medium, and did not depend on the source of the cells. Likewise, the modulation of IL-10 
production in response to 5. typhimurium LPS also depended on the presence of DGLA in 
culture medium, and a similar trend was seen for IL-6 and IL-la levels (data not shown). 
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Figure 3. The influence of cell- and serum-source on TNF-a production by peritoneal 
macrophages. Macrophages were cultured in presence of pooled scrum derived from the 
control group or from the 2% DGLA group, in presence off. coli LPS or S typhimurium 
LPS for 24 h. * Controls were cells from mice that received control diet and were cultured 
in pooled serum of the control group. Data represent mean ± SEM of 10 samples per 
group. .P<0.05 compared with controls.a f-iO.OS. 
Survival from endotoxemia 
Since DGLA was able to modulate cytokine production, effects of DGLA on lethal 
endotoxemia were investigated. After three weeks of dietary supplementation, mice were 
challenged with E. coli or S. typhimurium LPS, and survival was monitored every 12 h as 
described above. Injection of 1 mg/mouse oiE. coli LPS induced 10% mortality in the conlrol 
group (Figure 4). In contrast, approximately 50% of mice receiving DGLA rich diets had died 
within 150 h after E. coli LPS injection. Injection of 0.25 mg/mouse of S typhimurium LPS 
induced death of all animals within 50 h irrespective of the diet group. Injecting 0.15 mg of S. 
typhimurium LPS per animal resulted in a death rate of control animals similar to that seen 
after 1 mg of E. coli LPS injection. However, in contrast to mortality induced by E. coli LPS, 
no differences in death rates between the experimental groups were observed. 
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Figure 4. The effects of DGLA on survival from E coli (upper graphic) and S. 
typhimurium (lower graphics) induced endotoxemia. Mice (n=10) were fed diets for three 
weeks and were subsequently injected with 1.0 mg/mouse E. coli LPS, 0.25 mg/mouse S. 
typhimurium LPS, or 0.15 mg/mouse 5. typhimurium LPS. Survival was monitored every 
12 h. *P<0.05. 
Discussion 
Results presented in this report show that dietary supplementation of DGLA effectively 
increases DGLA tissue levels, reduces ex vivo cytokine production by peritoneal macrophages 
and, depending on the type of LPS used, increases the susceptibility to endotoxic shock. 
In general, studies describing increased DGLA tissue levels have used GLA-nch oils such as 
borage oil"''27'"55 and only a small number of studies have applied direct supplementation of 
pure DGLA2422442"6. It has been indicated that dietary fat of mice should at least contain 40% 
GLA to obtain DGLA concentrations in splenocyte phospholipids similar to the current 
study'55. This implies that, although elongation of GLA into DGLA was described to occur 
readily34"56, supplementation of DGLA might be more efficient in increasing DGLA levels in 
splenocytes than supplementation of GLA is. In addition, our results show that DGLA 
supplementation did not increase the concentration of AA, the A5-desaturase product of 
DGLA, in splenocytes, despite increased AA concentrations in serum and liver. The increase 
in AA levels in serum and liver is likely to result from A5-desaturase activity predominantly 
present in the liver168. The unchanged A A levels found in splenocytes after DGLA 
supplementation are in line with the fact that quiescent leukocytes have no or very little Δ5-
desaturase activity'57. Overall, our data indicate that during DGLA supplementation the AA 
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levels of splenocytes are not directly related to the AA concentrations in serum and that 
splenocytes preferentially increase DGLA in contrast to AA concentrations. 
In vitro studies using human peripheral blood mononuclear cells (PBMC) have shown that 
DGLA modulated the LPS-induced cytokine production1",40. These findings are in line with 
our observations that DGLA-enriched serum reduced LPS-induced production of TNF-a, IL-
6, IL-10 and intracellular levels of IL-la by murine macrophages. The effects were directly 
related to presence of DGLA-rich serum in the cell-cultures and could even be induced in 
cells of mice that received the control diet. This indicates that pre-enrichment of peritoneal 
macrophages by dietary supplementation was not necessary to induce the inhibitory effects. 
However, since DGLA-enriched serum was derived via dietary supplementation, it is unclear 
whether effects are caused by DGLA directly or by an in vivo synthesized metabolite. Results 
from our in vitro studies with human PBMC have indicated that DGLA exerts its effects 
independent from cyclooxygenase activation140. This might implicate that the factor 
responsible for the inhibition of cytokine production ex vivo is not synthesized by 
cyclooxygenase. Ex vivo and in vivo experiments using cyclooxygenase inhibitors in 
combination with DGLA may provide more information about this. Assuming that 
cyclooxygenase activation can play a role in the effects of dietary DGLA on ex vivo cytokine 
production, certain eicosanoids would be relevant. It has been described that prostaglandin-E 
(PGE)-sublypes effectively inhibit TNF-a production2"3'' and DGLA supplementation could 
induce a shift from PGE2 towards PGEi production by immune cells274"'. However, the 
subtypes derived from DGLA, AA and EPA, which are PGEi, PGE2 and PGE3 respectively, 
modulated the cytokine production of human PBMC equally115, indicating that a shift in PGE-
subtype production from PGE2 towards PGEi by DGLA is not responsible for the change in 
cytokine production. An increase in the total PGE amount, irrespective of the subtype, could 
theoretically influence TNF-a production. Unfortunately, measurement of PGE 
concentrations in culture supematants in this study was, for technical reasons, not performed. 
The inhibitory effects of DGLA on the production of pro-inflammatory cytokines may have 
suggested protective effects in LPS-induced lethality, since blocking of TNF-a production 
was shown to improve survival fromf. coli LPS injection'4"483". Surprisingly, challenge with 
E. coli LPS led to deterioration of survival compared to that in control mice. Although this is 
in contrast to what was expected based on the decreased cytokine production, studies with the 
M-6 precursor fatty acids of DGLA, GLA, also showed negative effects in experimental 
endolcxernia35'1™ and sepsis35*160. Compared with similar studies using the omega-3 PUF A 
eicosapenlaenoic acid, EPA (20:5«-3), it appears that DGLA acts rather opposite to EPA. 
EPA has been shown to increase murine LPS-induced {ex vivo) TNF-a production2202162593" 
and to increase survival from endotoxemia362 or gram-negative infection161. However, others 
have shown EPA or EPA-rich oils to be ineffective in, or even worsened the outcome after 
endotoxin or bacterial challenge224163 366. Together with other reports describing discrepancies 
between TNF-a levels and survival from endotoxemia367, this might indicate that the amount 
of TNF-a after PUFA supplementation is not indicative for the survival rate after LPS 
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challenge. 
Studies have indicated that the relation between the pro-inflammatory cytokine profile and 
death from endotoxemia is related to the kind of LPS. E. coli LPS has been shown to induce 
another circulating cytokine profile than S. typhimurium LPS14*. In E. coli LPS induced 
lethality TNF-a was indicated to play a central role, whereas in lethal effects of S. 
typhimurium LPS multiple pro-inflammatory cytokines like interferon-γ (IFN-γ), IL-1 and 
IL-18 were involved"6. Since DGLA reduced the TNF-a production by macrophages, the 
central role of TNF-a in E. coli lethality would indicate protective effects of DGLA after E. 
coli LPS injection. The fact that in the current study the opposite of this was found, again 
indicates that the lethality induced by E. Coli LPS injection was, at least in this experiment, 
not predicted by the effect of DGLA on TNF-a produced ex vivo. 
Death induced by LPS is caused by a matrix of pathological events such as hypotension, intra­
vascular coagulation, hepatic damage and renal failure. Although pro-inflammatory cytokines 
might have a major influence on initiating these events368, other factors can direct the outcome. 
Lipoproteins such as high-, low- and very-low density lipoproteins and chylomicrons can bind 
endotoxin and thereby reduce the toxic properties of LPS147'''"·"4. The protective effects 
involved the redirection of LPS from Kupffer cells to liver parenchymal cells, resulting in 
reduced macrophage activation '". Since supplementation of GLA has been shown to decrease 
lipoprotein levels169, it could be speculated that DGLA-induced changes in lipoprotein 
constitution or concentrations altered the LPS clearance followed by increased mortality150. 
In conclusion, our data confirm that DGLA supplementation decreases the production of 
TNF-a similar to the experiments with human leukocytes140. Since blocking of TNF-a was 
conclusively associated with relieve of symptoms during chronic-inflammatory conditions 
such as rheumatoid arthritis50, DGLA supplementation might exert positive effects in these 
circumstances. 
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The effects of dietary γ-linolenìc, dihomo-y-Iinolenic, arachidonic and 
eicosapentaenoic acids on Bio-melanoma growth and metastasis in mice. 
Abstract 
It was described that dietary «-3 PUFAs exert anti-tumor effects, whereas «-6 PUFAs were 
associated with tumor progression. In the current study a direct comparison of the anti-tumor 
effects of γ-linolenic acid (GLA, I8:3rt-6), dihomo-y-linolenic acid (DGLA, 20:3«-6), 
arachidonic acid (AA, 20:4w-6) and eicosapentaenoic acid (EPA, 20:5«-3) was made. Mice 
were fed diets containing 5% of each fatty acid in dietary fat and were inoculated 
intracutanously with Β16 melanoma cells high in melanin (HM, 5xl0 5 mouse) or low in 
melanin levels (LM, IxlO6 mouse), in the left or right flank, respectively. Parallel groups were 
injected with B16 cells in the tail-vein (3xl0 6 cells/mouse) to study effects on tumor 
metastasis. GLA supplementation moderately increased HM tumor growth from 25 days after 
inoculation on. In contrast, LM tumor growth was significantly inhibited in EPA 
supplemented mice. EPA also decreased the number of lung metastases, in contrast to the «-6 
PUFAs. The DTH response in these mice, measured before tumor inoculation, was lowered in 
both EPA, GLA and DGLA fed mice, indicating that a change in cellular immunity was not 
responsible for the anti-tumor effects of EPA. Dietary fatty acids were clearly represented in 
serum, splenocytes and the HM tumors. GLA, DGLA and AA increased AA concentrations in 
serum and HM tumors, whereas EPA strongly reduced AA and increased «-3 fatty acids 
concentrations. EPA might therefore exert its effects by reducing synthesis of AA derived 
mediators. Overall, results indicate that EPA, in contrast to n-6 PUFAs, inhibits melanoma-
growth and metastasis in mice. 
Maaike M.B.W. Dooper, Paul Vos, Jan de Groot", Allan J. Masterson", Rik J. Scheper" and 
Laura M'Rabet. 
" Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands 
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Introduction 
Dietary polyunsaturated fatty acids (PUFAs) have been indicated to play a role in the 
development and progression of cancer. High intake of the n-6 fatty acid linoleic acid (LA, 
18:2«-6), present in com or sunflower seed oil and abundant in the Western diet, enhanced 
tumor growth™ and the incidence of metastases'711". In contrast, epidemiological and 
experimental studies correlated consumption of fish oil, that contains the «-3 PUFAs 
eicosapentaenoic acid (EPA, 20:5«-3) and docosahexacnoic acid (DHA, 22:6«-3), with a 
reduced of incidence or growth of malignancy. Overall, n-6 PUFAs were associated with 
tumor-progression, while n-3 PUFAs were thought to be protective. However, this distinction 
is not conclusive, since the n-6 PUFA γ-linolenic acid (GLA, 18:3«-6) inhibited tumor growth 
in some studies246·"4"5. 
The exact mechanism by which PUFAs affect malignancy is yet unknown. A direct 
relationship was made between the rates of tumor LA uptake and formation of mediators from 
LA, and tumor growth in v/'vo"^"9. Also, the elongation and desaturation product of LA, 
arachidonic acid (AA, 20:4«-6) was supposed to be involved. AA is a major PUFA in human 
tissues and many tumors, and substrate for the synthesis of eicosanoids". Cyclooxygenase-2 
(COX-2) expression, the rate limiting enzyme in the inducible synthesis of prostanoids from 
AA, was found to be upregulated in malignancy. Recent attention has focused on the use of 
COX inhibitors as preventative agents in the development of colorectal carcinoma m, and 
possible other types of cancer181"12. In addition, prostaglandin-Ei synthesis from AA was 
correlated to the suppression of immunity often observed in tumor patients381·384. Increased 
production of COX metabolites from AA might therefore be an important negative factor in 
cancer. 
Fatty acids that are structurally related to AA, such as EPA, GLA and dihomo-y-linolenic acid 
(DGLA, 20:3M-6), can compete with AA metabolism and might therefore slow down tumor 
growth by altering production of growth-enhancing lipid mediators11"3*7. Therefore, in the 
present study a direct comparison was made between the effects of GLA, DGLA, AA and 
EPA on B16 melanoma growth and metastasis in mice. The effects were related to the change 
in tissue fatty acid composition as a read out for the substrate availability for the synthesis of 
lipid mediators. In addition, since tumor progression and metastasis are often accompanied by 
a general immune suppression388, the influence of the fatty acids on a delayed type 
hypersensitivity response/T-helper-1 response was monitored. 
Methods 
Materials 
BHT (butylated hydroxytoluene), ethylenediaminetetracetic acid (EDTA), boron-trifluoride 
(BF3), dinitrochlorobenzene (DNCB) and PHA were obtained from Sigma-Aldrich Chemie 
BV (Zwijndrechl, The Netherlands). Chloroform, methanol, hexane and iso-octane were 
purchased from Merck (Darmstadt, Germany). Phospholipid extraction columns, vacuum 
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system and capillary column were obtained from Varian Chrompack (Bergen op Zoom, The 
Netherlands). Methyl tricosanoate standards were obtained from Nu Chek Prep Inc. (Elysian, 
USA). Palm oil was obtained from Karlshamns (Karlshamns BV, Zaandijk, The Netherlands), 
Sunflower oil from Cargill (Cargill, Minneapolis, US), Crossential GLA TG40 oil and 
Incromega EPA 500TG SR oil were kind gifts from Croda Oleochemicals (Leek, UK), 
SUNTGD DGLA rich oil was obtained from Suntory Ltd. (Tokyo, Japan),, 
Optimar1M700/100 arachidonic acid oil was purchased from DSM Food Specialties (Delft, 
The Netherlands). 
Animals and diets 
Female, 8-10 weeks old C57B1/6 mice (Harlan, Netherlands BV, Horst) were divided into 
groups of 10 animals with a similar mean body weight. They were housed under conventional 
conditions in a 12-h light-dark cycle and were fed standard laboratory food (Hope Farms, The 
Netherlands) and water ad libitum. Dietary supplementation was based on standard fatty acid-
free synthetic lab chow (Research Diet Services BV., Wijk bij Duurstede, The Netherlands) 
containing 7.5% weight percentage fat and 60 mg/kg α-tocopherol. The diets were kept under 
nitrogen and stored at -20°C until use. The fatty acid composition of the diets is shown in 
Table 1. 
Table 1. Fatty acid composition (molar percentage) of experimental diets. 
Diet groups 
Control GLA DGLA AA EPA 
Fatty acid 
14:0 
16:0 
18:0 
19:0 
18:1/1-7 
18:1 «-9 
20:l«-9 
18:2/7-6 
18:3/7-6 
20:3/J-6 
20:4/7-6 
20:5n-3 
22:6n-3 
Remaining 
1.2 
34.8 
4.6 
1.7 
0.7 
46.0 
0.1 
9.6 
0.0 
0.0 
0.0 
0.0 
0.0 
1.3 
1.0 
29.7 
4.2 
4.6 
0.6 
40.4 
0.8 
10.9 
5.6 
0.0 
0.0 
0.0 
0.0 
2.1 
1.3 
34.0 
4.6 
5.7 
0.6 
37.6 
0.1 
8.8 
0.3 
4.6 
0.0 
0.0 
0.0 
2.2 
1.2 
30.0 
5.3 
6.0 
0.6 
39.5 
0.2 
8.7 
0.4 
0.5 
5.5 
0.0 
0.0 
2.0 
1.1 
30.6 
4.0 
6.0 
0.7 
39.8 
0.1 
8.4 
0.1 
0.0 
0.4 
6.1 
1.1 
1.7 
Tumors 
The B16 melanoma tumor line was derived from a malignant melanoma that arose 
spontaneously in a C57BL/6 mouse at the Jackson Laboratories (Bar Harbor, Maine, USA)1". 
Sub-clones of this tumor line were obtained from KJRIN Brewery Co, Ltd Gunma Japan. For 
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the solid tumor experiments sub-clones characterized as high-melanin tumor cells (HM) and 
low-melanin tumor cells (LM) were used For the metastasis experiments B16-F10, a poorly 
immunogenic melanoma, kindly provided by the Department of Cell-Biology (VUMC, The 
Netherlands), was used390 392 
Experimental protocols 
Solid tumor experiments. Mice were inoculated with tumor cells 10 days after start of the 
experimental diets Implantation of HM tumor cells was performed intracutaneously on the 
left flank (5xl05/mouse) LM tumor cells were inoculated intracutaneously on the right flank 
(lxl06/mouse) Body weight, food intake and tumor sue were measured on alternate days 
The tumor size was calculated by multiplying the longest and the shortest diameters of the 
tumors After 27 days of tumor inoculation (day 37 after start of experimental diets), mice 
were anesthetized by ether, blood was collected by orbital plexus puncture and mice were 
killed by cervical dislocation 
Spleens were dissected and kept on PBS at 4°C until further use Spleens were gently 
homogenized manually using filter-chambers Erythrocytes were removed by use of an 
erythrocyte shock buffer (1 4 M NH^Cl, 0 017 M Tris, pH 7 2) Cell suspensions were washed 
with ice-cold PBS and stored at -80°C in a volume of 250 μΐ PBS until analysis HM tumors 
were dissected, quickly frozen in liquid nitrogen and stored at -80oC until analysis 
Metastasis experiments. In this experiment induction and assessment of DTH were 
performed before tumor inoculation 8 days after start of the experimental diets, mice were 
sensitized by the epicutaneous application of 1% DNCB onto shaved abdomens 5 days after 
sensitization (day 13 after start with diets) mice were challenged with 20 μΐ of 0 3% DNCB 
epicutaneously on the left ear, commencing a specific DTH reaction, and 30 μΐ of 30 μg 
phytohaemagglulinin (PHA) intracutamously in the right ear to elicit a non-specific immune 
reaction The increase in ear thickness was measured 24, 48 and 72 h later with a micrometer 
(Mitutoyo, Japan) At day 17 after start of the diets, serum samples (±50 μΐ/mouse) were 
collected by orbital plexus puncture to determine the incorporation of fatty acids At day 20, 
B16 tumor cells were inoculated in the tailvein (3xl05 cells/mouse) At day 37, mice were 
anesthetized by ether, blood was collected by orbital plexus puncture and mice were killed by 
cervical dislocation Spleens were dissected and kept on PBS at 40C until further use 
Splenocytes were obtained and stored as described above To assess the number of 
metastases, longs were dissected and fixated 3 minutes in Fekete's solution and subsequently 
in 4% formaldehyde Separated lobs were photographed digitally under a preparation 
microscope The percentages of tumor-area compared to the total lung area were analyzed and 
calculated with a cell and tissue analysis program (Q-prodit, Leica) 
The ethics committee on animal experiments of the Vrije Universiteit of Amsterdam had 
approved the experiments 
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Fatty acid analysis 
FA extraction from scrum, spleen leukocytes or HM tumor homogenates was performed 
according to Bligh and Dyer (1959)152. Fatty acid extracts were converted to their methyl 
esters by using 14% BF3 in ethanol at 100oC for 60 min. After hexane extraction, derivatized 
phospholipids were dissolved in iso-octane and analyzed by gas chromatography (GC) with a 
capillary column (50m χ 0.25mm, CP-SIL88-fame). Peaks were identified by commercial 
reference standards. 
Statistical analysis. 
Fatty acid concentrations were analyzed by ANOVA (single factor), followed by the Least 
Significant Difference at P-iO.OS. Body and tumor weights, food consumption and results of 
the DTH responses were analyzed by Student's /-test (assuming unequal variances). Tumor 
growth data were analyzed whether the numbers were normally distributed using the K-test. 
Since it appeared that all groups had a normal distribution, the Student's /-test (assuming 
unequal variances) was applied. 
Results 
Effect of diet on food consumption, spleen weight and body weight. 
Dietary modification by GLA, DOLA, AA and EPA did not to alter either the food 
consumption or spleen weight (data not shown). Body weights were somewhat reduced in all 
experimental groups compared to control mice in the solid tumor experiment, whereas no 
differences were observed in the metastasis experiment (Table 2). 
Table 2. Effect of diet on body weight (g/mouse). 
Experiment 
Group Solid tumor Metastasis 
Control 21.4 ±0.5 20.6 ±0.5 
GLA 20.0 ± 0.4* 20.3 ± 0.4 
DGLA 20.0 ±0.3* 20.9 ± 0.3 
AA 19.8 ±0.3* 21.0 ±0.4 
EPA 20.4 ±0.3* 20.9 ± 0.3 
Values are mean ± S.E.M., η = 9-10 mice. *Statistical significance, ρ < 0.05. 
HM and LM tumor progression 
HM and LM were inoculated simultaneously to monitor possible differences between the 
progression of these lumors. The inoculation of Β16 resulted in progressive tumor growth of 
both the HM and LM tumors (Figure 1). Growth of the HM tumor was significantly increased 
in mice that received the GLA rich diet from 25 days after tumor inoculation on. The growth 
rate of the LM tumor was significantly depressed in mice receiving the EPA rich diet, in 
contrast to the other diet groups. Within the EPA diet group, one mouse had a relatively large 
tumor compared to the group members. A Dixons Q test revealed that this tumor was larger 
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than the critical value for this group. This mouse was therefore excluded from the results. 
Overall, the GLA rich diet was associated with an increase in HM tumor growth, whereas the 
EPA rich diet exerted inhibitory effects on LM tumor growth. 
HM tumor LM tumor 
0 4 1 1 1 1 . 0 4 · 1 1 1 
17 19 21 25 27 17 19 21 25 27 
Time (days after tumor inoculation) Time (days after tumor inoculation) 
Figure 1. The effect of PUF As on HM and LM tumor progression. Mice were inoculated 
intracutaneously with 5x10' HM cells/mouse and IxlO6 LM cells/mouse on the right and 
left flank respectively. Data are expressed as mean ± SEM, n=10. *P<0.05 compared to 
other groups. 
Tumor metastasis 
In order to determine the effects of dietary PUFA supplementation on Β16 tumor metastasis, 
mice received experimental diets for 20 days and were subsequently inoculated intravenously 
with tumor cells. At this time point, the serum fatty acid levels were identical to levels 
measured at the end of the solid tumor experiment (data not shown), which indicates that the 
fatty acid metabolism at these time points was already at plateau levels in serum. 
In the control group, 25% of the lung area was affected with tumor metastasis 17 days after 
tumor inoculation (Figure 2). 
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Figure 2. The effect of PUFAs on the area-percentage of metastasis in lungs BI6 
melanoma cells were injected intravenously and the area-percentage of tumor affected 
tissue compared to the total lung area was measured 17 days after tumor inoculation Data 
represent the mean area-percentage of metastases ± SEM, n=10 *P<0 05 compared to 
other groups 
The groups receiving n-6 fatly acid supplementation did not differ in the percentage of 
metastasis-area from the control group In contrast, EPA supplementation reduced the number 
of metastases strongly towards 10% of affected area, which is an inhibition of 60% 
Serum, splenocyte and HIM tumor fatty acid composition 
The fatty acid composition of scrum and splcnotytcs of mice from both the solid tumor and 
the metastasis experiments were determined The total duration in which mice received the 
experimental diets was 37 days in both experiments The serum and splenocyles fatty acid 
levels were nearly identical between the two experiments Therefore, only data from the solid 
tumor experiments are shown 
Differences in fatty acid composition of serum, splcnocytes and the HM tumor were observed 
(Figure 3) In serum of control mice, LA (18 2n-6) and AA (20 4n-6) were the major fatly 
acids present Supplementation with GLA increased the GLA and AA concentrations, while 
DGLA concentrations were unchanged DGLA supplementation increased DGLA and AA 
levels AA supplementation increased the AA levels even further and induced a small increase 
in the elongase and desalurase products of AA Supplementation of EPA induced a 
pronounced increase in both EPA and DHA concentrations, whereas AA concentrations were 
strongly reduced 
The changes induced by the different diets in the splcnocytes were comparable to the changes 
in serum However, splenocyles contained less LA and more AA than serum In addition, the 
AA concentrations were slightly increased after GLA and AA supplementation, whereas AA 
concentrations were unchanged after DGLA supplementation Dietary EPA strongly increased 
the concentrations of EPA, DPA (22 5w-3) as well as DHA and this was accompanied by 
decreased AA concentrations m splenocyles The increase in DPA was not observed in serum 
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In HM tumors the main PUFAs present in control mice were, similar to serum, LA and AA. 
The changes induced by the experimental diels were largely similar to those observed in 
scrum. Differences compared to serum were a lower increase in DGLA levels after DGLA 
supplementation and a larger increase in DPA after EPA supplementation. 
In summery, supplementation of GLA, DGLA and A A lead to increased AA concentrations in 
serum and HM tumors. Supplementation of EPA strongly increased the total amount of M-3 
PUF A present at the expense of A A. 
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Figure 3. Fatty acid composition of serum, splenocytes and HM tumor of mice inoculated 
subcutaneously with high- and low-melanin containing B16 cells. The fatty acid 
concentrations were measured 27 days after tumor inoculation (37 days after start of 
experimental diets). Data represent mean ± SD (n=5). Fatty acid nomenclature: Ι8:2η-6, 
LA; Ι8:3η-6, GLA; 20;3/;-6, DGLA; 20:4«-6, AA; 22:4«-6, docosatetraenoic acid; 22:5«-
6, γ-docosapentacnoic acid; 18:3«-3, α-linolenic acid; Ι8:4η-3, stearidonic acid; 20:5«-3, 
EPA; 22:5n-3, a-docosapentaenoic acid; 22:6n-3, DHA. 
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Effect of PUFA supplementation on DTH response 
In order to investigate whether the effects on tumor growth and metastasis were accompanied 
by changes in the cellular immune response, a DTH reaction was elicited 13 days after start of 
dietary supplementation. Both a specific (DNCB induced) and non-specific (PHA) immune 
response was evoked. Groups that received the GLA, DGLA and EPA rich diets had a 
decreased specific DTH reaction, as measured by lower increase in car-thickness 48 and 72 h 
after DNCP challenge (Figure 4). In contrast, the non-specific immune reaction elicited by 
PHA was reduced in groups that received GLA and DGLA (Figure 4). However, these 
changes were only significantly different from the control group when the data were analyzed 
by a one-tailed Student's /-test. 
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Figure 4. The effect of PUF As on DNCB induced DTH response. Contact sensitization 
was elicited as described in methods. Data represent mean ± SEM, n=10. '/^O.OS 
compared to control group for two-tailed Students /-test. "f^ O.OS compared to control 
group for one-tailed Students /-test. 
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Discussion 
This study revealed that dietary EPA, in contrast to GLA, DGLA and A A, effectively reduces 
the local growth and invasive behaviour of melanomas in mice. This finding is in line with 
other studies describing that intake of fish oil is associated with a reduced rate of tumor 
growth and metastasis"3''95. 
It was indicated that EPA caused its anti-tumorigenicity effects by inhibiting LA uptake into 
cancer cells, since a strong relation between the amount of dietary LA and tumor progression 
was described previously370·"'. In line with this, we found that EPA reduced the tumor LA 
levels. However, GLA, DGLA and AA supplementation reduced the LA levels similarly to 
EPA without inhibiting tumor progression. This indicates that the effects of EPA are not 
mediated via inhibition of the LA incorporation into tumor cells. A second suggested 
mechanism by which EPA affects tumor growth or metastasis, was increasing the immunity 
of the tumor-host1%. Increased production of interferon-γ, a cytokine that is dominant in T-
helper-l mediated immune responses such as DTH, has been shown to reduce tumor 
growlb3'7'398. The effects of EPA in this study are however not explained by a change in the T-
helper-1 mediated immune responses, since the DTH response was reduced after EPA 
supplementation (current study and ^ , An additional proposed mechanism for the tumor 
growth-inhibitory effects of «-3 fatty acids included the inhibition of growth-promoting 
eicosanoids from AA3'5·'100'101 or alteration of the n-6/n-3 fatty acids-ratio in cell membranes402. 
In line with this, we found a strong reduction of the amounts of AA in serum, tumor and 
splenocytes and reduced n-6/n-3 ratios after EPA supplementation. This indicates that the 
amount of AA, available for eicosanoid synthesis in the tumor and in immune cells, is 
reduced by EPA. EPA might, nonetheless, also affect tumor growth and metastasis by 
inhibiting COX enzyme activity. Dietary «-3 PUF As were shown to inhibit COX-2 activity, 
whereas n-6 PUFAs increased the COX-2 expression in tumors403. Also, studies have 
described that NSAIDs reduced the tumor loads similarly to «-3 PUFAs and that these 
compounds were likely to act through the inhibition of tumor COX enzymes, primarily COX-
2m-"'5. Overall, this might indicate that EPA exerts its inhibitory effects by reducing the 
amount of AA available for eicosanoid production as well as by inhibiting the rate-limiting 
enzymes responsible for production of immune-suppressing lipid mediators like 
prostaglandin^3"3. 
The inhibitory effects on tumor growth of EPA were observed on LM tumor growth, in 
contrast to the HM tumor. It might be possible that the growth of the HM tumor was too 
aggressive to be altered by EPA. Compared to melanoma development and growth in 
human40*·407, the growth rate of the HM tumor of this study was extraordinary high. In this 
respect, the LM tumor growth in this study might have more resemblance, and therefore 
relevance, to human situations than the HM tumor growth. 
The possibility exists that the effects on tumor-growth and metastasis in the group that 
received EPA were (partially) induced by DHA. In this group the tissue DHA concentrations 
were comparable to the EPA concentrations and DHA was shown to inhibit tumor growth 
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before408. Participation of DHA in the anti-tumor effects described in the current study can 
therefore not be excluded. In order to further investigate the effects of DHA versus EPA, 
DHA should be supplied m combination with compounds that can inhibit the rctroconversion 
of DHA into EPA by D4 enoyl reductase and D3, D2 enoyl CoA isomerases in 
peroxisomes40'""1. 
The current finding that GLA did not reduce and even enhanced melanoma progression is in 
contrast to other studies that described protective effects of GLA246"4"'412,14 The mechanism 
by which GLA would exert its effects was related to increased concentrations of DGLA, the 
direct elongation product of GLA DGLA can compete with AA for synthesis of eicosanoids 
and might therefore attenuate formation of AA-denved metabolites27'""5'"6 However, the lack 
of both positive effects of DGLA and negative effects of AA in the current study does not 
support this hypothesis To obtain further knowledge about the role of AA levels in the effects 
of GLA, a combination of dietary GLA with a A5-dcsalurase inhibitor, which inhibits the 
metabolism of DGLA into AA, could be used Overall, our data indicate that the detrimental 
effects of GLA are independent from the increased DGLA and AA concentrations induced by 
GLA supplementation. 
In conclusion, results of the current study reinforce previous data on the anti-tumongenicity 
of EPA EPA might exert its effects by affecting the amount of AA available for formation of 
tumor derived metabolites and/or by directly reducing tumor COX-cnzyme activity. 
Moreover, a positive contribution was made to the idea that EPA can act as a possible 
chemotherapeutic agent against melanoma growth and metastasis in human 
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and survival from gram-negative infection in mice 
Abstract 
γ-Linolcnic acid (GLA, 18:3«-6) is an omega-6 polyunsaturated fatly acid (PUFA) and its 
dietary intake was described to be beneficially in inflammatory diseases. The mechanism of 
action likely involves the direct metabolite of GLA, dihomo-y-linolcnic acid (DGLA, 20:3n-
6), in immune cells. However, DGLA can be further metabolized into arachidonic acid (AA, 
20:4«-6) by A5-desaturase enzymes, which is supposed to be harmful in inflammatory 
diseases. We currently investigated whether simultaneous use of GLA and the omega-3 
PUFA stearidonic acid (SA, 18:4«-3) affects the disadvantageous conversion of DGLA into 
AA in immune cells and compared the effects to those of eicosapcntaenoic acid (EPA, 20:5«-
3). SA and GLA were incorporated in human PBMC in vitro in relatively low quantities and 
had moderate effects on AA levels, whereas EPA was incorporated profoundly and strongly 
reduced AA levels. Since human PBMC appeared to have very little A5-desaturase activity, 
neither SA nor EPA exerted positive effects on the DGLA amounts metabolized from GLA. 
In contrast, daily supplementation of mice with GLA and SA in equal ratios for three weeks 
increased DGLA and reduced AA levels in splenocytes compared to administration of GLA 
alone. EPA exerted less effect on DGLA accumulation, but induced a much stronger 
reduction in AA levels. Despite effects on fatty acid metabolism, survival from Klebsiella 
pneumoniae infection was not increased by GLA, SA or EPA, either applied alone or in 
combination. In conclusion, these results indicate that SA might inhibit A5-desaturasc 
conversion of DGLA into AA in vivo, but positive effects on immune activation and host 
defence remain to be obtained. 
Maaike M.B.W. Dooper, Alieke G. Vonk#, Bart Jan Kullberg", Jos W.M. van der Meer", Yvo 
M.F. Graus and Laura M'Rabet. 
* Department General Internal Medicine, UMC St Radboud, Nijmegen. 
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Introduction 
Studies on the influence of polyunsaturated fatty acids (PUFAs) on immunity have merely 
focused on the immunoregulalory effects M-3 versus n-6 fatty acids"8417. Replacement of the n-
6 fatty acid arachidonic acid (AA, 20:4«-6) by «-3 PUF As was correlated with the beneficial 
effects of fish oil in inflammatory conditions418. However, not only w-3 fatty acids are 
beneficial in inflammatory diseases. The n-6 PUFA γ-linolenic acid (GLA, 18:3w-6) that is 
present in borage oil, also exerted positive effects200275, which were at least in part mediated 
via its elongase product dihomo-y-linolenic acid (DGLA, 20:3«-6)1912572". Unfortunately, 
DGLA can be further metabolized into AA by A5-desaturase enzymes, a process that takes 
place mostly in the liver1684". 
Since the «-3 and n-6 PUF As are both metabolized by the same panel of desaturase and 
elongase enzymes4", «-3 PUF As can theoretically compete and affect the A5-desaturation of 
DGLA into AA. Indeed, it was shown that addition of the «-3 fatty acid eicosapentaenoic acid 
(EPA, 20:5«-3) to a GLA rich diet significantly increased DGLA levels in human neutrophils 
after dietary supplementation. The DGLA accumulation was likely to be caused by selective 
inhibition of A5-dcsaturase activity in the liver356. 
Plant oils, such as echium oil420 and black current seed oil421 are nutritional sources of 
slearidonic acid (SA, 18:4M-3). SA is an intermediate in the metabolism from the essential «-3 
fatty acid α-lino lenic acid (18:3/J-3) to longer n-3 PUF As. As a direct substrate for elongase 
enzymes, SA can be metabolized into cicosalctracnoic acid (ETA, 20:4n-3) and subsequently 
into EPA by A5-desaturase enzymes422. Nutritional sources for SA are plant oils like echium 
oil420 and black current seed oil421. The in vivo metabolism of SA has been studied in 
rodents422·42' and SA was recently described to exert anti-inflammatory effects in mice215. 
Since SA might interfere with A5-desaturase enzymes used for the transition of n-6 PUFAs, 
the present study was undertaken to investigate the effects of SA on the metabolism of GLA 
in human PBMC in vitro and murine splenocytes after dietary supplementation. Additionally, 
in vivo effects of PUFA combinations were determined by assessing survival from a lethal 
Gram-negative infection with Klebsiella pneumoniae in mice. 
Materials and methods 
Materials 
Phosphate buffered saline (PBS), RPMI 1640 medium supplemented with L-glutamine and 25 
mM HEPES, penicillin/streptomycin and sodium pyruvate were obtained from Gibco BRL 
(Life Technologies, Breda, The Netherlands). Fatty acids (free acids), lipopolysaccharide 
(LPS, B05:55), (±)-a-locopherol, ascorbic-acid, BHT (butylated hydroxytoluenc), 
ethylenediaminetetracetic acid (EDTA) and boron-trifluoride (BF3) were ordered from Sigma-
Aldrich Chemie BV (Zwijndrecht, The Netherlands). Chloroform, methanol, hexane and iso-
oclanc were purchased from Merck (Darmstadt, Germany). Human serum was derived from 
Bio-Whittaker (Verviers, Belgium). Ficoll (Ficoll-Paque®) was obtained from Amersham 
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Pharmacia Biotech AB (Uppsala, Sweden). LympholiteM was from Cederlane (Cedarlane 
Laboratories, Homsby, Ontario, Canada). The lipid standard dinonadccanoyl-SN-glycero-
phosphatidylcholine (CI9:0) was obtained from Avanti Polar Lipids (Birmingham, UK). 
Phospholipid extraction columns, vacuum system and capillary column were obtained from 
Varian Chrompack (Bergen op Zoom, The Netherlands). Methyl tricosanoate standards were 
purchased from Nu Chek Prep Inc. (Elysian, USA). The fat blends used in this study were 
obtained from (companies between bars): Palm oil (Karlshamns BV, Zaandijk, The 
Netherlands), sunflower oil (Cargill, Minneapolis, US), echium oil (Croda Chemicals, Leek, 
UK), 20:5n-3 (EPA) enriched oil (TG5015, Croda Chemicals, Leek, UK) and 18:3/1-6 (GLA) 
enriched oil (TG40, Croda Chemicals, Leek, UK) 
Culture of PBMC 
Human peripheral blood mononuclear cells (PBMC) from healthy donors were prepared from 
buffy-coats by Ficoll gradient centrifiigation. In short, 10 ml of Ficoll-Paque® was stratified 
under 20 ml of peripheral blood and centrifiigation was performed at 400 X g for 20 minutes 
at room temperature (RT). Recovered PBMC were washed three times with PBS 
supplemented with 2%FCS. Cells were cultured in RPMI-1640 culture medium containing 25 
mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1.0 mM 
sodium-pyruvate, 12 mM D-glucosc and 20% heat inactivated human serum. 
Saponification of fat-blends 
The fatly acid composition of echium oil and the control fat blend used in the in vitro 
incubations are given in Table 1. For the use of in vitro culture, free fatly acids from these fat 
blends were generated by saponification. In short, triglycerides were dissolved in 1 Ν ethanol-
KOH and heated at 90oC under reflux for 1 h. After acidification with concentrated HCl to pH 
2-3, free fatty acids were extracted with hexane/diethylether (5:1), and washed with H2O. 
Organic phase was dried with sodiumsulfate and removed by rotary evaporation. Free fatty 
acids were stored under nitrogen at -20oC until further use. 
Free fatty acids were dissolved in 100 % ethanol and kept at -80oC under nitrogen until use. 
Human serum was enriched with ascorbic acid and α-tocopherol, and final concentrations in 
culture wells were 75 and 25 μΜ, respectively. Fatly acids were dissolved by direct addition 
into pre-warmed human serum. The final ethanol concentration never exceeded 0.2%. Culture 
of PBMC was performed for 3 days in 6-well flat bottom plates (107 cells per well) using a 
total volume of 5 ml culture medium in a humidified 5% CO2 atmosphere at 370C. After 
incubation, cells were washed with cold PBS for three times, dissolved in 250 μΐ PBS, and 
frozen at -80oC until analysis. 
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Table 1. Fatty acid composition of the fat blends used during in vitro Incubations 
Fat blend 
echium oil palm/sunflower oil 
fatty acids (%) 
16:0 6.9 36.2 
18:0 3.8 4.1 
18:l«-9 15.7 34.4 
18:2n-6 14.7 20.4 
18:3n-6 10.4 0.0 
18:3«-3 32.8 0.4 
18:4n-3 115 0 0 
1
 80% palm oil, 20% sunflower oil. This blend represents the control fat blend used in in vitro 
experiments. 
Animals and diets 
Female C57B1/6 mice (aged 6 weeks) were obtained from Jacksons Laboratory (Bar Harbour, 
ME) and housed (6 mice per cage) under specific pathogen-free conditions in a 12-h light-
dark cycle. The ethics committee on animal experiments of the Catholic University Nijmegen 
approved the experiments. Mice were divided into six groups of six mice with similar mean 
body weight per group and were fed standard laboratory food (Hope Farms, The Netherlands) 
and water ad libitum. After 7 days of acclimatization, mice received 220 μΐ of oil-mixture by 
gastric instillation (200 mg oil/mouse/day) consisting of various combinations and ratios of 
GLA, SA and EPA per group (Table 2). During the experiment, the oil-mixturcs were kept at 
4°C until use. After 21 days of oil supplementation, mice were killed by cervical dislocation, 
the spleens were removed and kept in PBS at 4°C until further use. Spleen leukocytes were 
obtained by homogcnization and gradient separation using LympholyteM. Until further 
analysis, splenocytes were stored at -80 degrees as dry pellets. 
Table 2. Fatty acid composition of the daily supplementation oil concentrates' 
Group 
Control EPA GLA GLA&EPA GLA&SA GLA&EPA&SA 
Fatty acid (%) 
16:0 
18:ln-9 
18:2«-6 
18:3n-6 
20:4«-6 
18:3n-3 
18:4/i-3 
20:5/i-3 
22:6/)-3 
Others 
/j-3 / /I-6 
37.8 
33.6 
19.3 
0.0 
0.0 
0.1 
0.0 
0.0 
0.0 
9.3 
0.0 
20.9 
19.0 
11.1 
0.2 
1.6 
0.0 
1.5 
24.5 
11.1 
10.2 
3.7 
17.3 
18.3 
21.8 
28.7 
0.0 
0.0 
0.0 
0.0 
0.0 
13.9 
0.0 
19.1 
18.6 
16.4 
14.5 
0.8 
0.0 
0.7 
12.3 
5.6 
12.0 
0.6 
6.9 
15.2 
16.4 
13.6 
0.0 
28.2 
11.7 
0.0 
0.0 
7.8 
1.3 
11.6 
16.5 
14.6 
9.1 
0.5 
18.8 
8.3 
8.2 
3.7 
36.7 
1.6 
g per 100 g total fatty acids. Mice were fed standard laboratory chow with daily supplementation of 
200 mg of the oil concentrates described in the table by gastric instillation. 
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Gram-negative bacterial infection 
Female C57B1/6 mice were supplemented with the fat blends as described above in 'Animals 
and diets' After 21 days of diet, Klebsiella pneumoniae (ATCC 43816, 5xl05 
baclena/mouse), a strain that produces a lethal infection in normal mice, was inoculated in the 
right thigh muscle, as described elsewhere"24 Survival was monitored every 12 for 6 days 
Total fatty acid and phospholipid analysis 
Fatty acid extraction was performed according to Bligh and Dyer (1959)152 using C19 0 as an 
internal standard Phospholipids were separated from total cellular lipids using Bond-Elut® 
solid phase extraction columns and the Vac-Elut SPS 24™ system Total fatty acid extracts or 
phospholipids extracts were then converted into methyl esters by using 14% BF3 in ethanol at 
100oC for 60 mm After hexane extraction denvatized fatty acids or phospholipids were 
dissolved in iso-octane and analyzed by gas chromatography (GC) with a capillary column 
(50m χ 0 25mm, CP-SIL88-fame) Peaks were identified by commercial reference standards 
Statistical analysis 
Statistical analyses were done using SPSS version 11 0 Fatty acid analysis and DGLA/AA 
ratio's data were analyzed by one-way analysis of variance (ANOVA) followed by the Least 
Significance Difference (LSD) lest for multiple comparisons Survival data were analyzed 
using the Kaplan-Meyer log rank test 
Results 
Echium oil supplementation in vitro 
Previous studies have shown that a three days culture period of cells with fatly acid enriched 
medium (100 μΜ) induced profound and steady state incorporation of supplemented falty 
acids (Chapter 3 of this thesis) This protocol was therefore used in our in vitro studies with 
human PB MC To investigale the change in the fatty acid composition of human PBMC after 
supplementation of fatty acids derived from echium oil, PBMC were cultured with echium oil 
or the control fat blend for three days (100 μΜ, fatty acid constitution of blends is shown in 
Table 1 ) A moderate change in the fatly acid composition of human PBMC was seen (Figure 
1 ) A relatively high increase in α-linolenic acid (LNA, 18 3M-3) was observed, concomitant 
with increased concentrations of SA and EPA and the n-6 fatty acids linolcic acid (LA, 18 2n-
6), GLA and DGLA In contrast, 22 4M-6 and palmitic acid (16 0) concentrations were 
decreased Overall, with exception of LA, the specific increases in «-3 and w-6 fatty acids 
correlated closely to the fatty acids present in echium oil 
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Figure 1. The metabolism of fatty acids from echium oil into total cellular lipids of 
human PBMC in vitro. Cells (n=4) were incubated in presence of 100 μΜ of free fatty 
acids from echium oil or control Blend (Table I) for three days as described in the 
methods section. Data are expressed as % of total fatty acid-area ± SEM. *Significantly 
different from control fat blend treated cells (P < 0.05). 
Table 3. n-6 and «-3 fatty acid composition of human PBMC cultured with 20:3«-6 for 72 h (area % 
of total fatty acids). 
Added fatty acid 
Analyzed fatty acid 
18:2«-6 
18:3/i-6 
20:3n-6 
20:4;i-6 
22:4/j-6 
22:5/1-6 
18:3/i-3 
18:4/i-3 
20:5«-3 
22:5/i-3 
22:6«-3 
Total 
DGLA 
6.4 ±0.2 
0.3 ± 0.0 
30.4 ± 07 
10.5 ±0.4 
0.2 ± 0.0 
0.2 ±0.0 
0.0 ±0.0 
0.0 ±0.0 
0.1 ±0.0 
0.9 ±0.1 
0.7 ±0.1 
fatty acids 
Control blend 
8.3 ±0.1 
0.1 ±0.0 
2.0 ±0.4 
19.6 ±0.3 
3.1 ±0.5 
0.5 ±0.0 
0.0 ±0.0 
0.0 ±0.0 
0.3 ±0.0 
2.0 ±0.2 
2.2 ±0.3 
Phospholipids 
DGLA 
6.1 ±0.8 
0.1 ±0.1 
12.2 ±0.8 
15.3 ±1.0 
1.8 ±0.3 
0.4 ±0.1 
0.0 ±0.1 
0.0 ±0.1 
0.3 ±0.1 
1.5 ±0.2 
1.6 ±0.3 
Control blend 
7.2 ±0.9 
0.0 ±0.0 
1.3 ±0.6 
21.1 ±0.7 
2.6 ±0.3 
0.5 ±0.1 
0.1 ±0.1 
0.0 ±0.0 
0.4 ±0.1 
2.0 ±0.2 
2.5 ±0.4 
Cells were cultured with 100 μΜ DGLA or control fat blend for 72 h and fatty acid analysis of total 
cellular fatty acids and phospholipids was performed. Numbers represent mean ± SD (n=4 for total 
fatty acids; n=8 for phospholipids) and are area percentages of total fatty acids. 
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Furthermore, the small increase in amounts of EPA indicates that human PBMC can 
metabolize some of the SA into EPA in vitro (Figure 1). Since this transition involves Δ5-
desaturation, we investigated to what extent DGLA is desaturated into AA in these cells. 
Supplementation of cells with DGLA largely increased the DGLA concentrations in total fatty 
acid extracts as well as phospholipid extracts (Table 3). In contrast, concentrations of A A and 
the n-6 metabolites 22:4/1-6 and 22:5w-6 were decreased after DGLA supplementation. These 
results indicate that human PBMC have at least very low A5-desaturase activity in vitro. 
GLA, SA and EPA combined in vitro 
Echium oil consists of a mixture of GLA, SA and other fatty acids (Table 1 ). Therefore, we 
subsequently investigated the effects of the combination of pure GLA and SA on fatty acid 
composition of human PBMC and compared the effects to those of GLA alone. Likewise, the 
combination of GLA with EPA was investigated to compare effects of SA to EPA. 
SA or EPA in combination with GLA, equally reduced the concentrations of GLA and its 
metabolite DGLA, compared to supplementation of GLA alone (Figure 2 A). In contrast, EPA 
and its elongation product 22:5«-3 were incorporated in much larger amounts than GLA and 
SA. In addition, EPA strongly reduced AA concentrations and this was only scarcely affected 
by the presence of GLA and SA. 
In order to reveal the effects of SA on DGLA accumulation further, the DGLA/AA ratios 
were calculated. Despite the relatively low incorporation of GLA compared to EPA, the 
DGLA/AA ratios were increased by incubation with GLA (Figure 2B). Combining GLA with 
SA lowered the DGLA/AA ratios compared to supplementation with GLA alone, but the 
concentrations still exceeded those of control incubations. Combining GLA and EPA did not 
affect the increased ratio induced by GLA supplementation, since EPA reduced both DGLA 
and AA. 
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Figure. 2 Fatty acid composition of the total fatty acids from human PBMC cultured with 
different combinations of GLA, SA and EPA (A) and the corresponding DGLA/AA 
(20:3«-6/20:4«-6) ratio's (B). Cells were supplemented with 100 μΜ fatty acids or fatty 
acid mixtures (individual fatty acids in equal ratio's) as shown in legend. Control cells 
were incubated with 100 μΜ of control blend (Table 1). The fatty acid composition of 
control cells was similar to the composition of control cells showed in Figure 1. Symbols 
with different letters next to the bars in Figure 2B are significantly different {P < 0.05). 
GLA, SA and EPA combined in vivo 
Next, combinations of SA, EPA and GLA were investigated in an in vivo situation. The 
composition of the fatty acids provided to female C57B1/6 mice (Table 2) was reflected in the 
total lipid extracts of splenocytes (Figure 3A). Supplementation of GLA increased the DGLA 
concentrations (Figure 3A) and consequently the DGLA/AA ratio (Figure 3B) compared to 
the control group. 
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Figure. 3. Effects of dietary supplementation for 21 days with combinations of GLA, SA 
or EPA on the total fatty acid composition of murine spleen cells (A, n=4) and the 
corresponding DGLA/AA (20:3«-6/20:4n-6) ratio's (B). The compositions of the diets are 
shown in Table 2. The fatty acid composition of splenocytes of the control group was as 
follows: palmitic acid 23.24%; stearic acid 15.97%; oleic acid («-9) 7.95%; oleic acid («-
7) 2.24%; LA 3.26%; GLA 0.00%; DGLA 0.85%; AA 18.66%; LNA 0.04%; SA 0.00%; 
EPA 0.05%; DPA 0.20% and DHA 6.40%. * P< 0.05 (GLA concentrations of SA&GLA 
group compared to all other groups), # Ρ < 0.05 (AA concentrations of SA&GLA groups 
compared to GLA-alone group). Symbols with different letters next to the bars in Figure 
3B arc significantly different (P < 0.05). 
Also, a trend towards increased AA concentrations was obtained by GLA supplementation. 
Combining GLA with SA significantly increased DGLA concentrations and decreased AA 
concentrations compared to supplementation of GLA alone. The DGLA/AA ratio was 
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therefore increased in the presence of SA. Furthermore, the combination of GLA with SA 
increased docosapentaenoic acid (DPA, 22:5n-3), whereas it reduced DHA concentrations. 
Despite large amounts of LNA supplemented in this group, the amount of LNA was similar as 
in splenocytes of the control group. However, combining GLA with EPA decreased AA 
concentrations to a larger extent, whereas DGLA concentrations were unaffected compared to 
GLA supplementation alone. Overall, the combination of GLA and EPA increased the 
DGLA/AA ratio similarly to the GLA group. EPA alone induced a DGLA/AA ratio 
comparable to the control group due to lowering of both DGLA and AA concentrations. A 
combination of the three fatty acids GLA, SA and EPA was not associated with a further 
change in DGLA concentrations compared to the combination of GLA with EPA. In short, 
combining dietary GLA with SA stimulated DGLA accumulation and these effects of SA 
appeared to be stronger than those induced by EPA. 
Klebsiella pneumoniae infection 
To investigate the effects of the fatty acid combinations (Table 2) on lethal Gram-negative 
infection, mice were challenged with 5xl05 live Klebsiella pneumoniae bacteria after 21 days 
of oil supplementation. No differences were observed in survival from infection between any 
diet groups (Figure 4). 
-O- Control 
- • -EPA 
-•-GLA 
- * - GLA & EPA 
-X- GLA & SA 
- • -GLA&EPA&SA 
Figure. 4 Survival of C57B1/6 mice after intra-muscular administration of 5x105 cfu of 
Klebsiella pneumoniae. 
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Discussion 
Dietary intake of GLA rich oils has shown to relieve of signs and symptoms of chronic 
inflammatory diseases200·202·"5. Although in vitro studies have shown that GLA can affect 
inflammatory cytokine production directly"1·192, some of the beneficial effects of GLA rich 
oils were correlated to the elongase product of GLA, DGLA"US72,,. We found that oral 
supplementation of SA combined with GLA increased the concentrations of DGLA in 
immune cells of mice compared to supplemcntalion of GLA alone. Furthermore, the effects of 
SA on DGLA concentrations exceeded those induced by EPA. 
Echium oil is a major source for dietary SA and also contains large amounts of GLA and 
LNA. In the current study it was shown that these fatly acids were readily taken up into 
cellular lipids of human PBMC and increased the DGLA concentrations of these cells. The 
DGLA levels measured after echium oil or GLA supplementation in vitro and in vivo are in 
line with percentages found in immune cells of other studies'""'·155. Culture with pure DGLA 
however, lead to DGLA levels of approximately five limes the levels obtained by 
supplementation of pure GLA. This suggests that in an in vivo siluation DGLA levels might 
be increased more efficiently by application of a DGLA rich oil instead of a GLA rich oil. 
The in vitro metabolism of DGLA and SA in human PBMC were informative for the amount 
and selectivity of desaturase enzymes in these cells. A5-desaturase enzymes can metabolize 
both DGLA and ETA, the elongation product of SA, into structural products containing one 
double bond more, which are AA and EPA respectively. The accumulation of DGLA al the 
expense of AA after DGLA supplementation indicated very low A5-desaturase activity. In 
contrast, the «-3 fatty acid SA caused a significant but small increase in EPA levels indicating 
that the cells express at least some A5-desalurase activity for this transition. Although Ihc 
results clearly indicated very low A5-desaturase activity in human PBMC in vitro, the data 
also indicated that A5-dcsaturase enzymes prefer metabolism of «-3 PUF As over n-6 PUFAs, 
which is in line with previous findings"6"128. Furthermore, after supplementation with EPA, 
accumulation of the elongation product of EPA, DPA, and decreased levels of the Δ6-
desaturase product, DHA, in PBMC were observed. These data indicate that, in addition to 
pore A5-desaturase activity, human PBMC in vitro express low or none A6-desaturase 
activity. 
The current study shows a clear difference between the in vitro and in vivo effects of SA on 
DGLA accumulation. Two main factors determining the DGLA accumulation are Δ5-
desaturation and competition with other PUFAs for incorporation in cellular lipids. Since 
human PBMC in vitro expressed little A5-desaturation enzyme activity, DGLA levels were 
influenced mainly by competition with other PUFAs. In this respect EPA, bul not SA, was 
shown to inhibit DGLA incorporation. In contrast, A5-desaturation was present in the in vivo 
experiments of this study, allowing SA to affect DGLA levels by interference with the 
desaturation of DGLA. In fact, dietary supplementation of GLA in combination with SA 
positively influenced DGLA accumulation and decreased AA levels in murine leukocytes in 
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vivo compared to application of a GLA rich oil alone. The DGLA accumulation induced by 
SA in vivo is therefore probably caused by inhibition of DGLA desaturation. Moreover, the 
inhibitory effects of SA on the desaturation of DGLA might be explained by the preference of 
the A5-desalurasc enzyme for n-3 fatly acids over n-6 fatly acids as seen by us and others426 "'. 
In addition, the increase in DGLA levels in splenocytes was rather pronounced taken inlo 
account that the amount of GLA provided in combination with SA was half of that of the 
GLA group. 
The in vivo data of this report showed stronger effects of SA on DGLA accumulation than 
EPA did. However, the combination of EPA, but not SA, with GLA strongly reduced AA 
levels compared to GLA supplementation alone. These results are in line with a recent study 
that showed that addition of EPA to GLA in dietary intake prevented the increase of AA 
levels in human neutrophils. When DGLA/AA ratios are taken into account, the combination 
of GLA with EPA increased the ratio further than the combination of GLA with SA. 
Unfortunately, it has not yet elucidalcd whether beneficial effects of GLA supplementation in 
inflammatory conditions are due to decreased eicosanoid production from AA or due to 
increased DGLA amounts per se. 
Studies have described protective effects of EPA on lethality induced by a gram-negative 
bacterial infection"142'"410, although the opposite has also been shown2"·43'4". The present study 
did not show any protective effects of EPA, nor of the other PUF As studied on survival of 
mice from a lethal gram-negative infection. The outcome was not related to insufficient fatty 
acid metabolism, since EPA supplementation had profound effects on fatty acid composition 
of spleen leucocytes. A possible explanation for the incapability of EPA to improve survival 
from lethal Klebsiella pneumoniae infection is that the inoculum may have been too high. 
Indeed, it has been shown that the influence of fish-oil supplementation on survival from 
Klebsiella pneumoniae infection is dependent on the amount of the inoculum3". 
In conclusion, data from the present study indicate that SA stimulates DGLA accumulation 
induced by GLA supplementation in vivo and these effects appear to be stronger than those 
induced by EPA. It was suggested that the DGLA accumulation induced by SA might be 
related to the inhibition of A5-desaturalion activity. Despite changes in fatly acid composition 
of immune cells, no effects of the fatty acid combinations were seen on survival from 
experimental gram-negative infection. Functional effects of DGLA accumulation induced by 
«-3 PUF As in combination with GLA rich oils might, however, still be obtained in less 
aggressive models for inflammation. 
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Until now, treatment of inflammatory diseases is often incompletely effective and 
accompanied by side effects. Application of specific dietary oils for treatment is conceptually 
interesting, but these substances have not gained a definitive place in treatment yet. Many 
scientists have described the potential of «-3 and w-6 polyunsaturated fatty acids (PUFAs), 
and the general understanding is that PUFAs have immune suppressing effects"4. The studies 
described in the current thesis had the aim to obtain further information on the (immune-) 
modulatory effects of PUFAs. This research was predominantly directed at the n-6 PUFA 
dihomo-y-linolenic acid (DGLA). 
It was previously described that prostaglandin^ (PGE2), a major eicosanoid produced from 
arachidonic acid (AA), is a potent inhibitor of tumor necrosis factor-α (TNF-a) production. A 
difference in the capacity between PGE-subtypes derived from other C20 PUFAs than AA 
might theoretically provide an explanation for the immune suppressive effects of 
eicosapentaenoic acid (EPA) or γ-linolenic acid (GLA) rich oils, because these oils provide 
substrate for PGE3 and PGE| synthesis, respectively. This assumption has in fact been 
suggested repeatedly by authors who found immunosuppressive effects of EPA or GLA rich 
oils2™272274. Therefore, in Chapter 2 a direct comparison of the effects of three prostaglandin-E 
subtypes derived from the three major C20 PUFAs AA (PGE2), DGLA (PGE,) and EPA 
(PGE3) on cytokine production by human PBMC was made. Two different stimuli were used 
to induce cytokine production, lipopolysaccharide (LPS) or Concanavalin-A (ConA), which 
stimulate mainly monocyte/macrophages, or T-cells respectively. It was found that the PGE-
subtypes exerted strong inhibitory effects on TNF-a production, independent of the stimulus 
used. At high PGE concentration, synthesis of the anti-inflammatory cytokine IL-10 was 
induced after LPS, but not ConA, stimulation. This implies that high PGE2 concentrations 
increase the synthesis of IL-10 in monocyte-dominated responses, while IL-10 is inhibited 
slightly by PGE2 in T-cell-mediated responses. Moreover, the effects on cytokine production 
were similar between the PGE-subtypes. This shows that the cytokine modulation of EPA or 
GLA rich oils cannot be explained by a differential induction of PGE-subtypes. Since the 
effects of PGEs were dose-responsive, an increase in total PGE-amount induced by PUFA 
supplementation may theoretically provide an explanation for inhibition of TNF-a 
production. This is however not likely to occur since most studies have reported an inhibition 
of eicosanoid production from AA by EPA or GLA rich oils2152252744'5. In addition, a strong 
increase in total PGE-amounts induced by EPA or GLA rich oils is not expected to occur, 
since it was found that both DGLA and EPA have an equal or lower substrate affinity for 
cyclooxygenase-2 (COX-2) than AA2'S,266. 
The effects of PGE-subtypes on TNF-a were only present when the PGEs were added within 
a certain time frame after cell-stimulation. The time frame correlated with the kinetics of 
TNF-a protein synthesis. This, together with previous studies"41" indicates that PGEs are 
capable of inhibiting synthesis of TNF-a directly, but do not affect the turnover of previously 
excreted TNF-a. During LPS stimulated immune responses, PGE2 is produced in large 
amounts at later time points than early pro-inflammatory cytokines (TNF-a, IL-1) are'38. This 
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would indicate that PGE2 does not regulate the initial responses, but is rather involved in later 
phases. A recent report stated that during monocyte/macrophage dominated responses, a 
balance exist between the anti-inflammatory PGE2 and pro-inflammatory eicosanoid TXA2-
'""". In contrast to this, we observed a dose-dependent inhibition of TNF-a production by 
PGEs, as well as by a stable TXA2 analogue (Chapter 3). Our data therefore suggest that, with 
emphasis on cytokine production, PGE2 and TXA2 are merely immune-suppressive agents, 
involved in the resolution phase of (monocyte/macrophage dominated) immune responses. 
This is in line with the fact that nonsteroidal anti-inflammatory drugs (NSAID) treatment, 
which strongly inhibits the production of COX derived eicosanoids, potentated TNF-a 
production in some, (but not all) studies'" l",;!7843*. 
Since it was shown that the PGE-subtypes do not differ in the effect on cytokine production, a 
next aim was to investigate direct effects of PUFAs. In Chapter 3, a comparison of the 
effects of most prevalent «-6 and «-3 PUFAs on the lipid composition and LPS-induced 
cytokine production of human PBMC was made. An in vitro model was developed in which 
cells were cultured for several days to ensure that the lipid composition of these cells was 
modulated effectively. High amounts of human serum, and a control fat blend similar to the 
dietary fat consumption for a human society, were used. It is likely that during the incubation 
period monocytes differentiated into macrophage-like cells, which arc known to respond 
different from monocytes. For instance, in cultured macrophages production of IL-Iß is low, 
whereas TNF-a production is comparable to or higher than that of monocytes (own 
observations and 4Ï7438). This provides an explanation for the low or undetectable amounts of 
IL-lß in supemalants of LPS stimulated human PBMC that were cultured for several days. 
The individual n-6 and «-3 PUFAs were incorporated in different concentrations into cellular 
phospholipids. In cells treated with control blend AA concentrations exceeded the amounts of 
other PUFAs. Overall, a preference was seen for the 20-carbon fatty acids DGLA and EPA, 
and for docosahcxaenoic acid (DHA), whereas shorter fatty acids were incorporated to a 
lesser extent. These differences might be caused by a selective affinity of lipid transport 
proteins for C20 or longer PUFAs. The differences in incorporation between the PUFAs were 
not reflected by the effects on cytokine production. DGLA inhibited TNF-a synthesis by 
40%, in contrast to the other PUFA that had no or less (AA) effect. The effects of DGLA 
were not affected by presence of GLA, were in a dose dependent fashion, and kinetics showed 
that DGLA inhibited the peak production of TNF-a. In order to gain insight in the mechanism 
by which DGLA affected cytokine production, we investigated the direct effects of the 
eicosanoids produced from DGLA and compared them to eicosanoids derived from AA or 
EPA. It was previously shown that a shift between PGEi and PGE2 could not be responsible 
for the effects of DGLA (Chapter 2). In contrast, the 15-LOX product 15-HETrE was of 
interest, since it has previously been shown that this product inhibits leukotriene 
formation247251, products that are known to act 'pro-inflammatory'120. Our results showed that 
both leukotrienes and 15-HETrE exerted no effects on LPS induced cytokine production at 1 
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μΜ concentrations (Chapter 3). In contrast, the stable TXA2 analogue CCTXA2, inhibited 
TNF-α production dose-dependently. Analysis showed that DGLA increased the amounts of 
TXB (the stable metabolite of TXA analogues) as well as PGE| in the culture supematants 
towards concentrations that were shown to inhibit TNF-α production. However, addition of 
indomethacin, a COX inhibitor, did not change the effects of DGLA, indicating that the 
effects of DGLA are not regulated via COX products. An explanation for the lack of effect of 
indomethacin is that both thromboxanes and PGEs are produced at later time points than 
TNF-α and were therefore not able to influence the synthesis of TNF-α. Indeed, it was shown 
that COX-2 protein expression was minimal, though delectable, after 6 h of LPS stimulation, 
and expressed more abundantly from 10 h on, while TNF-α concentrations were already 
maximal after 6 h of LPS stimulation118. The mechanism by which DGLA inhibits TNF-α has 
not been elucidated yet. Since the peak-concentrations of the TNF-α synthesis were affected, 
it is possible that DGLA directly affects the translation or mRNA stability of TNF-α. 
Numerous potential mechanisms by which DGLA inhibits LPS induced TNF-α synthesis can 
be given; for example, a change in the LPS-rcceptor complex (CD 14, Toll-like receptors, 
MD-2)IM '", an increase in the production of soluble TNF-receptors", direct inhibition of 
NFKB activation12"71''0 , increased synthesis of transforming growth faclor-ß (TGF-ß)4" and 
p38-MAP-kinase inhibition440. 
Although the mechanism by which DGLA affects cytokine production has not been 
elucidated yet, a practical approach was to investigate whether the effects would also be 
observed after dietary intervention. Female C57B1/6 mice were fed DGLA enriched diets (0, 2 
or 4% of dietary fat) and peritoneal macrophages were stimulated with LPS ex vivo in 
presence of autologous or control serum (Chapter 4). It was found that presence of DGLA-
rich serum downregulated TNF-α production, in contrast to cultures in which serum from 
control mice was used. These data showed that DGLA can also inhibit TNF-α production 
after in vivo metabolism. This implies that DGLA might also be an effective inhibitor of 
human TNF-α production after oral intake. However, the negative effects of DGLA on E. 
Coli induced endotoxemia indicate that DGLA might have harmful effects in such conditions. 
In animal models for endotoxemia anti-TNF treatment was often effective, also in the model 
used in Chapter 4 (E. coli LPS lethality)"6348'5'. However, discrepancies between the amount 
of TNF-α and survival rate have been observed in the present thesis (Chapter 4) and by 
others225361, indicating that TNF-α may not always be the determining factor in endotoxemia 
and sepsis. Furthermore, anti-TNF treatment by use of p55-TNF-rcceptor-fùsion proteins in 
patients with sepsis generated improvement in some patients, but overall rendered no 
statistical differences". Overall, it can be anticipated that supplementation of DGLA in 
patients that suffer severe infections that can lead to sepsis is not desirable. 
Use of anti-TNF-a treatment in rheumatoid arthritis and Crohn's disease was convincingly 
effective. In preliminary experiments we have found that supplementation with DGLA in an 
experimental model for colitis in SCID mice, induced by adoptive transfer of 
CD4(+)CD45RB(high)-T cells, had no effect, even not when DGLA levels were 20% of 
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dietary fat This discrepancy can be explained by the fact that in this model anti-TNF-a 
treatment is only partially protective441442 and clinical data on use of anti-TNF treatment in 
colitis are much less abundant than reports on Crohn's disease Overall, DGLA 
supplementation of rheumatoid arthritis or Crohn's disease patients would be of primary 
interest Since DGLA was shown to affect TNF-a production independent from COX 
activation, combined application of DGLA and NSAIDs might have cumulative effects 
In Chapter 5 the effects of GLA, DGLA, AA and EPA on melanoma growth and metastasis 
were investigated Female C57B1/6 mice were supplemented with approximately 5% of the 
specific PUFA in dietary fat and inoculated subcutaneously with high- or low-melanin 
containing cells to investigate fast and slow growing melanomas respectively, or injected 
intravenously with Β16 cells to investigate tumor metastasis It was found that GLA 
supplementation increased the size of fast growing melanomas, while EPA reduced the 
growth of slow growing melanomas EPA, but not the n-6 PUFAs, also reduced the number of 
metastases Fatty acid analysis showed that supplementation of GLA, DGLA and AA 
increased the levels of these fatty acids and their elongase and desaturase metabolites in 
serum, splenocytes and tumors to some extent, with large increases m AA levels in scrum en 
tumors, but not in splenocytes In contrast, EPA strongly reduced AA levels, and increased 
EPA and DHA levels Based on these changes, it can be concluded that the effects of EPA are 
accompanied by decreased AA levels However, no detrimental effects of AA 
supplementation were observed in these experiments, indicating that AA might not be a 
critical factor in cancer or that the levels induced by the control diet were already deleterious 
The effects of EPA were not explained by an increase in cellular immunity, since delayed-
type hypersensitivity responses were decreased by EPA, GLA as well as DGLA 
supplementation EPA might exert its effects via inhibition of COX-activity40' or production 
of eicosanoids from AA in the tumor383 This is in agreement with the finding that prostanoids 
were suggested to be immune-suppressive and tumor-promoting factors, produced by the 
tumor3" 
Previous studies have shown that intake of a combination of n-6 and «-3 PUFAs can affect the 
activity of desaturase enzymes For instance, intake of GLA and EPA rich oils by human 
individuals resulted in an accumulation of DGLA in neutrophils, presumably by inhibition of 
A5-desaturase enzymes in the liver3" In line with this, we investigated the effects of 
combinations of oral GLA (borage oil), SA (echium oil) and EPA (fish oil) in female C57B1/6 
mice on DGLA accumulation and survival from Klebsiella pneumoniae infection (Chapter 
6) Supplementation with EPA and GLA induced changes that were in line with data of 
Chapter 5, GLA increased the DGLA concentrations, whereas EPA increased EPA and DHA 
concentrations at the expense of AA SA, present in echium oil, was incorporated scarcely 
into murine splenocytes, which was in line with our in vitro experiments with human PBMC 
However, SA was effective in increasing the DGLA concentrations induced by GLA 
supplementation, and these effects were stronger than the effects observed after combined 
GLA-EPA supplementation These data indicate that intake of a combination of borage and 
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echium oil might increase the DGLA levels of human immune cells. Similar results are 
possible when a combination of echium oil and an oil rich in DGLA is used. The changes in 
fatty acid composition induced by the combinations of borage, echium and fish oil had no 
effects on the survival from a lethal Klebsiella pneumonia infection, although the size of 
bacterial inoculum might have been too high to detect differences'". 
Conclusion 
Data of the current thesis show that DGLA can inhibit TNF-a production of mononuclear 
phagocytes. The in vitro modulation was independent of COX-activation: PGE-subtypes 
derived from DGLA, AA or EPA were equally effective in reducing TNF-a production and 
the effects of DGLA were not abolished by COX-inhibition. In addition, DGLA increased the 
sensitivity for E. coli induced endotoxemia in mice, and did not affect melanoma growth and 
metastasis. DGLA might however still be effective in chronic inflammatory diseases in which 
TNF-a has conclusively been reported as a central factor. In these diseases the effects of 
DGLA can possibly be supported by combined use of DGLA with stearidonic acid and/or 
NSAIDs. 
Future prospects 
Intake of specific dietary oils is unlikely to provide a complete resolution of inflammatory 
diseases, but might have considerable beneficial effects on disease symptoms. Application of 
DGLA in inflammatory conditions that are primarily TNF-a mediated should be considered, 
since the effects of DGLA on cytokine production reported in this thesis were substantial. 
Previous studies on dietary application of DGLA to healthy human subjects did not report any 
adverse effects, which indicates that dietary intervention with DGLA in healthy volunteers, in 
order lo investigate ex vivo cytokine production, is expected to hold little risk. If positive 
results would be obtained, a pilot study in TNF-a mediated diseases, such as rheumatoid 
arthritis, would be a next step. However, the adverse effects on endotoxemia described in this 
study emphasize the need for caution of the use of DGLA in critical patients. 
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Summary 
Intake of polyunsaturated fatty acids (PUFAs) was suggested as a tool to modulate immune 
function Attention has concentrated on oils rich in γ-linolenic acid (GLA, 18 3«-6), such as 
borage oil, and eicosapentaenoic acid (EPA, 20 5«-3), such as fish oil, since these oils 
reduced the disease seventy and need for non-steroid anti-inflammatory drugs (NSAIDs) 
intake in inflammatory diseases In the current thesis, the immuno-modulalory effects of 
PUF As were investigated further It was known that prostaglandin^ (PGE2), derived from 
arachidonic acid (A A, 20 4w-6), is a potent inhibitor of proinflammatory cytokine production 
In the past, researchers have suggested that the beneficial effects of GLA or EPA-nch oils, 
could be explained by a difference in the biological activity of the cicosanoids from the direct 
metabolite of GLA, dihomo-7-linolenic acid (DGLA, 20 3w-6) (which is PGE|), or EPA 
(PGE3) compared to PGE2 In contrast to this assumption, we found that these three PGE-
subtypes modified the cytokine production by human peripheral blood mononuclear cells 
(PBMCs) equally (Chapter 2) The effects were dose dependent and only observed when the 
PGE-concenlrations were high at early time points after initiation of cytokine production 
From these data we conclude that the immuno-modulatory effects of GLA or EPA rich oils 
are not caused by a shift in PGE-subtype synthesis 
A next step was to compare the effects of PUFAs on cytokine production directly (Chapter 3) 
To this end, human PBMCs were cultured with PUFA-ennched medium for several days A 
preference for incorporation of C20 fatty acids (DGLA, AA and EPA) and the long-chain 
PUFA docosahexaenoic acid (DHA, 22 6«-3) was observed, which exceeded incorporation of 
shorter PUFAs Metabolism of PUFAs was merely restricted to elongation, which is in line 
with previous studies that described that human PBMC have little desaturase-enzyme activity 
Moreover, DGLA inhibited hpopolysacchande (LPS) induced tumor necrosis faclor-α (TNF-
a) production towards 60% of control levels, whereas other PUFAs had no or less effect The 
effects of DGLA were dose-dependent and kinetic studies showed that DGLA strongly 
affected the peak-production of TNF-a Addition of a cyclooxygenase (COX) inhibitor 
(indomethacin) did not change the effects of DGLA, which indicates that the TNF-a 
inhibition is not caused by a COX-denved product 
As a follow up, it was investigated whether DGLA modulated cytokine production after in 
vivo metabolism Therefore, female C57B1/6 mice were supplemented with DGLA (2 and 4% 
of dietary fat) In line with Chapter 3, DGLA reduced the pro-inflammatory cytokine 
synthesis (TNF-a, IL-la) of LPS stimulated murine splenocytes ex vivo Effects were 
dependent on presence of DGLA-nch serum in culture medium and were even induced when 
serum was used in cultures of cells from control mice Based on literature that showed 
correlations between TNF-a and mortality during endotoxemia, the inhibition of TNF-a 
would suggest a reduced sensitivity to endotoxemia However, we found an increased 
mortality after E coli LPS injection in DGLA-supplemented mice In contrast, sensitivity for 
S typhimunum was not altered From these results we concluded that DGLA is effective m 
— 96 — 
Chapter 8 
reducing TNF-α production after in vivo metabolism and suggested that DGLA might exert 
positive effects in conditions that are primarily mediated by TNF-a 
In a next study, the effects of different PUF As on melanoma growth and metastasis were 
investigated From literature it is known that both EPA and GLA can have anti-tumor effects 
and the current study was aimed at the direct comparison of GLA, DGLA, AA and EPA 
Female C57B1/6 mice were supplemented with the specific PUFAs (5% of dietary fat) One 
group was inoculated subculaneously with high-melanin-contaimng B16-cells, which develop 
into a fast growing melanoma, and low-melanin-containing B16 cells, which develop a slow 
growing melanoma, on the left and right flank, respectively A parallel group was injected 
intravenously with B16 cells and the number of metastases in the lungs was measured It was 
found that GLA supplementation increased the size of the fast-growing tumor, whereas EPA 
reduced the size of the low-mclanin growing tumors EPA also reduced the number of 
metastases The effects of EPA were accompanied by a strong reduction in A A levels and an 
increase in EPA and DHA concentrations in serum, splenocytes and tumor The effects of 
EPA were, however, not explained by a change in cellular immunity, since the delayed-typc 
hypersensitivity was reduced after both GLA, DGLA as well as EPA supplementation to 
some extent Overall, it was concluded that EPA, but not GLA, DGLA and AA, exerted anti­
tumor effects 
The last study was conducted to investigate whether combinations of GLA with SA and/or 
EPA would influence the accumulation of DGLA, presumably induced by inhibition of Δ5-
desalurase conversion of DGLA into AA In vitro studies with human PBMC, which have 
very low A5-desaturase activity, showed that SA and EPA had no positive effects on DGLA 
accumulation induced by GLA supplementation In contrast, in vivo experiments showed that 
supplementation of SA in combination with GLA increased DGLA and reduced AA 
concentrations in splenocytes compared to administration of GLA alone EPA exerted less 
effect on DGLA accumulation, but reduced AA concentrations to a larger extent Despite the 
effects on fatty acid metabolism, survival from Klebsiella pneumonia infection was not 
affected by supplementation with GLA, EPA and/or SA It was therefore concluded that SA 
might inhibit A5-desaturase conversion of DGLA into AA in vivo, but positive effects on host 
defence remain to be revealed 
In sum, in vitro and in vivo studies of the current thesis indicate that DGLA is an effective 
inhibitor of TNF-α production by mononuclear phagocytes These effects arc presumably not 
caused by a shift in PGE-subtype synthesis or other COX-denved products Negative effects 
or lack of effects of DGLA on endotoxemia and cancer respectively, suggest that DGLA is 
not applicable in these conditions Further investigations are necessary to elucidate a possible 
role for DGLA in conditions that are primarily TNF-α dependent, such as rheumatoid arthritis 
and Crohn's disease 
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Inflammatoire ziekten, zoals ernstige infecties en rheumatische ziekten, vormen een belangrijk 
probleem in de menselijke populatie Voor het ontwikkelen van nieuwe behandel-methoden zijn in 
het verleden de effecten van meervoudig-onverzadigde vetzuren (afgekort met PUFAs, van 
'polyunsaturated fatty acids') onderzocht Dergelijke studies laten zien dat de inname van visolie of 
olie afkomstig van borage (Borago officinalis, ook wel Komkommerkruid genoemd) gunstige 
effecten kan hebben bij immuun gerelateerde ziekten Visolie is een belangrijke bron van omcga-3 
vetzuren zoals eicosapentaeenzuur (EPA), terwijl borage olie omega-6 vetzuren zoals 
gammalinoleenzuur (GLA) bevat Zowel EPA als GLA kunnen een remmende werking op de 
activiteit van het immuunsysteem in het menselijk lichaam hebben, wat gunstig is in ziekten waarbij 
het immuunsysteem overactief is 
De activiteit van het immuunsysteem hangt samen met de hoeveelheid mediatoren (signaalstoffen) 
die door immuuncellen worden geproduceerd Cytokines zijn eiwitten met zo'n signaalfunctie en 
worden geproduceerd zodra immuuncellen geactiveerd zijn Er zijn verschillende types cytokines 
pro-inflammatoire cytokines (zoals tumor necrosis factor-α (TNF-α), interleukine-1 (IL-1) en 
interferon-γ (IFN-γ)) die zorgen voor een verdere activatie van de immuun respons, en anli-
inflammatoire cytokines (zoals IL-10) die de immune respons remmen Een andere klasse van 
mediatoren zijn de cicosanoiden Dit zijn metabolieten van PUFAs die uit 20 koolstof-atomen 
bestaan Dergelijke vetzuren zijn arachidonzuur (AA), EPA en dihomogammalinolccnzuur (DGLA, 
een direct metaboliet van GLA) Eicosanoiden kunnen worden ingedeeld in drie klassen, te weten 
Prostaglandinen, thromboxanen en leukotrienen, en zijn van belang voor een groot aantal 
fysiologische processen zoals bloedslolling, pijmnductie en mucus-productie in de darm Omdat er 
verschillende vetzuren bestaan uil 20 koolslof-atomen, kunnen meerdere subtypes eicosanoiden 
gesynthetiseerd worden Vanuit AA wordt bijvoorbeeld Prostaglandine-E2 geproduceerd, terwijl 
DGLA en EPA substraat zijn voor de productie van respectievelijk PGE| en PGE3 
In de wetenschappelijke literatuur is gesuggereerd dat de gunstige effecten van een EPA- of GLA-
njk dieet op inflammatoire ziekten gerelateerd zijn aan een verschuiving van de productie van de 
PGE-subtypes Verondersteld werd dat PGE2 (afkomstig van AA) andere effecten op het 
immuunsysteem zou hebben dan de andere PGE-subtypes (afkomstig van DGLA of EPA) Om deze 
hypothese te toetsen hebben wc in een celkweeksysteem de effecten van de drie PGE-subtypes 
PGE|, PGE2 en PGE3 op de productie van cytokines door humane bloedcellen vergeleken 
(Hoofdstuk 2) De resultaten lieten zien dat de PGE's de productie van pro-inflammaloire cytokines 
(TNF-α, IFN-γ) sterk inhiberen bij hoge concentraties, en belangrijker, dat de effecten van de drie 
subtypes identiek zijn Deze bevindingen vormen een sterke aanwijzing dat de effecten van een 
visolie of borage-njke dieet niet veroorzaakt worden door een verschuiving binnen de PGE-
subtypes 
In een volgende studie hebben we de effecten van een aantal verschillende PUFAs op de activiteit 
van menselijke immuuncellen onderzocht (Hoofdstuk 3) Het merendeel van de vetzuren had geen 
effect op cytokineproduclic Echter, DGLA remde de productie van TNF-α met 40% Omdat dit een 
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aanzienlijke remming is, zijn de effecten van DGLA verder onderzocht Resultaten heten zien dal 
de productie van zowel TNF-α als IL-10 dosisafhankelijk door DGLA werden geremd, hoe hoger 
de DGLA concentratie, hoe meer remming Vetzuuranalyse van de cellen gekweekt met DGLA 
wees uit dat er een sterke stijging van intracellulair DGLA aanwezig is, terwijl een sterke reductie 
in de AA concentraties optrad Om te testen of een verschuiving in de synthese van eicosanoid 
subtypes vanaf AA naar DGLA verantwoordelijk zou kunnen zijn voor de effecten van DGLA, zijn 
een aantal eicosanoid subclassen in hetzelfde kweeksysteem getest Effecten van PGE-sublypes zijn 
ter controle meegenomen De resultaten lieten zien dat buiten de PGE's ook thromboxane-A de 
productie van TNF-α kan inhiberen Dit bleek echter geen verband te houden met de effecten van 
DGLA, omdat remming van de thromboxane (en PGE) productie de effecten van DGLA niet 
veranderde Uit deze gegevens konden we concluderen dat DGLA de productie van TNF-α door 
humane immuuncellen onderdrukt middels een mechanisme dat niet direct gerelateerd is aan de 
productie van PGEs en thromboxanen 
Om informatie te verkrijgen of DGLA ook effect op cytokineproductie heeft na orale toediening, 
hebben we in Hoofdstuk 4 de effecten van DGLA op de immuunaclivatie in muizen bestudeerd Het 
DGLA-njke dieet (waann 2 of 4% van de totale vetten uit DGLA bestond) werd door de muizen 
vergelijkbaar gegeten als het controle-dieet (0% DGLA) en het vetzuur DGLA werd goed 
opgenomen in weefsels (lever, bloedcellen) Wederom werd de TNF-α productie door DGLA 
geinhibeerd wanneer immuuncellen van de gesupplementeerde muizen werden gestimuleerd tol 
cytokine productie, bleek de TNF-α productie lager te zijn dan in controle incubalies Deze effecten 
zijn dus overeenkomstig met de bevindingen met humane PBMCs uit Hoofdstuk 3 Vervolgens 
hebben we onderzocht of de inhibitie van de TNF-α producile ook een ziektebeeld waarin TNF-α 
een grote rol speelt, zoals sepsis, zou kunnen beïnvloeden Helaas vonden we in deze proeven 
tegenstrijdige resultaten DGLA gesupplementeerde muizen bleken gevoeliger te zijn voor een 
letale dosis LPS afkomstig van Escherichia Coli bactenen dan de controle muizen Deze 
bevindingen zijn moeilijk te verklaren 
In een volgend experiment werden de effecten van verschillende PUFAs op melanoma-tumor groei 
en métastase binnen een studie vergeleken In de wetenschappelijke literatuur is reeds beschreven 
dat zowel EPA als GLA anti-tumor effecten kunnen hebben en de huidige studie was erop gericht 
om de effecten van GLA, DGLA, AA en EPA op tumor-groei en lumor-mclastase te vergelijken 
Hiervoor werden muizen gesupplementeerd met de verschillende vetzuren (5% van het dieetvet) In 
een eerste groep werden muizen op hun linkerflank subcutaan geinoculeerd met een snelgroeiende 
tumor (met een hoog melamnc-gehalte), terwijl in de rechterflank een langzaam groeiende tumor 
werd geinoculeerd (laag melanine-gehalte) Een paralelle groep werd intraveneus geïnjecteerd met 
tumorcellen om vervolgens hel aantal metastasen in de long te kunnen bepalen We vonden 
verschillende effecten van de vetzuren GLA-supplementatie leidde tol een vcrgroling van de 
snelgroeiende tumor, terwijl EPA de groei van de langzaamgroeiende tumor inhibeerde EPA 
reduceerde ook het aantal metastases in de long Deze effecten werden mei veroorzaakt door een 
verandering van de cellulaire immuniteit in de muizen Samengevat, uil deze experimenten is naar 
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voren gekomen dat EPA, in tegenstelling tol GLA, DGLA en AA, anti-tumor effecten kan 
uitoefenen 
In de laatste studie was onderzocht of een specifieke combinatie van vetzuren te weten GLA, EPA 
en steandonzuur (SA) kan leiden tot een accumulatie van DGLA in de weefsels In een 
kweeksysteem met humane immuuncellen vonden we geen effecten van deze combinaties van 
vetzuren Wanneer de combinaties van vetzuren echter gegeven werden aan muizen, bleek dat door 
hel gebruik van SA in combinatie met GLA, de DGLA-hoeveelheid vergroot werd EPA had 
minder effect op de DGLA-accumulatie, maar gaf wel een sterke daling in de hoeveelheid AA In 
aanvullende expenmenlen werd onderzocht of deze combinaties vetzuren het verloop van een 
bactenele infectie met Klebsiella pneumonia zouden kunnen beïnvloeden, maar dit werd niet 
gevonden Geconcludeerd werd dat SA (echium olie) een positief effect heeft op de DGLA 
accumulatie, en dat de effecten van de verschillende vetzuur combinaties op het immuunsysteem 
verder onderzoek behoeven 
Conclusie 
De studies in het huidige proefschrift laten zien dat DGLA de productie van TNF-a door 
immuuncellen kan inhiberen Deze effecten worden waarschijnlijk niet veroorzaakt door een 
verschuiving in de synthese van proslaglandine-E-subtypcs of door thromboxane synthese De 
negatieve effecten en het uitblijven van effecten van DGLA op respectievelijk sepsis en kanker 
impliceren dat DGLA niet gebruikt kan worden in deze condities Verder onderzoek is nodig om te 
bepalen of DGLA het verloop van chronisch inflammatoire ziekten die sterk samenhangen met 
TNF-a productie, zoals Rheumatoide Arthritis en de ziekte van Crohn, gunstig kan beïnvloeden 
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AA 
CAMP 
CCTXA2 
ConA 
COX 
DAG 
DOLA 
DHA 
DMSO 
DPA 
DTH 
ELISA 
EPA 
ETA 
PCS 
GLA 
HETE 
HuS 
IL 
IFN 
LA 
LBP 
LNA 
LOX 
LPS 
LT 
NFKB 
NSAIDs. 
OA 
PA 
PBMC 
PBS 
PG 
PUFA 
SA 
Th 
TNF-a 
TX 
arachidonic acid, 20 4«-6 
cyclic adenosine monophosphate 
carbocyclic-thromboxane-A2 
concanavalin-A 
cyclooxygenase 
diacylglycerol 
dihomo-y-linolenic acid, 20 3n-6 
docosdhexaenoic acid, 22 6«-3 
dimethylsulphoxide 
docosapentaenoic acid, 22 5«-6 
delayed type hypersensitivity 
enzyme-linked immunosorbent assay 
eicosapentaenoic acid, 20 5/7-3 
eicosatetraenoic acid, 20 4«-3 
fetal calf serum 
γ-linolenic acid, 18 3/J-6 
hydroxyeicosatclraenoic acid 
human serum 
interleukin 
interferon 
linoleic acid, 18 2n-6 
LPS binding protein 
α-linolenic acid, 18 3n-3 
lipoxygenase 
lipopolysacchande 
leukotnene 
nuclear factor kappa Β 
non-steroid anti-inflammatory drugs 
oleic acid, 18 1 
palmitic acid, 16 0 
peripheral blood mononuclear cells 
phosphate buffered saline 
prostaglandin 
polyunsaturated fatty acids 
steandomc acid, 18 4n-3 
T-helper 
tumor necrosis factor-α 
thromboxane 
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Stellingen 
behorende hij het proefschrift 
Immune-modulating effects of polyunsaturated fatty acids: 
focus on dihomo-y-linolenic acid 
1. Aangezien de prostaglandine-E subtypes de cytokine productie door humane leukocyten 
op gelijke wijze moduleren, is het onwaarschijnlijk dat een verschuiving in de productie 
van Prostaglandine-E-subtypes verantwoordelijk is voor de effecten van borage- en/of vis-
oliën op cytokine productie (dit proefschrift). 
2. De voorkeur voor de inbouw van bepaalde meervoudig onverzadigde vetzuren is niet 
uniform (dit proefschrift). 
3. DGLA kan de TNF-a productie door immuuncellen remmen (dit proefschrift). 
4. Van de PUFAs die gebruikelijk in voedingsproducten voorkomen, verlaagt EPA het 
arachidonzuur in de phospholipiden van immuuncellen het meest effectief (dit 
proefschrift). 
5. Het geld dat gebruikt wordt voor het 'teruggeven' van agrarisch land aan de natuur zou 
mondiaal gezien beter gebruikt kunnen worden voor aankoop van bedreigde oerwouden. 
6. Een goede cursus statistiek in de opleiding tot Bioloog maakt diens leven als onderzoeker 
aanzienlijk makkelijker. 
7. Ter bevordering van een goede gezondheid heeft een verhoogde inname van gunstige 
vetzuren prioriteit boven een verminderde inname van ongunstige vetzuren. 
8. Als het welzijn van slachtvee evenredig zou zijn met het genot waarmee deze dieren 
worden genuttigd, zouden ze een beter leven hebben. 
9. Het bestaan van een epigenetische code impliceert dat de metafoor: "Het humane DNA is 
een blauwdruk voor het leven', een overschatting is. 
10. Wie te vroeg juicht, heeft toch alvast plezier gehad (Dr. Ir. Regine W. Vroom). 
Maaike Dooper, Nijmegen, 5 maart 2004. 



